

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number
WO 01/09303 A2

- (51) International Patent Classification⁷: **C12N 15/00** Gary, George [US/US]; 3159 Via De Caballo, Encinitas, CA 92024 (US).
- (21) International Application Number: **PCT/US00/20679**
- (22) International Filing Date: **31 July 2000 (31.07.2000)** (74) Agents: **STEFFE, Eric, K. et al.**; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).
- (25) Filing Language: **English** (81) Designated States (*national*): **CA, JP, US.**
- (26) Publication Language: **English** (84) Designated States (*regional*): **European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).**
- (30) Priority Data: **60/146,170 30 July 1999 (30.07.1999) US**
- (71) Applicant (*for all designated States except US*): **VICAL INC.** [US/US]; Suite 100, 9373 Towne Centre Drive, San Diego, CA 92121 (US). Published:
— *Without international search report and to be republished upon receipt of that report.*
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **HERMANSON,** *For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/09303 A2

(54) Title: **Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER**

(57) Abstract: The present invention provides a pharmaceutical composition, comprising a first non-infectious, non-integrating nucleic acid molecule construct comprising a polynucleotide encoding a Flt-3 ligand, and a second non-infectious, non-integrating nucleic acid molecule construct comprising a polynucleotide encoding an antigen or a cytokine. The present invention also provides a method broadly directed to enhancing immune response of a vertebrate in need of immunotherapy which entails administering *in vivo*, into a tissue of a vertebrate, a Flt-3 ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides. The polynucleotides are incorporated into the cells of the vertebrate *in vivo*, and a prophylactically or therapeutically effective amount of a Flt-3 ligand and one or more antigens is produced *in vivo*.

Flt-3 Ligand-encoding Polynucleotide as a Polynucleotide-based Vaccine Enhancer

Field of the Invention

5 The present invention relates generally to immunogenic compositions and to methods useful for polynucleotide-based vaccination to help protect a vertebrate from a disease, to treat a diseased vertebrate, or both.

More particularly, the immunogenic compositions of the present invention comprise a Flt-3 ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides. The present invention further provides methods of enhancing the immune response of a vertebrate by administering to the tissues of a vertebrate a Flt-3 ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides.

15 ***Background of the Invention***

Fms-like tyrosine kinase (Flt-3 ligand, Lyman SD *et al.*, *Cell* 75(6):1157-67 (1993)) has been shown to produce systemic immunity to tumor cells when injected as a protein (Chen K *et al.*, *Cancer. Res.* 57:3511-3516 (1997)).

Administration of 500 µg/kg/day of Flt-3 ligand protein for ten days protected animals challenged with a murine breast cancer cell line. This protection was transient and lasted for less than four weeks. When a retrovirus expressing Flt-3 ligand was used to infect the murine breast cancer cells before implantation into the mice, the mice developed a long-lived immunity to the breast cancer challenge. Repeated systemic injection of Flt-3 ligand protein into mice results in the proliferation and mobilization of CD34+ hematopoietic stem cells as well as an increase in the numbers of natural killer cells (NK), mature dendritic cells (DC), B-cells, T-cells and other hematopoietic cells.

Another study showed that mice injected with 10 µg of Flt-3 ligand protein per day for 19 days showed complete tumor regression when challenged with B10.2 fibrosarcoma cells. This effect was shown to be due to the stimulation of a tumor-specific CTL response as well as non-specific anti-tumor

-2-

effects possibly due to increased Natural Killer (NK) cell response (Lynch DH, *Crit. Rev. Immunol.* 18:99-107 (1998)).

Another study showed that co-injection of mouse Flt-3 ligand can increase the B- and T-cell responses to poorly immunogenic antigens, influence the quality
5 of the immune response (e.g., change the class of antibody produced) to a specific antigen, and enable the elicitation of an immune response to an antigen that would otherwise induce tolerance (Pulendran, *et al.*, *J. Exp. Med.* 188:2075-2082). The effect was hypothesized to be due to the induction of dendritic cells.

U.S. Patent No. 5,676,954 reports on the injection of genetic material,
10 complexed with cationic liposome-carriers, into mice. U.S. Patent Nos. 4,897,355; 4,946,787; 5,049,386; 5,459,127; 5,589,466; 5,693,622; 5,580,859; 5,703,055; and International Patent Application No. PCT/US94/06069 (publication no. WO 04/9469) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466; 5,693,622; 5,580,859;
15 5,703,055, and international patent application no. PCT/US94/06069 (publication no. WO 04/9469) provide methods for delivering DNA-cationic lipid complexes to mammals.

There remains a need in the art for convenient, safe, and efficacious immunogenic compounds to treat or prevent vertebrate diseases. The present
20 invention provides simple and safe yet effective immunogenic compounds and methods to prevent and/or treat vertebrate diseases using such immunogenic compounds.

Summary of the Invention

25

The present invention is broadly directed to enhancing immune response of a vertebrate in need of immunotherapy by administering *in vivo*, into a tissue of a vertebrate, a Flt-3 ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides. The polynucleotides are incorporated into
30 the cells of the vertebrate *in vivo*, and a prophylactically or therapeutically

-3-

effective amount of a Flt-3 ligand and one or more antigens or cytokines is produced *in vivo*.

The present invention provides a pharmaceutical composition comprising about 1 ng to 10 mg of nucleic acid molecule comprising a first polynucleotide

5 selected from the group consisting of (a) a polynucleotide that hybridizes under stringent conditions to a reference nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, and SEQ ID NO:22, wherein the polynucleotide encodes a polypeptide

10 that has immunity-enhancing activity when administered to a vertebrate; (b) a polynucleotide that encodes a first polypeptide which, except for at least one but not more than 20 amino acid substitutions, deletions, or insertions, is identical to a second polypeptide selected from the group consisting of: amino acids 1 to 163, or 28 to 163 of SEQ ID NO:8, amino acids 1 to 189 or 28 to 189 of SEQ ID

15 NO:8, amino acids 1 to 231 or 28 to 231 of SEQ ID NO:8, amino acids 1 to 220, or 28 to 220 of SEQ ID NO:11, amino acids 1 to 232, or 28 to 232 of SEQ ID NO:13, amino acids 1 to 172, or 28 to 172 of SEQ ID NO:17, amino acids 1 to 160, or 27 to 160 of SEQ ID NO:19, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:19, amino acids 1 to 235, or 27 to 235 of SEQ ID NO:19, amino acids 1

20 to 178, or 27 to 178 of SEQ ID NO:21, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:23, and amino acids 1 to 235, or 27 to 235 of SEQ ID NO:23, wherein said polypeptide has immunity-enhancing activity when administered to a vertebrate; (c) a polynucleotide that encodes an amino acid sequence that is at least 90%, preferably at least 95%, and more preferably at least 97% identical to

25 a reference amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24, wherein said polynucleotide encodes a polypeptide having immunity-enhancing activity when administered to a vertebrate; (d) a polynucleotide encoding a polypeptide

30 comprising at least 15, preferably at least 30, more preferably at least 50, and

more preferably at least 150 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24, wherein said polypeptide has immunity-enhancing activity when administered to a vertebrate; (e) a polynucleotide that encodes a polypeptide selected from the group consisting of: amino acids 1 to 163, or 28 to 163 of SEQ ID NO:8, amino acids 1 to 189 or 28 to 189 of SEQ ID NO:8, amino acids 1 to 231 or 28 to 231 of SEQ ID NO:8, amino acids 1 to 220, or 28 to 220 of SEQ ID NO:11, amino acids 1 to 232, or 28 to 232 of SEQ ID NO:13, amino acids 1 to 172, or 28 to 172 of SEQ ID NO:17, amino acids 1 to 160, or 27 to 160 of SEQ ID NO:19, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:19, amino acids 1 to 235, or 27 to 235 of SEQ ID NO:19, amino acids 1 to 178, or 27 to 178 of SEQ ID NO:21, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:23, and amino acids 1 to 235, or 27 to 235 of SEQ ID NO:23, wherein said polypeptide has immunity-enhancing activity when administered to a vertebrate; (f) a polynucleotide encoding three amino acid regions comprising amino acid residues 34 to 41 of SEQ ID NO:19 arranged consecutively, amino acid residues 107 to 113 of SEQ ID NO:19 arranged consecutively, and amino acid residues 142 to 150 of SEQ ID NO:19 arranged consecutively, wherein said polynucleotide encodes a polypeptide having immunity-enhancing activity when administered to a vertebrate; (g) a polynucleotide encoding a polypeptide which, except for at least one amino acid substitution at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147 of SEQ ID NO:19, is identical to amino acids 27 to 160 of SEQ ID NO:19, wherein said amino acid substitution increases the immunity enhancing activity of said polypeptide; (h) a polynucleotide encoding a polypeptide which, except for at least one amino acid substitution at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147 of SEQ ID NO:23, is identical to amino acids 27 to 185 of SEQ ID NO:23, wherein said amino acid substitution increases the immunity enhancing activity of said polypeptide; and

-5-

(i) the complement of any of said polynucleotides; and about 1 ng to 30 mg of a nucleic acid molecule comprising a second polynucleotide encoding one or more antigens, wherein said first and second polynucleotides are non-infectious and non-integrating, and are operably associated with control sequences which direct the expression thereof in a subject in need of immunotherapy. The first and second polynucleotides can be present in a single nucleic acid molecule construct, or on separate nucleic acid molecule constructs.

In one embodiment, the pharmaceutical composition of the present invention further comprises about 1 ng to 10 mg of a nucleic acid molecule comprising a third non-infectious and non-integrating polynucleotide encoding a cytokine, chemokine, or other immunity-enhancing compound, wherein the third polynucleotide is operably associated with control sequences which direct its expression.

The present invention also provides a method of enhancing immune response of a vertebrate, comprising administering into a tissue of the vertebrate (a) a nucleic acid molecule comprising a first non-infectious, non-integrating polynucleotide encoding a Flt-3 ligand, or an active variant, or fragment thereof as described herein, and (b) a nucleic acid molecule comprising a second non-infectious, non-integrating polynucleotide encoding one or more antigens (e.g. an antigenic protein) and/or cytokines, such that the polynucleotides are expressed *in vivo* in an amount effective to enhance the immune response of the vertebrate to the encoded antigen or cytokine. The first and second polynucleotides can be present in a single nucleic acid molecule construct, or in separate nucleic acid molecule constructs. In some embodiments, the nucleic acid molecule construct(s) can be complexed with a cationic lipid formulation as described herein. When the polynucleotide is complexed with a cationic lipid formulation, the formulation preferably comprises a cationic lipid mixed with a co-lipid.

Brief Description of the Figures

A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same become better understood
5 by reference to the following detailed description when considered in connection with the accompanying figures.

Figure 1 shows the plasmid map of VR1623 which is the bicistronic chimeric idiotype (Id) plasmid DNA, referred to as pId, and having the nucleotide sequence SEQ ID NO:1. The cytomegalovirus immediate-early gene promoter,
10 enhancer, and 5' untranslated sequences (5'UTR + intron A) drive the expression of the chimeric immunoglobulin light and heavy chain coding sequences. The transcriptional terminator region includes polyadenylation and termination signals derived from the bovine growth hormone gene. This plasmid expresses a functional chimeric Id immunoglobulin that stimulates a partially protective B
15 and T cell response to the tumor.

Figure 2 shows the plasmid map of VR1605 which is the bicistronic plasmid containing the human immunoglobulin kappa light and gamma 1 heavy chain constant region DNA, referred to as pNegative, and having the nucleotide sequence SEQ ID NO:2. The plasmid contains the cytomegalovirus immediate-
20 early gene promoter, enhancer, and 5' untranslated sequences (5'UTR + intron A) followed by the immunoglobulin light and heavy chain constant region coding sequences. The transcriptional terminator region includes polyadenylation and termination signals derived from the bovine growth hormone gene. This plasmid DNA (pDNA) contains the human constant regions only and not the mouse
25 variable region sequences. This plasmid does not express a functional protein and therefore does not generate anti-Id antibodies or protect mice from 38C13 tumor challenge. It is used as a negative control for VR1623.

Figure 3 shows the plasmid map of VR 1642 (VAXID plasmid) which is the patient-specific bicistronic chimeric idiotype (Id) plasmid DNA used to treat
30 B-cell lymphoma patients. This plasmid has the nucleotide sequence SEQ ID

-7-

NO:3. The cytomegalovirus immediate-early gene promoter, enhancer, and 5' untranslated sequences (5'UTR + intron A) drive the expression of the chimeric immunoglobulin light and heavy chain coding sequences. The human light and heavy chain variable regions are derived from each patient's tumor immunoglobulin sequence. VR1642 contains the light and heavy chain variable regions from the cell line RAMOS (Klein G *et al.*, Intervirology, 5:319-334 (1975); GenBank accession numbers Z74694 and Z74695) fused to the murine kappa light chain and gamma 1 heavy chain constant regions. The transcriptional terminator region includes polyadenylation and termination signals derived from the bovine growth hormone gene. This plasmid expresses a functional chimeric Ig immunoglobulin to stimulate a B and T cell response to the patient's tumor.

Figure 4 shows VR1632 which is the bicistronic plasmid containing the murine immunoglobulin kappa light and gamma 1 heavy chain constant region DNA, having the nucleotide sequence SEQ ID NO:4. The plasmid contains the cytomegalovirus immediate-early gene promoter, enhancer, and 5' untranslated sequences (5'UTR + intron A) followed by the immunoglobulin light and heavy chain constant region coding sequences. The transcriptional terminator region includes polyadenylation and termination signals derived from the bovine growth hormone gene. This pDNA only contains the murine constant regions without any human variable region sequences. Tumor-specific variable regions from each patient are PCR amplified and cloned into this vector to produce each patient's vaccine construct.

Figure 5 shows the plasmid map of the expression plasmid VR1051, referred to as pBlank, and having the nucleotide sequence SEQ ID NO:5. The plasmid contains the cytomegalovirus immediate-early gene promoter, enhancer, and 5' untranslated sequences (5'UTR + intron A) followed by a multiple cloning site for inserting genes to be expressed. The transcriptional terminator region includes polyadenylation and termination signals derived from the rabbit beta globin gene. VR1051 is the expression plasmid without any insert and is used as a DNA mass control for VR6200.

-8-

Figure 6 shows the plasmid map of VR6200, which expresses a secreted form of the murine Flt-3 ligand. This plasmid is referred to herein as pFlt-3 lig, and has the nucleotide sequence SEQ ID NO:6. The Flt-3 ligand polypeptide encoded by this construct has been truncated to remove the transmembrane domain and cytoplasmic tail, leading to a secreted form of Flt-3 ligand. The insert is cloned as an *EcoRI*-*NheI* fragment in the VR1051 vector.

Figure 7 is a tumor cell survival curve demonstrating that the co-injection of a Flt-3 ligand-encoding plasmid with a tumor-specific antigen-encoding plasmid enhances protection from tumor challenge.

Figure 8 is a bar graph demonstrating that the co-injection of the Flt-3 ligand-encoding plasmid with an Id antigen-encoding plasmid results in greatly enhanced anti-Id antibody titer. This graph shows the total IgG anti-Id antibody response in ng/ml after plasmid vaccination and prior to tumor challenge.

Figure 9 is a tumor cell survival curve demonstrating that pFlt-3 ligand, while increasing the immune response to the co-injected plasmid (i.e., pID), does not have an effect by itself.

Detailed Description of Preferred Embodiments of the Invention

It will be apparent to one skilled in the art, in view of the following detailed description and the claims appended hereto, that various substitutions
5 and modifications can be made to the present invention without departing from the scope of the invention as claimed.

The present invention is broadly directed to enhancing the immune response of a vertebrate to an antigen or a cytokine by administering *in vivo*, into a tissue of a vertebrate, a Flt-3 ligand-encoding polynucleotide and one or more
10 antigen- or cytokine-encoding polynucleotides. The polynucleotides are incorporated into the cells of the vertebrate *in vivo*, and a prophylactically or therapeutically effective amount of a Flt-3 ligand and one or more antigens or cytokines is produced *in vivo*.

In one embodiment, the present invention provides a pharmaceutical
15 composition comprising about 1 ng to 10 mg of a nucleic acid molecule comprising a first polynucleotide selected from the group consisting of: (a) a polynucleotide that hybridizes under stringent conditions to a reference nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID
20 NO:16, SEQ ID NO:18, SEQ ID NO:20, and SEQ ID NO:22, wherein the polynucleotide encodes a polypeptide that has immunity-enhancing activity when administered to a vertebrate; (b) a polynucleotide that encodes a first polypeptide which, except for at least one but not more than 20 amino acid substitutions, deletions, or insertions, is identical to a second polypeptide selected from the
25 group consisting of: amino acids 1 to 163, or 28 to 163 of SEQ ID NO:8, amino acids 1 to 189 or 28 to 189 of SEQ ID NO:8, amino acids 1 to 231 or 28 to 231 of SEQ ID NO:8, amino acids 1 to 220, or 28 to 220 of SEQ ID NO:11, amino acids 1 to 232, or 28 to 232 of SEQ ID NO:13, amino acids 1 to 172, or 28 to 172 of SEQ ID NO:17, amino acids 1 to 160, or 27 to 160 of SEQ ID NO:19, amino
30 acids 1 to 185, or 27 to 185 of SEQ ID NO:19, amino acids 1 to 235, or 27 to 235

-10-

of SEQ ID NO:19, amino acids 1 to 178, or 27 to 178 of SEQ ID NO:21, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:23, and amino acids 1 to 235, or 27 to 235 of SEQ ID NO:23, wherein said polypeptide has immunity-enhancing activity when administered to a vertebrate; (c) a polynucleotide that encodes an amino acid sequence that is at least 90%, preferably at least 95%, and more preferably at least 97% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24, wherein said polynucleotide encodes a polypeptide having immunity-enhancing activity when administered to a vertebrate; (d) a polynucleotide encoding a polypeptide comprising at least 15, preferably at least 30, more preferably at least 50, and more preferably at least 150 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24, wherein said polypeptide has immunity-enhancing activity when administered to a vertebrate; (e) a polynucleotide that encodes a polypeptide selected from the group consisting of: amino acids 1 to 163, or 28 to 163 of SEQ ID NO:8, amino acids 1 to 189 or 28 to 189 of SEQ ID NO:8, amino acids 1 to 231 or 28 to 231 of SEQ ID NO:8, amino acids 1 to 220, or 28 to 220 of SEQ ID NO:11, amino acids 1 to 232, or 28 to 232 of SEQ ID NO:13, amino acids 1 to 172, or 28 to 172 of SEQ ID NO:17, amino acids 1 to 160, or 27 to 160 of SEQ ID NO:19, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:19, amino acids 1 to 235, or 27 to 235 of SEQ ID NO:19, amino acids 1 to 178, or 27 to 178 of SEQ ID NO:21, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:23, and amino acids 1 to 235, or 27 to 235 of SEQ ID NO:23, wherein said polypeptide has immunity-enhancing activity when administered to a vertebrate; (f) a polynucleotide encoding three amino acid regions comprising amino acid residues 34 to 41 of SEQ ID NO:19 arranged consecutively, amino acid residues 107 to 113 of SEQ ID NO:19 arranged consecutively, and amino acid residues 142 to 150 of SEQ ID NO:19 arranged

-11-

consecutively, wherein said polynucleotide encodes a polypeptide having immunity-enhancing activity when administered to a vertebrate; (g) a polynucleotide encoding a polypeptide which, except for at least one amino acid substitution at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147 of SEQ ID NO:19, is identical to amino acids 27 to 160 of SEQ ID NO:19, wherein said amino acid substitution increases the immunity enhancing activity of said polypeptide; (h) a polynucleotide encoding a polypeptide which, except for at least one amino acid substitution at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147 of SEQ ID NO:23, is identical to amino acids 27 to 185 of SEQ ID NO:23, wherein said amino acid substitution increases the immunity enhancing activity of said polypeptide; and (i) the complement of any of said polynucleotides; about 1 ng to 30 mg of a nucleic acid molecule comprising a second polynucleotide encoding one or more antigens or cytokines; and a pharmaceutically-acceptable carrier, wherein said first and second polynucleotides are non-infectious and non-integrating, and are operably associated with control sequences which direct the expression thereof in a subject in need of immunotherapy.

In another embodiment, the present invention provides an immunogenic composition obtained by mixing about 1 ng to 10 mg of a nucleic acid molecule comprising a polynucleotide selected from the group consisting of: (a) a polynucleotide that hybridizes under stringent conditions to a reference nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, and SEQ ID NO:22, wherein the polynucleotide encodes a polypeptide that has immunity-enhancing activity when administered to a vertebrate; (b) a polynucleotide that encodes a first polypeptide which, except for at least one but not more than 20 amino acid substitutions, deletions, or insertions, is identical to a second polypeptide selected from the group consisting of: amino acids 1 to 163, or 28 to 163 of SEQ ID NO:8, amino

-12-

acids 1 to 189 or 28 to 189 of SEQ ID NO:8, amino acids 1 to 231 or 28 to 231 of SEQ ID NO:8, amino acids 1 to 220, or 28 to 220 of SEQ ID NO:11, amino acids 1 to 232, or 28 to 232 of SEQ ID NO:13, amino acids 1 to 172, or 28 to 172 of SEQ ID NO:17, amino acids 1 to 160, or 27 to 160 of SEQ ID NO:19, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:19, amino acids 1 to 235, or 27 to 235 of SEQ ID NO:19, amino acids 1 to 178, or 27 to 178 of SEQ ID NO:21, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:23, and amino acids 1 to 235, or 27 to 235 of SEQ ID NO:23, wherein said polypeptide has immunity-enhancing activity when administered to a vertebrate; (c) a polynucleotide that encodes an amino acid sequence that is at least 90%, preferably at least 95%, and more preferably at least 97% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24, wherein said polynucleotide encodes a polypeptide having immunity-enhancing activity when administered to a vertebrate; (d) a polynucleotide encoding a polypeptide comprising at least 15, preferably at least 30, more preferably at least 50, and more preferably at least 150 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24, wherein said polypeptide has immunity-enhancing activity when administered to a vertebrate; (e) a polynucleotide that encodes a polypeptide selected from the group consisting of: amino acids 1 to 163, or 28 to 163 of SEQ ID NO:8, amino acids 1 to 189 or 28 to 189 of SEQ ID NO:8, amino acids 1 to 231 or 28 to 231 of SEQ ID NO:8, amino acids 1 to 220, or 28 to 220 of SEQ ID NO:11, amino acids 1 to 232, or 28 to 232 of SEQ ID NO:13, amino acids 1 to 172, or 28 to 172 of SEQ ID NO:17, amino acids 1 to 160, or 27 to 160 of SEQ ID NO:19, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:19, amino acids 1 to 235, or 27 to 235 of SEQ ID NO:19, amino acids 1 to 178, or 27 to 178 of SEQ ID NO:21, amino acids 1 to 185, or 27 to 185 of SEQ ID NO:23, and amino acids 1 to 235, or 27 to 235 of

-13-

SEQ ID NO:23, wherein said polypeptide has immunity-enhancing activity when administered to a vertebrate; (f) a polynucleotide encoding three amino acid regions comprising amino acid residues 34 to 41 of SEQ ID NO:19 arranged consecutively, amino acid residues 107 to 113 of SEQ ID NO:19 arranged consecutively, amino acid residues 142 to 150 of SEQ ID NO:19 arranged consecutively, wherein said polynucleotide encodes a polypeptide having immunity-enhancing activity when administered to a vertebrate; (g) a polynucleotide encoding a polypeptide which, except for at least one amino acid substitution at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147 of SEQ ID NO:19, is identical to amino acids 27 to 160 of SEQ ID NO:19, wherein said amino acid substitution increases the immunity enhancing activity of said polypeptide; (h) a polynucleotide encoding a polypeptide which, except for at least one amino acid substitution at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147 of SEQ ID NO:23, is identical to amino acids 27 to 185 of SEQ ID NO:23, wherein said amino acid substitution increases the immunity enhancing activity of said polypeptide; and (i) the complement of any of said polynucleotides; with one or more constructs comprising 1 ng to 30 mg of a nucleic acid molecule comprising one or more polynucleotides encoding one or more antigens or cytokines, wherein said polynucleotides are non-infectious and non-integrating, and are operably associated with control sequences which direct the expression thereof in a subject in need of immunotherapy.

The present invention also provides a method of enhancing the immune response of a vertebrate, comprising administering into a tissue of the vertebrate an immunogenic composition comprising (1) about 1 ng to 10 mg of a nucleic acid molecule comprising a first non-infectious, non-integrating polynucleotide encoding a Flt-3 ligand, or an active variant, or fragment thereof as described herein, and (2) about 1 ng to 30 mg of a nucleic acid molecule comprising a second non-infectious, non-integrating polynucleotide encoding one or more antigens (e.g. an antigenic protein) or cytokines, such that the polynucleotides are

-14-

expressed *in vivo* in an amount effective to enhance the immune response of the vertebrate to the encoded antigen or cytokines.

One example of a preferred embodiment of the present invention provides for the prophylactic or therapeutic treatment of B-cell lymphoma. This embodiment provides immunogenic compositions comprising (1) about 1 ng to 10 mg of a nucleic acid molecule comprising a first polynucleotide encoding a Flt-3 ligand; and (2) about 1 ng to 30 mg of a nucleic acid molecule comprising a second polynucleotide encoding a variable region of an immunoglobulin expressed by the B-cell lymphoma, including tumor-specific idiotype determinants, and a constant region. The immunogenic composition is administered into a tissue of a mammal, wherein specific anti-Id antibody responses are induced and such response is enhanced by the encoded Flt-3 ligand.

The preferred amount for both polynucleotides for this embodiment is about 10 µg to 10 mg, and the more preferred amount is about 0.1 mg to 5 mg, and the most preferred amount is about 0.5 mg to 2.0 mg.

The term "nucleic acid molecule" is intended to encompass a singular "nucleic acid molecule" as well as plural "nucleic acid molecules," and refers to an isolated molecule or construct comprising any one or more polynucleotides. The term "polynucleotide" refers to any one or more nucleic acid segments or constructs (e.g., DNA or RNA oligomers, mRNA or pDNA). The polynucleotide may be provided in linear, circular (e.g., plasmid), or branched form as well as double-stranded or single-stranded form. The polynucleotide may comprise a conventional phosphodiester bond or a non-conventional bond (e.g., an amide bond, such as found in peptide nucleic acids (PNA)).

The first and second polynucleotides of the present invention can be present in a single nucleic acid molecule construct, e.g., on a single plasmid, or in separate nucleic acid molecule constructs, e.g., on separate plasmids. Furthermore, either the first or second polynucleotide may encode a single protein, e.g., a single antigen, cytokine, or a Flt-3 ligand, or may encode more than one protein, e.g., a nucleic acid molecule may comprise a second

-15-

polynucleotide encoding two or more antigens and/or cytokines, either as separate proteins or as a fusion protein, or a nucleic acid molecule may comprise a first polynucleotide encoding a Flt-3 ligand and a second polynucleotide encoding one or more antigens and/or cytokines, either as separate proteins or as one or more fusion proteins. The first and second polynucleotides may also encode a single fusion protein which combines one or more antigens and/or cytokines and a Flt-3 ligand, active variant, or fragment thereof as described herein.

Immunogenic compositions of the present invention include a nucleic acid molecule comprising at least one polynucleotide encoding an antigen or a cytokine. In certain embodiments of the present invention, the immunogenic compositions can include multiple antigen- or cytokine-encoding polynucleotides. The term "antigen" is intended to encompass a singular "antigen" as well as plural "antigens." As used herein, an "antigen" is any compound comprising at least one epitope. An "epitope," is the minimum portion of an antigen required to interact with an immune molecule generated by a vertebrate, e.g., with an antibody or a T-cell receptor. Antigens and their epitopes can comprise, for example, carbohydrates, lipids, nucleic acids, amino acids, and a wide range of synthetic organic chemicals. An antigen of the present invention is encoded by a polynucleotide, and accordingly, comprises either nucleic acids or amino acids. However, it is within the scope of the present invention for an antigen comprised of amino acids to incorporate, during its synthesis *in vivo*, modifications including, but not limited to, the addition of carbohydrate antigens and lipid antigens. Preferably, an antigen of the present invention is a protein antigen, i.e., it comprises epitopes composed of amino acids. The minimum size of a protein epitope is generally understood by those skilled in the art to be about 6-12 amino acids, either consecutive on the amino acid chain, i.e., a continuous epitope, or formed through the interactions of non-consecutive amino acid residues due to the secondary or tertiary structure of a protein, i.e., a discontinuous epitope. See, e.g., Harlow and Lane, *Antibodies A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, New York (1988), and

-16-

Janeway, *et al.*, *Immunobiology: Immune System in Health and Disease*, Current Biology Publication, New York, New York (1999), both of which are incorporated herein by reference.

In certain embodiments of the present invention, the immunogenic
5 compositions can include one or more cytokine-encoding polynucleotides. The term "cytokine" is intended to encompass a singular "cytokine" as well as plural "cytokines." Examples of cytokines include, but are not limited to granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), colony
10 stimulating factor (CSF), erythropoietin (EPO), interleukin 2 (IL-2), interleukin 3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12), interleukin 15 (IL-15), interleukin 18 (IL-18), interferon alpha (IFN α), interferon beta (IFN β), interferon gamma (IFN γ), interferon omega (IFN ω) and interferon
15 tau (IFN τ), interferon gamma inducing factor (IGIF), transforming growth factor beta (TGF- β) RANTES (regulated upon activation, normal T-cell expressed and presumably secreted), macrophage inflammatory proteins (e.g., MIP-1 alpha and MIP-1 beta), *Leishmania* elongation initiating factor (LEIF), stromal cell derived factor 1 (SDF-1), and monocyte chemotactic protein-3.

20 The term "vertebrate" is intended to encompass a singular "vertebrate" as well as plural "vertebrates," and comprises mammals and birds, as well as fish, reptiles, and amphibians.

The term "mammal" is intended to encompass a singular "mammal" and plural "mammals," and includes, but is not limited to humans; primates such as
25 apes, monkeys, orangutans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras, food animals such as cows, pigs, and sheep; ungulates such as deer and giraffes; and bears. Preferably, the mammal is a human subject.

As used herein, an "immune response" refers to the ability of a vertebrate
30 to elicit an immune reaction to a composition delivered to that vertebrate.

-17-

Examples of immune responses include an antibody response or a cellular, e.g., T-cell, response. An immunogenic composition of the present invention may be used to treat a vertebrate prophylactically, e.g., as a prophylactic vaccine, to establish or enhance immunity in a healthy vertebrate prior to exposure or contraction of a disease or disorder, thus preventing the disease or reducing the severity of disease symptoms or to reducing the severity of a metabolic disorder. An immunogenic composition of the present invention may also be used to treat a vertebrate already suffering from a disease or a metabolic disorder to further stimulate the immune system of the vertebrate, thus reducing or eliminating the symptoms associated with that disease or disorder. As defined herein, "treatment of a vertebrate" refers to the use of an immunogenic composition of the present invention to prevent, cure, retard, or reduce the severity of disease symptoms in a vertebrate; to reduce tumor size, reduce the rate of metastasis, and/or slow tumor growth, and/or result in no worsening in disease over a specified period of time. It is not required that an immunogenic composition of the present invention provide total immunity or totally cure or eliminate all disease symptoms. As used herein, a "subject in need of immunotherapy" refers to a vertebrate which it is desirable to treat, i.e., to prevent, cure, retard, or reduce the severity of disease symptoms; to reduce tumor size, reduce the rate of metastasis, and/or slow tumor growth, and/or result in no worsening in disease over a specified period of time.

In some circumstances, an antigen of the present invention is capable of eliciting, without more, an immune response in a vertebrate when administered to that vertebrate. Such antigens are referred to herein as immunogenic antigens. However, antigens that do not normally elicit an immune response upon administration to a vertebrate, i.e., non-immunogenic antigens, are also within the scope of the present invention. Indeed, one advantage of the present invention is the ability to elicit or greatly enhance an immune response in a vertebrate to a non-immunogenic antigen, for example, an antigen to which the vertebrate is tolerant, when a polynucleotide encoding that antigen is co-administered with a

-18-

polynucleotide encoding a Flt-3 ligand or an active variant, or fragment thereof as described herein.

Antigens that normally do elicit an immune response in a vertebrate, i.e., "immunogens," are also within the scope of the present invention. The term
5 "immunogen" is meant to encompass any compound capable of eliciting an immune response in a vertebrate.

An antigen of the present invention includes any compound that is capable of being encoded by a polynucleotide, for example, a polypeptide, DNA, or RNA molecule. Preferably, an antigen of the present invention comprises a
10 polypeptide. Such an antigen may comprise one or more complete proteins, or may be a fragment of a protein. At a minimum, a polypeptide antigen of the present invention must include at least one epitope capable of interaction with the immune system of a vertebrate. In one preferred embodiment, a polypeptide antigen of the present invention is derived from a heterologous organism, such
15 as a pathogen. Other preferred polypeptide antigens of the present invention include allergens, tumor-associated antigens, and self-antigens linked to cells associated with autoimmune diseases. Examples of suitable antigens are disclosed herein.

In a preferred embodiment, the present invention can be applied to the
20 treatment of B-cell lymphoma. In one example of this embodiment, the antigen-encoding polynucleotide comprises a polynucleotide encoding a variable region of a B-cell lymphoma immunoglobulin having tumor-specific idiotype determinants. An "idiotype determinant" is the region of an immunoglobulin molecule that directly and specifically binds to an epitope of a given antigen. The
25 polynucleotide can further encode a constant region. The antigen-encoding polynucleotide can be a polycistronic plasmid DNA (pDNA). As defined herein, a "cistron" is a translational coding region, and "polycistronic" refers to a polynucleotide comprising two or more "cistrons." In one embodiment, an antigen-encoding polycistronic polynucleotide comprises a first cistron, encoding
30 a variable light chain region of a B-cell lymphoma immunoglobulin with a tumor-

-19-

specific idiotype determinant fused in-frame to a light chain constant region and a second cistron encoding a variable heavy chain region of a B-cell lymphoma immunoglobulin with a tumor-specific idiotype determinant, fused in-frame to a heavy chain constant region. A preferred heavy or light chain constant region is a xenogeneic constant region (i.e., a constant region derived from a heterologous species relative to the variable region). For example, if a variable region is derived from mouse, it is fused in-frame to a constant region derived from human. The cistrons can be organized in a transcription unit under the control of a single promoter, and said polynucleotide can further comprise an internal ribosome entry site positioned between the cistrons. Suitable internal ribosome entry sites are disclosed, for example, in Duke, *et al.*, *J. Virol.* 66:1602-1609 (March, 1992), and Gan and Rhoads, *J. Biol. Chem.* 271:623-626 (January, 1996). In this embodiment, the antigen- or cytokine-encoding polynucleotides or the immunogenic compositions containing the polynucleotides are preferably custom made to express the idiotype determinants of each patient's own tumor immunoglobulin (Ig).

In one embodiment, the present invention comprises a nucleic acid molecule comprising a first polynucleotide that hybridizes under stringent conditions to a reference nucleic acid molecule that encodes a Flt-3 ligand, or a fragment or variant thereof as described herein, or a complement of any such reference nucleic acid molecule, wherein the first polynucleotide encodes a polypeptide that has immunity-enhancing activity when administered to a vertebrate. "Stringent hybridization conditions" are those experimental parameters that allow an individual skilled in the art to identify similarities between heterologous nucleic acid molecules. See, for example, Sambrook, *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press, Cold Spring Harbor, NY (1989), and Meinkoth, *et al.*, *Anal. Biochem.* 138:267-284 (1984), both of which are incorporated herein by reference. The determination of stringent hybridization conditions involves the manipulation of a set of variables, including ionic strength (M, in moles/liter), the hybridization temperature (°C),

-20-

the concentration of helix destabilizing agents (such as formamide), the average length of the shortest chain in the duplex (n), and the percent G + C composition of the fragments being hybridized. For nucleic acid molecules longer than about 50 nucleotides, these variables are inserted into a standard formula to calculate the melting temperature, or T_m , of a given nucleic acid molecule, which is the temperature at which two complementary nucleic acid molecule strands will disassociate, assuming 100% complementarity between the two strands:

$$T_m = 81.5^\circ\text{C} + 16.6 \log M + 0.41(\%G + C) - 500/n - 0.61(\%\text{formamide}).$$

For nucleic acid molecules smaller than about 50 nucleotides, hybrid stability is defined by the dissociation temperature (T_d), the temperature at which 50% of the duplexes dissociate. For these smaller molecules, the stability, at a standard ionic strength, is defined by the following equation:

$$T_d = 4(G + C) + 2(A + T).$$

A temperature of 5°C below T_d is used to detect hybridization between perfectly matched molecules.

It is also well known by those skilled in the art how base-pair mismatch will affect T_m or T_d for nucleic acid molecules of different sizes. For example, T_m decreases about 1°C for each 1% of mismatched base-pairs for hybrids greater than about 150 base pairs (bp), and T_d decreases about 5°C for each mispaired base-pair for hybrids below about 50 bp. Conditions for hybrids between about 50 and about 150 base-pairs can be determined empirically. This allows one skilled in the art to set the hybridization conditions (by altering, for example, the salt concentration, the formamide concentration or the temperature) such that only hybrids with greater than a specified % base-pair mismatch will hybridize. Stringent hybridization conditions are commonly understood by those skilled in the art to be those experimental conditions that will allow no more than about 3-5% base-pair mismatch (i.e., about 95-97% identity between the hybrid strands). "Stringent conditions" for a hybridization probe larger than 100 nucleotides, for example, may comprise hybridization by overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (750 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran

-21-

sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by repeatedly washing the filters (at least three times) in 0.1x SSC and 0.1% sodium dodecyl sulfate (w/v) for 20 minutes at about 65°C. Using the formula described above with a probe of about 1000 nucleotides, having an about 40% G + C content, the T_m of fully complementary hybrids will be about 67 °C. Thus, the stringent wash at 65 °C will allow detection of hybrids having 2% or less base-pair mismatch.

It will be recognized in the art that some amino acid sequences of Flt-3 ligand and antigen- or cytokine-encoding polypeptides described herein can be varied without significant effect on the functional activity of the polypeptides. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the polypeptide which determine activity. Such variations include deletions, insertions, inversions, repeats, and type substitutions. Guidance concerning which amino acid changes are likely to be phenotypically silent can be found in Bowie, J.U., *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," (*Science* 247:1306-1310 (1990)), which is incorporated herein by reference in its entirety. Polypeptides suitable for use in the present invention can be assayed by methods known to those skilled in the art, examples of which are described in the Examples, *infra*.

Amino acids that are critical for, e.g., cytokine activity can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith, *et al.*, *J. Mol. Biol.* 224:899-904 (1992) and de Vos, *et al.* *Science* 255:306-312 (1992)).

To encompass variants of a Flt-3 ligand containing suitable deletions, insertions, inversions, repeats, and type substitutions, one embodiment of the present invention provides a nucleic acid molecule comprising a first polynucleotide that encodes an amino acid sequence that is at least 90%, preferably at least 95%, and more preferably at least 97% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ

-22-

ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:23, wherein said polynucleotide encodes a polypeptide having immunity-enhancing activity when administered to a vertebrate. As a practical matter, whether any particular amino acid sequence is at least 90%, 95%, or 97%, identical to, for instance, reference amino acid sequences having the above SEQ ID NOs can be determined conventionally using known computer programs such as the Bestfit program with default parameters (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 5371 1). Bestfit uses the local homology algorithm of Smith and Waterman, *Advances in Applied Mathematics* 2:482-489 (1981), to find the best segment of homology between two sequences.

The present invention further relates to using variants of Flt-3 ligand and antigen- or cytokine-encoding polynucleotides, which encode portions, analogs or derivatives of a Flt-3 ligand, antigen, or cytokine, wherein the portions, analogs, or derivatives of a Flt-3 ligand retain immunity-enhancing activity, and wherein the portions, analogs, or derivatives of an antigen retain at least one epitope. Variants may occur naturally, such as a natural allelic variant or a splice variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. *Genes II*, Lewin, B., ed., John Wiley & Sons, New York (1985). A "splice-variant" is a messenger RNA or gene product produced by the joining of alternative exons upon the processing of transcripts of a common gene. Examples of naturally-occurring allelic variants and splice variants of polynucleotides encoding a Flt-3 ligand are disclosed herein. Non-naturally occurring variants may be produced using art-known mutagenesis techniques.

Examples of allelic variants and splice variants of polynucleotides encoding full-length Flt-3 ligands include, for example, polynucleotides having nucleic acid sequences SEQ ID NO:7, encoding amino acid sequence SEQ ID NO:8; SEQ ID NO:10, encoding amino acid sequence SEQ ID NO:11; SEQ ID NO:12, encoding amino acid sequence SEQ ID NO:13; SEQ ID NO:14, encoding

-23-

amino acid sequence SEQ ID NO:15; SEQ ID NO:16, encoding amino acid sequence SEQ ID NO:17; SEQ ID NO:18, encoding amino acid sequence SEQ ID NO:19; SEQ ID NO:20, encoding amino acid sequence SEQ ID NO:21; and SEQ ID NO:22, encoding amino acid sequence SEQ ID NO:23.

5 In one naturally-occurring form, a mature Flt-3 ligand protein is bound to the surface of cells and comprises an extracellular domain, a transmembrane domain and a cytoplasmic domain. The full-length protein further comprises an N-terminal signal peptide. *See, e.g., Graddis, et al., J. Biol. Chem., 273:17626-17633 (1998), and U.S. Patent No. 5,554,512.*

10 It is believed that the N-terminal signal peptide of a full-length Flt-3 ligand polypeptide comprises the first 26 or 27 amino acids of that protein, e.g., amino acids 1-27 of SEQ ID NO:8 and SEQ ID NO:9, encoded by nucleotides 32-112 of SEQ ID NO:7; amino acids 1-27 of SEQ ID NO:11, encoded by nucleotides 7-87 of SEQ ID NO:10; amino acids 1-27 of SEQ ID NO:13, encoded by nucleotides 256-336 of SEQ ID NO:12; amino acids 1-27 of SEQ ID NO:15, encoded by nucleotides 1-81 of SEQ ID NO:14; amino acids 1-27 of SEQ ID NO:17, encoded by nucleotides 1-81 of SEQ ID NO:16; amino acids 1-26 of SEQ ID NO:19, encoded by nucleotides 84-161 of SEQ ID NO:18; amino acids 1-26 of SEQ ID NO:21, encoded by nucleotides 1-78 of SEQ ID NO:20; and amino acids 1-26 of SEQ ID NO:23 and SEQ ID NO:24, encoded by nucleotides 93-170 of SEQ ID NO:22.

 Examples of mature Flt-3 ligand polypeptides, i.e., where the N-terminal signal peptide has been removed, include a polypeptide having amino acids 28-231 of SEQ ID NO:8, encoded by nucleotides 113-724 of SEQ ID NO:7; a polypeptide having amino acids 28-189 of SEQ ID NO:9, encoded by nucleotides 113-598 of SEQ ID NO:7; a polypeptide having amino acids 28-220 of SEQ ID NO:11, encoded by nucleotides 88-666 of SEQ ID NO:10; amino acids 28-232 of SEQ ID NO:13, encoded by nucleotides 337-951 of SEQ ID NO:12; amino acids 28-220 of SEQ ID NO:15, encoded by nucleotides 82-660 of SEQ ID NO:14; amino acids 28-172 of SEQ ID NO:17, encoded by nucleotides 82-516

-24-

of SEQ ID NO:16; amino acids 27-235 of SEQ ID NO:19, encoded by nucleotides 162-788 of SEQ ID NO:18; amino acids 27-178 of SEQ ID NO:21, encoded by nucleotides 79-534 of SEQ ID NO:20; amino acids 27-235 of SEQ ID NO:23 encoded by nucleotides 171-797 of SEQ ID NO:22; and amino acids
5 27-185 of SEQ ID NO:24, encoded by nucleotides 171-647 of SEQ ID NO:22.

It is believed that the extracellular domain of a membrane bound Flt-3 ligand polypeptide comprises about 151-156 amino acids, e.g., from about amino acid 28 to about amino acid 188 of SEQ ID NO:8, encoded by nucleotides 113-595 of SEQ ID NO:7; from about amino acid 28 to about amino acid 188 of SEQ
10 ID NO:13, encoded by nucleotides 337-819 of SEQ ID NO:12; from about amino acid 27 to about amino acid 182 of SEQ ID NO:19, encoded by nucleotides 162-629 of SEQ ID NO:18; and from about amino acid 27 to about amino acid 182 of SEQ ID NO:23, encoded by nucleotides 170-638 of SEQ ID NO:22.

It is believed that the transmembrane domain of a membrane-bound Flt-3
15 ligand polypeptide comprises about 23-24 amino acids, e.g., from about amino acid 189 to about amino acid 211 of SEQ ID NO:8, encoded by nucleotides 596-664 of SEQ ID NO:7; from about amino acid 189 to about amino acid 212 of SEQ ID NO:13, encoded by nucleotides 820-891 of SEQ ID NO:12; from about amino acid 183 to about amino acid 205 of SEQ ID NO:19, encoded by
20 nucleotides 630-708 of SEQ ID NO:18; and from about amino acid 183 to about amino acid 205 of SEQ ID NO:23, encoded by nucleotides 639-697 of SEQ ID NO:22.

It is believed that the cytoplasmic domain of a membrane-bound Flt-3
ligand polypeptide comprises about 20-30 amino acids, e.g., from about amino
25 acid 212 to about amino acid 231 of SEQ ID NO:8, encoded by nucleotides 665-724 of SEQ ID NO:7; from about amino acid 213 to about amino acid 232 of SEQ ID NO:13, encoded by nucleotides 892-951 of SEQ ID NO:12; from about amino acid 206 to about amino acid 235 of SEQ ID NO:19, encoded by nucleotides 699-788 of SEQ ID NO:18; and from about amino acid 206 to about

amino acid 235 of SEQ ID NO:23, encoded by nucleotides 709-797 of SEQ ID NO:22.

Furthermore, a soluble mature Flt-3 ligand, lacking the secretory signal peptide, transmembrane and cytoplasmic domains, is biologically active. *See* 5 McClanahan, *et al.*, *Blood* 88: 3371-3382 (1996), which is incorporated herein by reference. Accordingly, a preferred variant of a polynucleotide encoding a Flt-3 ligand is a polynucleotide encoding a secreted form of a Flt-3 ligand. Naturally-occurring secreted forms of a Flt-3 ligand may be encoded by a polynucleotide comprising a splice variant lacking the coding regions for the transmembrane and 10 cytoplasmic domains, e.g., a Flt-3 ligand encoded by the polynucleotide having SEQ ID NO:10, encoding a full length polypeptide having the amino acid sequence SEQ ID NO:11; or a Flt-3 ligand encoded by the polynucleotide having SEQ ID NO:16, encoding a full length polypeptide having the amino acid sequence SEQ ID NO:17; or may be formed by post-translational processing of 15 a membrane bound form of Flt-3 ligand. *See*, e.g., McClanahan, *et al.*, *ibid.* Alternatively, a polynucleotide encoding a secreted form of a Flt-3 ligand may be constructed through standard cloning techniques. *See*, e.g., Examples 1 and 2, *infra*. Examples of constructed polynucleotides encoding full-length secreted forms of Flt-3 ligand include a polynucleotide having nucleotides 32-598 of SEQ 20 ID NO:7, encoding amino acid sequence SEQ ID NO:9, and a polynucleotide having nucleotides 93-647 of SEQ ID NO:22, encoding amino acid sequence SEQ ID NO:24.

Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially 25 preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the Flt-3 ligand, antigen, or portions thereof. Also especially preferred in this regard are conservative substitutions. For example, aromatic amino acids that can be conservatively substituted for one another include phenylalanine, tryptophan, and tyrosine. Hydrophobic amino 30 acids that can be conservatively substituted for one another include leucine,

-26-

isoleucine, and valine. Polar amino acids that can be conservatively substituted for one another include glutamine and asparagine. Basic amino acids that can be conservatively substituted for one another include arginine, lysine, and histidine. Acidic amino acids that can be conservatively substituted for one another include
5 aspartic acid and glutamic acid. Small amino acids that can be conservatively substituted for one another include alanine, serine, threonine, methionine, and glycine.

Substitutions, deletions, or insertions can be made outside of the region encoding the shortest active fragment of the Flt-3 ligand or outside of the epitopes
10 contained in the antigen, without affecting the activity of the immunogenic compound of the present invention. Further, mutated proteins (or muteins) often retain a biological activity that is similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268: 22105-22111 (1993)) conducted an extensive mutational analysis of the human cytokine IL-1 α . They
15 used random mutagenesis to generate over 3,500 individual IL-1 α mutants with an average of 2.5 amino acid changes per mutein over the entire length of the molecule. Multiple mutations were examined at every possible amino acid and, on average, each mutein's amino acid sequence was 98.4% identical to that of naturally occurring IL-1 α . The investigators observed that most of the molecule
20 could be mutated with little effect on either binding or biological activity, and that 75% of the molecule may not contribute significantly to the biological activity of the molecule.

More specifically, Graddis, *et al.*, *ibid.*, reported a random mutational analysis of the human Flt-3 ligand, screening over 60,000 potential mutants for
25 receptor binding and biological activity. They observed that mutations in three "hot spots" on the Flt-3 ligand polypeptide, amino acids 34 to 41, 107 to 113, and 142 to 150 of the full-length polypeptide i.e., SEQ ID NO:19 or SEQ ID NO:23, either enhanced or reduced biological activity, and that in the predicted three-dimensional structure of the molecule, these regions cluster together as a small
30 surface patch, which they hypothesize to be the receptor binding site. Graddis

-27-

and coworkers showed that certain non-conservative substitutions in the full-length polypeptide enhanced biological activity. These included substitutions, e.g., in polypeptides having amino acid sequences SEQ ID NO:19 or SEQ ID NO:23, at amino acid positions: His-34, e.g., substituted with Tyr; Lys-110, e.g., substituted with either Glu or Thr; Trp-144, e.g., substituted with Arg; and Gln-148, e.g., substituted with Arg. Graddis and coworkers found further substitutions that reduced, but did not eliminate activity. Two other mutations that reduced biological activity of the protein, at amino acid positions Lys-53 and Ala-90, mapped to the proposed dimerization interface, shifting the equilibrium of the population of Flt-3 ligand proteins from dimers to monomers. Mutations in other regions of the protein appeared to have no appreciable effect on activity of the molecule. Thus, even non-conservative substitutions could be made in these other regions without appreciably affecting activity of the Flt-3 ligand polypeptide.

Accordingly, a polynucleotide encoding a Flt-3 ligand or antigen of the present invention can encode a polypeptide having one to about twenty amino acid substitutions, deletions or insertions, either from natural mutations or human manipulation, relative to the full length, mature or secreted form of Flt-3 ligand or antigen. Preferably, no more than one to fifteen substitutions, deletions or insertions are present, relative to the full length, mature or secreted form of Flt-3 ligand or antigen, in addition to normal truncation of the transmembrane domain, cytoplasmic tail, and the secretory signal peptide sequence. More preferably, no more than one to ten substitutions, deletions or insertions are present. Still more preferably, no more than one to five substitutions, deletions or insertions are present. Even more preferably only one substitution, deletion or insertion is present.

Especially preferred is a polynucleotide encoding a human Flt-3 ligand of the present invention having one to about twenty amino acid substitutions, deletions or insertions in regions outside of the three "hot spots" on the Flt-3 ligand polypeptide, i.e., the substitutions, deletions, or insertions do not occur in regions identical to amino acids 34 to 41, 107 to 113, and 142 to 150 of a

-28-

polypeptide having amino acid sequence SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:24. Preferably, no more than one to fifteen substitutions, deletions or insertions are present outside of these regions, relative to the full length, mature or secreted form of a Flt-3 ligand, in addition to normal
5 truncation of the transmembrane domain, cytoplasmic tail, and the leader sequence. More preferably, no more than one to ten substitutions, deletions, or insertions are present. Still more preferably, no more than one to five substitutions, deletions, or insertions are present outside of these regions. Even more preferably, only one substitution, deletion, or insertion is present outside
10 of these regions.

Also especially preferred is a polynucleotide encoding a human Flt-3 ligand of the present invention having one or more activity-increasing substitutions at amino acid positions 34, 110, or 144, or 147 of a polypeptide having amino acid sequence SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or
15 SEQ ID NO:24.

Polynucleotide and amino acid sequences encoding a Flt-3 ligand include genomic sequences of human and murine Flt-3 ligand genes, as well as cDNA and protein sequences encoding full-length natural allelic variants and splice variants of human and murine Flt-3 ligands, mature human and murine Flt-3
20 ligands, and secreted forms of human and murine Flt-3 ligands, set forth, e.g., in U.S. Patent No. 5,554,512, Lyman, *et al.*, *Oncogene* 11:1165-1172 (1995), Lyman, *et al.*, *Oncogene* 10:149-157 (1995), Hannum, *et al.*, *Nature* 368:643-648 (1994), Graddis, *et al.*, *ibid.*, and McClanahan, *et al.*, *ibid.*

Secretion of a peptide from a cell can be facilitated by a leader sequence, also referred to as a secretory signal peptide. In a preferred embodiment, either
25 the native leader sequence is used, or a functional derivative of that sequence that retains the ability to direct the secretion of the peptide that is operably associated with it. Alternatively, a heterologous mammalian leader sequence, or a functional derivative thereof, may be used. For example, the wild-type leader sequence

-29-

may be substituted with the leader sequence of human tissue plasminogen activator or mouse β -glucuronidase.

In one embodiment, the pharmaceutical composition of the present invention can further include one or more known adjuvants. The term "adjuvant" refers to any material having the ability to (1) alter or increase the immune response to a particular antigen or (2) increase or aid an effect of a pharmacological agent. Accordingly, a Flt-3 ligand encoded by a polynucleotide of the present invention is considered an "adjuvant." This embodiment refers to a pharmaceutical composition comprising one or more additional adjuvants. Suitable adjuvants include, but are not limited to, cytokines and growth factors; bacterial components (e.g., endotoxins, in particular superantigens, exotoxins and cell wall components); aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins, viruses and virally-derived materials, poisons, venoms, and catatonic lipids. The ability of an adjuvant to increase the immune response to an antigen is typically manifested by a significant increase in immune-mediated protection. For example, an increase in humoral immunity is typically manifested by a significant increase in the titer of antibodies raised to the antigen, and an increase in T-cell activity is typically manifested in increased cell proliferation, or cellular cytotoxicity. An adjuvant may also alter an immune response, for example, by changing a primarily humoral or Th₂ response into a primarily cellular, or Th₁ response.

The preferred adjuvants are cytokines. It is known in the art that the biological activity of Flt-3 ligand works synergistically with other cytokines and growth factors, to greatly increase the immunomodulatory effect. See, e.g., Shurin, *et al.*, *Cytokine Growth Factor Rev.* 9:37-48 (1998). A pharmaceutical composition of the present invention can comprise one or more cytokines, chemokines, or compounds that induce the production of cytokines and chemokines, or a polynucleotide encoding one or more cytokines, chemokines, or compounds that induce the production of cytokines and chemokines. Examples include, but are not limited to granulocyte macrophage colony stimulating factor

(GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), colony stimulating factor (CSF), erythropoietin (EPO), interleukin 2 (IL-2), interleukin-3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12), interleukin 15 (IL-15), interleukin 18 (IL-18),
5 interferon alpha (IFN α), interferon beta (IFN β), interferon gamma (IFN γ), interferon omega (IFN ω), interferon tau (IFN τ), interferon gamma inducing factor I (IGIF), transforming growth factor beta (TGF- β), RANTES (regulated upon activation, normal T-cell expressed and presumably secreted), macrophage
10 inflammatory proteins (e.g., MIP-1 alpha and MIP-1 beta), and *Leishmania* elongation initiating factor (LEIF).

The immunogenic composition of the present invention can also include one or more transfection facilitating materials that facilitate delivery of polynucleotides to the interior of a cell, and/or to a desired location within a cell.
15 Examples of the transfection facilitating materials include, but are not limited to inorganic materials such as calcium phosphate, alum (aluminum sulfate), and gold particles (e.g., "powder" type delivery vehicles); peptides that are, for example, cationic, intercell targeting (for selective delivery to certain cell types), intracellular targeting (for nuclear localization or endosomal escape), and amphoteric
20 (helix forming or pore forming); proteins that are, for example, basic (e.g., positively charged) such as histones, targeting (e.g., asialoglycoprotein), viral (e.g., Sendai virus coat protein), and pore-forming; lipids that are, for example, cationic (e.g., DMRPE, DOSPA, DC-Chol), basic (e.g., steryl amine), neutral (e.g., cholesterol), anionic (e.g., phosphatidyl serine), and zwitterionic (e.g., DOPE,
25 DOPC); and polymers such as dendrimers, star-polymers, "homogeneous" poly-amino acids (e.g., poly-lysine, poly-arginine), "heterogeneous" poly-amino acids (e.g., mixtures of lysine & glycine), co-polymers, polyvinylpyrrolidone (PVP), and polyethylene glycol (PEG). A transfection facilitating material can be used alone or in combination with one or more other transfection facilitating
30 materials. Two or more transfection facilitating materials can be combined by

chemical bonding (e.g., covalent and ionic such as in lipidated polylysine, PEGylated polylysine) (Toncheva, *et al.*, *Biochim. Biophys. Acta* 1380(3):354-368 (1988)), mechanical mixing (e.g., free moving materials in liquid or solid phase such as "polylysine + cationic lipids") (Gao and Huang, 5 *Biochemistry* 35:1027-1036 (1996); Trubetskoy, *et al.*, *Biochem. Biophys. Acta* 1131:311-313 (1992)), and aggregation (e.g., co-precipitation, gel forming such as in cationic lipids + poly-lactide co-galactide, and polylysine + gelatin).

The preferred transfection facilitating agents are cationic lipids, which can bind effectively to negatively charged molecules of DNA. Examples of cationic 10 lipids are 5-carboxyspermylglycine dioctadecylamide (DOGS) and dipalmitoyl-phosphatidylethanolamine-5carboxyspermylamide (DPPES). Cationic cholesterol derivatives are also useful, including {3 β -[N-N',N'-dimethylamino]ethane]-carbomoyl}-cholesterol (DC-Chol). Dimethyldioctdecyl-ammonium bromide (DDAB), N-(3-aminopropyl)-N,N-(bis-(2-tetradecyloxyethyl))-N-methyl- 15 ammonium bromide (PA-DEMO), N-(3-aminopropyl)-N,N-(bis-(2-dodecyloxyethyl))-N-methyl-ammonium bromide (PA-DELO), N,N,N-tris-(2-dodecyloxy)ethyl-N-(3-amino)propyl-ammonium bromide (PA-TELO), and N¹-(3-aminopropyl)((2-dodecyloxy)ethyl)-N²-(2-dodecyloxy)ethyl-1-piperazinaminium bromide (GA-LOE-BP) can also be employed in the present invention.

20 Non-diether cationic lipids, such as DL-1,2-dioleoyl-3-dimethylaminopropyl- β -hydroxyethylammonium (DORI diester), 1-O-oleyl-2-oleoyl-3-dimethylaminopropyl- β -hydroxyethylammonium (DORI ester/ether), and their salts promote *in vivo* gene delivery. Preferred cationic lipids comprise groups attached via a heteroatom attached to the quaternary ammonium moiety 25 in the head group. A glyceryl spacer can connect the linker to the hydroxyl group.

Preferred cationic lipids for use in certain embodiments of the present invention include DMRIE ((\pm)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide), GAP-DMORIE ((\pm)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(*syn*-9-tetradeceneyloxy)-1-propanaminium

bromide), and GAP-DLRIE ((\pm)-N-(3-aminopropyl)-N,N-dimethyl-2,3-(bis-dodecyloxy)-1-propanaminium bromide).

A preferred cationic lipid of the present invention is a "cytofectin." As used herein, a "cytofectin" refers to a subset of cationic lipids which incorporate
 5 certain structural features including, but not limited to, a quaternary ammonium group and/or a hydrophobic region (usually with two or more alkyl chains), but which do not require amine protonation to develop a positive charge. Examples of cytofectins may be found, for example, in U.S. Patent No. 5,861,397.

Also preferred are (\pm)-N,N-dimethyl-N-[2-(sperminecarboxamido)ethyl]-
 10 2,3-bis(dioleoyloxy)-1-propaniminium pentahydrochloride (DOSPA), (\pm)-N-(2-aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propaniminium bromide (β -aminoethyl-DMRIE or β AE-DMRIE) (Wheeler, *et al.*, *Biochim. Biophys. Acta* 1280:1-11 (1996)), and (\pm)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propaniminium bromide (GAP-DLRIE) (Wheeler, *et al.*, *Proc.*
 15 *Natl. Acad. Sci. USA* 93:11454-11459 (1996)), which have been developed from DMRIE.

Other examples of DMRIE-derived cationic lipids that are useful for the present invention are (\pm)-N-(3-aminopropyl)-N,N-dimethyl-2,3-(bis-decyloxy)-1-propanaminium bromide (GAP-DDRIE), (\pm)-N-(3-aminopropyl)-N,N-dimethyl-
 20 2,3-(bis-tetradecyloxy)-1-propanaminium bromide (GAP-DMRIE), (\pm)-N-((N'-methyl)-N'-ureyl)propyl-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (GMU-DMRIE), (\pm)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide (DLRIE), and (\pm)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis-([Z]-9-octadecenylloxy)propyl-1-propanaminium bromide
 25 (HP-DORIE).

Preferred cytofectins for use in certain embodiments of the present invention include DMRIE ((\pm)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide), GAP-DMORIE ((\pm)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(*syn*-9-tetradecenylloxy)-1-propanaminium

bromide), and GAP-DLRIE ((\pm)-N-(3-aminopropyl)-N,N-dimethyl-2,3-(*bis*-dodecyloxy)-1-propanaminium bromide).

In the embodiments where the immunogenic composition comprises a cationic lipid, the cationic lipid is preferably mixed with one or more co-lipids.

- 5 For purposes of definition, the term "co-lipid" refers to any hydrophobic material which may be combined with the cationic lipid component and includes amphipathic lipids, such as phospholipids, and neutral lipids, such as cholesterol. Cationic lipids and co-lipids may be mixed or combined in a number of ways to produce a variety of non-covalently bonded macroscopic structures, including,
- 10 for example, liposomes, multilamellar vesicles, unilamellar vesicles, micelles, and simple films. A preferred class of co-lipids are the zwitterionic phospholipids, which include the phosphatidylethanolamines and the phosphatidylcholines. Most preferably, the co-lipids are phosphatidylethanolamines, such as, for example, DOPE, DMPE and DPyPE.
- 15 DOPE and DPyPE are particularly preferred; the most preferred co-lipid is DPyPE, which comprises two phytanoyl substituents incorporated into the diacylphosphatidylethanolamine skeleton.

- When the immunogenic composition comprises a cationic lipid:co-lipid, the preferred cationic lipid:co-lipid molar ratio of the present invention is from
- 20 about 9:1 to about 1:9. More preferably, the cationic lipid:co-lipid molar ratio is from about 4:1 to about 1:4 and, still more preferably, is from about 2:1 to about 1:2. The most preferred molar ratio is about 1:1.

- In order to maximize homogeneity, the cationic lipid and co-lipid components of the immunogenic compositions in certain embodiments of the
- 25 present invention are preferably dissolved in a solvent such as chloroform, followed by evaporation of the cationic lipid/co-lipid solution under vacuum to dryness as a film on the inner surface of a glass vessel (e.g., a Rotovap round-bottomed flask). Upon suspension in an aqueous solvent, the amphipathic lipid component molecules self-assemble into homogenous lipid vesicles. These lipid
- 30 vesicles may subsequently be processed to have a selected mean diameter of

-34-

uniform size prior to complexing with, for example, pDNA according to methods known to those skilled in the art. For example, the sonication of a lipid solution is described in Felgner *et al.*, *Proc. Natl. Acad. Sci. USA* 84,7413-7417 (1987) and in U.S. Pat. No. 5,264,618, the disclosures of which are incorporated herein
5 by reference.

In the embodiments where the pharmaceutical composition includes a cationic lipid, the nucleic acid molecule construct(s) are complexed with lipids by mixing, for example, a pDNA solution and a solution of cationic lipid:co-lipid liposomes. Preferably, the concentration of each of the constituent solutions is
10 adjusted prior to mixing such that the desired final pDNA/cationic lipid:co-lipid ratio and the desired pDNA final concentration will be obtained upon mixing the two solutions. For example, if the desired final solution is to be physiological saline (0.9% weight/volume), both pDNA and cationic lipid:co-lipid liposomes are prepared in 0.9% saline and then simply mixed to afford the desired complex.

15 The cationic lipid:co-lipid liposomes are preferably prepared by hydrating a thin film of the mixed lipid materials in an appropriate volume of aqueous solvent by vortex mixing at ambient temperatures for about 1 minute. The thin films are prepared by admixing chloroform solutions of the individual components to afford a desired molar solute ratio followed by aliquoting the desired volume of
20 the solutions into a suitable container. The solvent is removed by evaporation, first with a stream of dry, inert gas (e.g. argon) followed by high vacuum treatment.

Other hydrophobic and amphiphilic additives, such as, for example, sterols, fatty acids, gangliosides, glycolipids, lipopeptides, liposaccharides,
25 neobees, niosomes, prostaglandins and sphingolipids, may also be included in the immunogenic compositions of the present invention. In such compositions, these additives may be included in an amount between about 0.1 mol % and about 99.9 mol % (relative to total lipid). Preferably, these additives comprise about 1-50 mol % and, most preferably, about 2-25 mol %. Preferred additives include
30 lipopeptides, liposaccharides and steroids.

-35-

Nucleic acid molecules and/or polynucleotides of the present invention, e.g., pDNA, mRNA, linear DNA or oligonucleotides, may be solubilized in any of various buffers. Suitable buffers include, for example, phosphate buffered saline (PBS), normal saline, Tris buffer, and sodium phosphate (150 mM preferred). Insoluble polynucleotides may be solubilized in a weak acid or weak base, and then diluted to the desired volume with a buffer. The pH of the buffer may be adjusted as appropriate. In addition, a pharmaceutically acceptable additive can be used to provide an appropriate osmolarity. Such additives are within the purview of one skilled in the art.

10 The choice of polynucleotide form depends in part on the desired kinetics and duration of expression. When long-term delivery of the protein encoded by the polynucleotide is desired, the preferred form is DNA. Alternatively, when short-term transgene protein delivery is desired, the preferred form is mRNA, since RNA is rapidly translated into polypeptide, but is degraded more quickly than DNA.

In one embodiment, the polynucleotides of the present invention is RNA. Preferably, in this embodiment, the RNA is in the form of messenger RNA (mRNA). Methods for introducing RNA sequences into mammalian cells is described in U.S. Patent No. 5,580,859, the disclosure of which is incorporated herein by reference. A viral alphavector, a non-infectious vector useful for administering RNA, may be used to introduce RNA into mammalian cells. Methods for the *in vivo* introduction of alphaviral vectors to mammalian tissues are described in Altman-Hamamdzcic, S., *et al.*, *Gene Therapy* 4, 815-822 (1997), the disclosure of which is incorporated herein by reference. Viral replicons, i.e., non-infectious RNA vectors packaged in a viral coat, e.g., a picornavirus coat or an alphavirus coat, are also useful for efficient administration of RNA. See, e.g., US Patent No. 5,766,602, U.S. Patent No. 5,614,413, and PCT Publication No. WO 95/07994, the disclosures of which are incorporated herein by reference.

25 Preferably, the polynucleotide is DNA. In the case of DNA, a promoter is preferably operably associated with the polynucleotide. The promoter may be

a cell-specific promoter that directs substantial transcription of the DNA only in predetermined cells. Other transcription control elements, besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can be included with the polynucleotide to direct cell-specific transcription of the

5 DNA. An operable association is when a polynucleotide encoding molecule is associated to one or more regulatory sequences in such a way as to place expression of the molecule under the influence or control of the regulatory sequence(s). Two DNA sequences (such as a coding sequence and a promoter region sequence associated with the 5' end of the coding sequence) are operably

10 associated if induction of promoter function results in the transcription of mRNA encoding for the desired antigen and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the expression regulatory sequences to direct the expression of the antigen, or (3) interfere with the ability of the DNA template to

15 be transcribed. Thus, a promoter region would be operably associated with a DNA sequence if the promoter was capable of effecting transcription of that DNA sequence. A variety of transcription control regions are known to those skilled in the art. Preferred transcription control regions include those which function in vertebrate cells, such as, but not limited to, promoter and enhancer sequences

20 from cytomegaloviruses (preferably the intermediate early promoter, preferably in conjunction with intron-A), simian virus 40 (preferably the early promoter), retroviruses (such as Rous sarcoma virus), and picornaviruses (particularly an internal ribosome entry site, or IRES, enhancer region, also referred to herein as a CITE sequence). Other preferred transcription control regions include those

25 derived from mammalian genes such as actin, heat shock protein, bovine growth hormone transcription control regions, as well as other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers as well as lymphokine-inducible promoters (e.g., promoters inducible by interferons or

30 interleukins).

-37-

Preferably, the polynucleotides of the present invention is part of a circular or linearized plasmid containing a non-infectious (i.e., does not infect vertebrate cells), nonintegrating (i.e., does not integrate into the genome of vertebrate cells) polynucleotide. A linearized plasmid is a plasmid that was
5 previously circular but has been linearized, for example, by digestion with a restriction endonuclease. The polynucleotides of the present invention may comprise a sequence which directs the secretion of a polypeptide.

Polynucleotides of the present invention, e.g., pDNA, mRNA, linear DNA or oligonucleotides, may be solubilized in any of various buffers. Suitable
10 buffers include, for example, phosphate buffered saline (PBS), normal saline, Tris buffer, and sodium phosphate (150 mM preferred). Insoluble polynucleotides may be solubilized in a weak acid or weak base, and then diluted to the desired volume with a buffer. The pH of the buffer may be adjusted as appropriate. In addition, a pharmaceutically acceptable additive can be used to provide an
15 appropriate osmolarity. Such additives are within the purview of one skilled in the art.

In certain embodiments, a single antigen- or cytokine-encoding polynucleotide encoding one or more antigens or cytokines can be administered, either simultaneously or sequentially, with a polynucleotide expressing the pFlt-3
20 ligand or variant or fragment thereof as described herein. Alternatively, multiple antigen- or cytokine-encoding polynucleotides each encoding for one or more antigens or cytokines can be co-administered, either simultaneously or sequentially, with a polynucleotide expressing the pFlt-3 ligand or variant or fragment thereof as described herein. Methods of making various nucleic acid
25 molecule constructs comprising antigen- or cytokine-encoding polynucleotides are well known to those skilled in the art of molecular biology, and disclosed, for example, in U.S. Patent Nos. 4,713,339 and 4,965,196, the disclosures of which are incorporated herein by reference.

The immunogenic compositions of the present invention may be
30 administered according to any of various methods known in the art. For example,

-38-

U.S. Patent No. 5,676,954 reports on the injection of genetic material, complexed with cationic lipid carriers, into mice. Also, U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and PCT international patent application PCT/US94/06069 (WO 94/29469), the disclosures of which are incorporated
5 herein by reference, provide methods for delivering DNA-cationic lipid complexes to mammals.

More specifically, the immunogenic compositions of the present invention may be administered to any tissue of a vertebrate, including, but not limited to, muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart,
10 lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, tongue and connective tissue. Preferably, the compositions are administered to muscle, either skeletal or cardiac. Most preferably, the composition is administered to skeletal muscle.

Preferably, the immunogenic compositions of the present invention are
15 administered by intramuscular (i.m.) or subcutaneous (s.c.) routes. Other suitable routes of administration include transdermal, intranasal, inhalation, transmucosal (i.e., across a mucous membrane), intra-cavity (e.g., oral, vaginal, or rectal), and intravenous (i.v.) administration.

Any mode of administration can be used so long as the mode results in
20 the expression of the Flt-3 ligand and one or more antigenic molecules in an amount sufficient to elicit a measurable immune response in a vertebrate. This includes needle injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns" or pneumatic "needleless" injectors -- for example, Med-E-Jet (Vahlsing, H., *et al.*, *J. Immunol. Methods* 171,11-22 (1994)), Pigjet (Schrijver, R., *et al.*, *Vaccine* 15, 1908-1916 (1997)), Biojector (Davis, H., *et al.*, *Vaccine* 12, 1503-1509 (1994); Gramzinski, R., *et al.*, *Mol. Med.* 4, 109-118 (1998)), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppository solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during
30 surgery. The preferred mode of administration is injection.

Determining an effective amount of an immunogenic composition depends upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the subject, the precise condition requiring treatment and its severity, and the route of administration. Based on the above factors, determining the precise amount, number of doses, and timing of doses are within the ordinary skill in the art and will be readily determined by the attending physician or veterinarian.

In certain embodiments, the immunogenic composition is administered as a pharmaceutical composition. Such a pharmaceutical composition can be formulated according to known methods, whereby the substance to be delivered is combined with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their preparation are described, for example, in Remington's Pharmaceutical Sciences, 16th Edition, A. Osol, ed., Mack Publishing Co., Easton, PA (1980), and Remington's Pharmaceutical Sciences, 19th Edition, A.R. Gennaro, ed., Mack Publishing Co., Easton, PA (1995). The pharmaceutical composition can be formulated as an emulsion, gel, solution, suspension, lyophilized form, or any other form known in the art. In addition, the pharmaceutical composition can also contain pharmaceutically acceptable additives including, for example, diluents, binders, stabilizers, and preservatives.

Administration of pharmaceutically acceptable salts of the nucleic acid molecule constructs described herein is preferred. Such salts can be prepared from pharmaceutically acceptable non-toxic bases including organic bases and inorganic bases. Salts derived from inorganic bases include sodium, potassium, lithium, ammonium, calcium, magnesium, and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, basic amino acids, and the like.

For aqueous pharmaceutical compositions used *in vivo*, use of sterile pyrogen-free water is preferred. Such formulations will contain an effective amount of the immunogenic composition together with a suitable amount of

vehicle in order to prepare pharmaceutically acceptable compositions suitable for administration to a vertebrate.

The present invention can be used in connection with the prophylactic and/or therapeutic treatment of vertebrate infections arising from pathogens of various species, by administering into the tissues of the vertebrate a polynucleotide encoding a suitable antigen from a given pathogen, in combination with a polynucleotide encoding a Flt-3 ligand, or an active variant, or fragment thereof as described herein. Examples of such antigens include, but are not limited to bacterial antigens, viral antigens, parasite antigens, and fungal antigens. Examples of viral antigens include, but are not limited to, adenovirus antigens, alphavirus antigens, calicivirus antigens, e.g., a calicivirus capsid antigen, coronavirus antigens, distemper virus antigens, Ebola virus antigens, enterovirus antigens, flavivirus antigens, hepatitis virus (A-E) antigens, e.g., a hepatitis B core or surface antigen, herpesvirus antigens, e.g., a herpes simplex virus or varicella zoster virus glycoprotein antigen, immunodeficiency virus antigens, e.g., a human immunodeficiency virus envelope or protease antigen, infectious peritonitis virus antigens, influenza virus antigens, e.g., an influenza A hemagglutinin or neuraminidase antigen, leukemia virus antigens, Marburg virus antigens, oncogenic virus antigens, orthomyxovirus antigens, papilloma virus antigens, parainfluenza virus antigens, e.g., hemagglutinin/neuraminidase antigens, paramyxovirus antigens, parvovirus antigens, pestivirus antigens, picorna virus antigens, e.g., a poliovirus capsid antigen, pox virus antigens, e.g., a vaccinia virus antigen, rabies virus antigens, e.g., a rabies virus glycoprotein G antigen, reovirus antigens, retrovirus antigens, rotavirus antigens, as well as other cancer-causing or cancer-related virus antigens. Examples of bacterial antigens include, but are not limited to, *Actinomyces*, antigens *Bacillus* antigens, *Bacteroides* antigens, *Bordetella* antigens, *Bartonella* antigens, *Borrelia* antigens, e.g., a *B. bergdorferi* OspA antigen, *Brucella* antigens, *Campylobacter* antigens, *Capnocytophaga* antigens, *Chlamydia* antigens, *Clostridium* antigens, *Corynebacterium* antigens, *Coxiella* antigens, *Dermatophilus* antigens,

Enterococcus antigens, *Ehrlichia* antigens, *Escherichia* antigens, *Francisella* antigens, *Fusobacterium* antigens, *Haemobartonella* antigens, *Haemophilus* antigens, e.g., *H. influenzae* type b outer membrane protein antigens, *Helicobacter* antigens, *Klebsiella* antigens, L-form bacteria antigens, *Leptospira* antigens, *Listeria* antigens, *Mycobacteria* antigens, *Mycoplasma* antigens, *Neisseria* antigens, *Neorickettsia* antigens, *Nocardia* antigens, *Pasteurella* antigens, *Peptococcus* antigens, *Peptostreptococcus* antigens, *Pneumococcus* antigens, *Proteus* antigens, *Pseudomonas* antigens, *Rickettsia* antigens, *Rochalimaea* antigens, *Salmonella* antigens, *Shigella* antigens, *Staphylococcus* antigens, *Streptococcus* antigens, e.g., *S. pyogenes* M protein antigens, *Treponema* antigens, and *Yersinia* antigens, e.g., *Y. pestis* F1 and V antigens.

Examples of fungal antigens include, but are not limited to, *Absidia* antigens, *Acremonium* antigens, *Alternaria* antigens, *Aspergillus* antigens, *Basidiobolus* antigens, *Bipolaris* antigens, *Blastomyces* antigens, *Candida* antigens, *Coccidioides* antigens, *Conidiobolus* antigens, *Cryptococcus* antigens, *Curvalaria* antigens, *Epidermophyton* antigens, *Exophiala* antigens, *Geotrichum* antigens, *Histoplasma* antigens, *Madurella* antigens, *Malassezia* antigens, *Microsporum* antigens, *Moniliella* antigens, *Mortierella* antigens, *Mucor* antigens, *Paecilomyces* antigens, *Penicillium* antigens, *Phialemonium* antigens, *Phialophora* antigens, *Prototheca* antigens, *Pseudallescheria* antigens, *Pseudomicrodochium* antigens, *Pythium* antigens, *Rhinosporidium* antigens, *Rhizopus* antigens, *Scolecobasidium* antigens, *Sporothrix* antigens, *Stemphylium* antigens, *Trichophyton* antigens, *Trichosporon* antigens, and *Xylohypha* antigens.

Examples of protozoan parasite antigens include, but are not limited to, *Babesia* antigens, *Balantidium* antigens, *Besnoitia* antigens, *Cryptosporidium* antigens, *Eimeri* antigens *a* antigens, *Encephalitozoon* antigens, *Entamoeba* antigens, *Giardia* antigens, *Hammondia* antigens, *Hepatozoon* antigens, *Isospora* antigens, *Leishmania* antigens, *Microsporidia* antigens, *Neospora* antigens, *Nosema* antigens, *Pentatrichomonas* antigens, *Plasmodium* antigens, e.g., *P. falciparum* circumsporozoite (PfCSP), sporozoite surface protein 2 (PfSSP2),

carboxyl terminus of liver stage antigen 1 (PfLSA-1 c-term), and exported protein 1 (PfExp-1) antigens, *Pneumocystis* antigens, *Sarcocystis* antigens, *Schistosoma* antigens, *Theileria* antigens, *Toxoplasma* antigens, and *Trypanosoma* antigens.

Examples of helminth parasite antigens include, but are not limited to,

5 *Acanthocheilonema* antigens, *Aelurostrongylus* antigens, *Ancylostoma* antigens, *Angiostrongylus* antigens, *Ascaris* antigens, *Brugia* antigens, *Bunostomum* antigens, *Capillaria* antigens, *Chabertia* antigens, *Cooperia* antigens, *Crenosoma* antigens, *Dictyocaulus* antigens, *Diectophyme* antigens, *Dipetalonema* antigens, *Diphyllobothrium* antigens, *Diplydium* antigens, *Dirofilaria* antigens,

10 *Dracunculus* antigens, *Enterobius* antigens, *Filaroides*,antigens *Haemonchus* antigens, *Lagochilascaris* antigens, *Loa* antigens, *Mansonella* antigens, *Muellerius* antigens, *Nanophyetus* antigens, *Necator* antigens, *Nematodirus* antigens, *Oesophagostomum* antigens, *Onchocerca* antigens, *Opisthorchis* antigens, *Ostertagia* antigens, *Parafilaria* antigens, *Paragonimus* antigens,

15 *Parascaris* antigens, *Physaloptera* antigens, *Protostrongylus* antigens, *Setaria* antigens, *Spirocerc*a,antigens *Spirometra* antigens, *Stephanofilaria* antigens, *Strongyloides* antigens, *Strongylus* antigens, *Thelazia* antigens, *Toxascaris* antigens, *Toxocara* antigens, *Trichinella* antigens, *Trichostrongylus* antigens, *Trichuris* antigens. *Uncinaria* antigens, and *Wuchereria* antigens.

20 Examples of ectoparasite antigens include, but are not limited to, antigens (including protective antigens as well as allergens) from fleas; ticks, including hard ticks and soft ticks; flies, such as midges, mosquitos, sand flies, black flies, horse flies, horn flies, deer flies, tsetse flies, stable flies, myiasis-causing flies and biting gnats; ants; spiders, lice; mites; and true bugs, such as bed bugs and kissing

25 bugs.

Examples of tumor-associated antigens include, but are not limited to, a tumor-specific immunoglobulin variable region, a GM2 antigen, a Tn antigen, an sTn antigen, a Thompson-Friedenreich antigen (TF), a Globo H antigen, an Le(y) antigen, a MUC1 antigen, a MUC2 antigen, a MUC3 antigen, a MUC4 antigen,

30 a MUC5AC antigen, a MUC5B antigen, a MUC7 antigen, a carcinoembryonic

-43-

antigen, a beta chain of human chorionic gonadotropin (hCG beta) antigen, a HER2/neu antigen, a PSMA antigen, a EGFRvIII antigen, a KSA antigen, a PSA antigen, a PSCA antigen, a GP100 antigen, a MAGE 1 antigen, a MAGE 2 antigen, a TRP 1 antigen, a TRP 2 antigen, and a tyrosinase antigen.

5 Also included in the present invention are fragments or variants of the foregoing antigens, and any combination of the foregoing antigens. Additional antigens may be found, for example in "Foundations in Microbiology," Talaro, *et al.*, eds., McGraw-Hill Companies (Oct.,1998), Fields, *et al.*, "Virology," 3d ed., Lippincott-Raven (1996), "Biochemistry and Molecular Biology of
10 Parasites," Marr, et al., eds., Academic Press (1995), and Deacon, J., "Modern Mycology," Blackwell Science Inc (1997), which are incorporated herein by reference.

 In a preferred embodiment, the present invention can be applied as a prophylactic and/or therapeutic treatment of vertebral diseases associated with
15 parasites such as malaria. Preferred antigens encoded for such application includes pre-erythrocytic antigens from the human malaria parasite *Plasmodium falciparum* including circumsporozoite protein (PfCSP), sporozoite surface protein 2 (PfSSP2), carboxyl terminus of liver stage antigen 1 (PfLSA-1 c-term), exported protein 1 (PfExp-1), any fragment thereof, and any combination thereof.

20 In another preferred embodiment, the present invention can be applied as a prophylactic and/or therapeutic treatment for Aujeszky's disease (AD) in pigs caused by the alphaherpesvirus pseudorabies virus (PrV), also designated as *Suid Herpesvirus 1*.

 In yet another preferred embodiment, the present invention can be applied
25 as a prophylactic and/or therapeutic treatment for hepatitis B and C in human patients caused by hepatitis B virus (HBV) and hepatitis C virus (HCV).

 The present invention can also be applied in immunologically-based therapeutic and/or prophylactic treatments of cancer including, but not limited to, cancers of oral cavity and pharynx (i.e., tongue, mouth, pharynx), digestive
30 system (i.e., esophagus, stomach, small intestine, colon, rectum, anus, anal canal,

-44-

anorectum, liver, gallbladder, pancreas), respiratory system (i.e., larynx, lung), bones, joints, soft tissues (including heart), skin, melanoma, breast, reproductive organs (i.e., cervix, endometrium, ovary, vulva, vagina, prostate, testis, penis), urinary system (i.e., urinary bladder, kidney, ureter, and other urinary organs),
5 eye, brain, endocrine system (i.e., thyroid and other endocrine), lymphoma (i.e., B-cell lymphoma including non-hodgkin's lymphoma, hodgkin's disease), multiple myeloma, leukemia (i.e., acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia). Antigens to include in an immunogenic composition of the present invention are
10 described, e.g., in Chamberlain, *Drugs* 57(3):309-25 (March, 1999), Nawrocki and Mackiewicz, *Cancer Treat Rev* 25(1):29-46 (Feb., 1999), Rosenberg, *Immunity* 10(3):281-7 (Mar., 1999), Rosenberg *et al.*, *Adv Caner Res* 70:145-77 (1996), Pandey *et al.*, *Eur J Surg Oncol* 25(2):209-14 (Apr., 1999), Herlyn *et al.*, *Ann Med.* 31(1):66-78 (Feb., 1999), and Rosenberg, *Immunol Today* 18(4):175-82
15 (Apr., 1997), which are incorporated herein by reference.

In a preferred embodiment the present invention can be applied as a therapeutic treatment of B-cell lymphoma through the use of a polynucleotide encoding an antigen comprising a variable region of an immunoglobulin expressed by the B-cell lymphoma containing tumor-specific idiotype
20 determinants and a constant region.

An additional embodiment of the present invention is directed to combining any of the cancer treatment methods of the present invention with one or more additional cancer therapies including, but not limited to bone marrow transplant, cord blood cell transplant, surgery, chemotherapy, radiation therapy,
25 and immunotherapy. The polynucleotide, nucleic acid molecule construct(s), immunogenic composition or pharmaceutical composition of the present invention can be administered prior to the commencement of one or more of the additional cancer therapies, during the practice of one or more of the additional cancer therapies, and after the end of one or more of the additional cancer
30 therapies.

-45-

Types of bone marrow transplant include, but are not limited to autologous bone marrow transplant and heterologous (*i.e.*, from a donor) bone marrow transplant.

Types of surgery include, but are not limited to surgery for breast cancer,
5 prostate cancer, colon cancer, brain cancer, and head and neck cancer.

Chemotherapeutic agents include, but are not limited to alkylating agents, including mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, dicarbazine, streptazocine, carmustine, lomustine, semustine, chlorozotocin, busulfan, triethylenemelamine, thiotepa, hexamethylmelamine;
10 antimetabolites, including methotrexate; pyrimidine analogs, including fluorouracil, 5-fluorouracil, floxuridine (5'-fluoro-2'-deoxyuridine), idoxuridine, cytarabine, N-phosphonoacetyl-L-aspartate, 5-azacytidine, azaribine, 6-azauridine, pyrazofuran, 3-deazauridine, acivicin; purine analogs, including thioguanine, mercaptopurine, azathioprine, pentostatin,
15 erythrohydroxynonyladenine; vinca alkaloids, including vincristine and vinblastine; epipodophyllotoxins, including etoposide and teniposide; antibiotics, including dactinomycin, daunorubicin, doxorubicin, bleomycin sulfate, plicamycin, mitomycin; enzymes, including L-asparaginase; platinum coordination complexes, including cisplatin, carboplatin; hydroxyurea,
20 procarbazine, mitotane; and hormones or related agents, including adrenocorticosteroids such as prednisone and prednisolone; aminoglutethimide; progestins such as hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, estrogens and androgens such as diethylstilbestrol, fluoxymesterone, ethynyl estradiol, antiestrogens such as tamoxifen, and
25 gonadotropin-releasing hormone analogs such as leuprolide.

The present invention may also be applied in the therapeutic and/or prophylactic treatment of autoimmune diseases such as rheumatoid arthritis and osteoarthritis.

The present invention also provides kits for use in immunotherapy
30 comprising an administration means and a container means containing a Flt-3

-46-

ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides in a sterile environment. Also provided are kits for use in immunotherapy comprising an administration means and a container means containing a Flt-3 ligand-encoding polynucleotide, one or more antigen- or cytokine-encoding polynucleotides, and one or more cationic lipid compounds in a sterile environment. Examples of cationic lipid compounds are described above. The nucleic acid molecule constructs comprising a Flt-3 ligand-encoding polynucleotide, one or more antigen- or cytokine-encoding polynucleotides and the cationic lipid compounds may be in the same container means or in separate container means. Preferably, the polynucleotides are in the amount of 1 ng to 30 mg.

Container means include glass containers, plastic containers, or strips of plastic or paper. In one embodiment, the container means is a syringe and the administration means is a plunger. In another embodiment, the administration means is a catheter. The construct can be in the form of a pharmaceutical composition and can contain a pharmaceutically acceptable carrier. Pharmaceutical compositions are described above. The kit can further comprise a pharmaceutically acceptable carrier in a separate container means.

The kit can further comprise an instruction sheet for administration of the composition into a mammal. The polynucleotide components of the pharmaceutical composition are preferably provided as a liquid solution, such as a suspension, a solution, or an emulsion; or in lyophilized form as a dried powder or a cake. If the nucleic acid molecule construct(s) comprising a Flt-3 ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides are provided in lyophilized form, preferably the kit further comprises a container means containing a suitable vehicle, such as sterile pyrogen-free water, for reconstitution of the lyophilized nucleic acid molecule construct(s) comprising a Flt-3 ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides, or any buffer described herein, including PBS, normal saline, Tris buffer, and sodium phosphate vehicle.

-47-

The container in which the pharmaceutical composition is packaged prior to use can comprise a hermetically sealed container enclosing an amount of the lyophilized formulation or a solution containing the formulation suitable for a pharmaceutically effective dose thereof, or multiples of an effective dose. The pharmaceutical composition is packaged in a sterile container, and the hermetically sealed container is designed to preserve sterility of the pharmaceutical formulation until use. Optionally, the container can be associated with administration means and or instruction for use.

Having now generally described the invention, the same will become more readily understood by reference to the following specific examples which are included herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.

Described herein are: 1) the prophylactic application of a Flt-3 ligand-encoding polynucleotide in combination with a tumor specific antigen-encoding polynucleotide in a murine system; 2) a treatment regimen for using a Flt-3 ligand-encoding polynucleotide in combination with a tumor specific antigen-encoding polynucleotide in a humans; 3) prophylactic application of a Flt-3 ligand-encoding polynucleotide in combination with a malarial antigen-encoding polynucleotide in humans; 4) prophylactic application of a Flt-3 ligand-encoding polynucleotide in combination with a hepatitis B antigen-encoding polynucleotide; and 5) a treatment regimen with a Flt-3 ligand-encoding polynucleotide in combination with a hepatitis B or C antigen encoding polynucleotide for treatment of patients with chronic hepatitis.

*Example 1**Prophylactic Application of Flt-3 Ligand-encoding pDNA in
Combination with Tumor-specific Antigen-encoding pDNA in Murine
System*

5

The purpose of the present example is to demonstrate the ability of the present invention to enhance protection from tumor challenge in murine B-cell lymphoma model.

The 38C13 murine B-cell lymphoma tumor cell line displays a surface
10 immunoglobulin with a unique idiotype (Id). This idiotype is used as a tumor-specific antigen in immunization protocols designed to test various vaccine strategies. However, an anti-idiotypic antibody response may be necessary but is not sufficient to protect vaccinated mice from tumor challenge (Sternas LA *et al.*, *Cancer Treat. Res.* 99:267-273(1999); Kwak LW *et al.*, *Proc. Natl. Acad. Sci. U*
15 *S A* 93:10972-10977 (1996); King CA *et al.*, *Nat. Med.* 4:1281-1286 (1998); Haimovich J *et al.*, *Cancer Immunol. Immunother.* 47:330-336 (1999). Also, the generation of an anti-Id CTL response correlates with a better outcome in human non-Hodgkin's lymphoma patients (Nelson EL *et al.*, *Blood* 88:580-589 (1996)), and antibody depletion studies have shown that both CD4 and CD8 cellular
20 responses are required for protection (Kwak LW *et al.*, *Proc. Natl. Acad. Sci. U S A* 93:10972-10977 (1996); Biragyn A *et al.*, *Nat. Biotechnol.* 17:253-258 (1999).

The experimental vaccine protocol of the present example utilizes a human/mouse chimeric immunoglobulin DNA construct (pId). The light and
25 heavy chain variable regions of the 38C13 immunoglobulin cDNA are fused in-frame with the respective xenogeneic human kappa and gamma constant region sequences. The human constant region portion contains T helper epitopes that stimulate a robust CD4 response that is required for protection. The vector used in the present invention, VR-1623, comprises a bicistronic CITE sequence which
30 allows both chains of the immunoglobulin molecule to be expressed from a single

-49-

RNA transcript. This plasmid is co-injected with a Flt-3 ligand-encoding pDNA to demonstrate the immunogenicity enhancement activity of the pFlt-3 ligand on pId.

5 Preparation of pDNAs

VR6200 expresses a secreted form of murine Flt-3 ligand. Total bone marrow RNA was isolated from a single C57Bl/6 mouse using a Qiagen Rneasy Mini Kit (Valencia, CA, catalog # 74103) according to the manufacturer's protocol. Briefly, the bone marrow cells were flushed from the femurs with
10 sterile PBS using a 28 gauge needle. The bone marrow cells were pelleted by centrifugation, resuspended in Qiagen lysis buffer, and the protocol followed. Approximately 150 µg of total RNA was obtained.

First strand cDNA was synthesized from 5 µg of the bone marrow total RNA using the SuperScript Preamplification System (Life Technologies, Inc.,
15 Gaithersburg, MD. catalog# 18089-011). Two µl of bone marrow cDNA was used in a 50 µl PCR reaction using native *Pfu* polymerase from Stratagene (La Jolla, CA. catalog # 600136) with the supplied buffer. The forward PCR primer CAC GAA TTC GCC GCC ACC ATG ACA GTG CTG GCG CCA (SEQ ID NO:25) and the reverse primer GCC GCT AGC TCA CTG CCT GGG CCG
20 AGG CTC T (SEQ ID NO:26) were synthesized by Sigma-Genosys (The Woodlands, TX). The forward primer codes for an *EcoRI* restriction site followed by a consensus Kozak sequence followed by the Flt-3 ligand ATG start site and coding region. The reverse primer codes for an *NheI* restriction site, and places a stop codon just 5' of the transmembrane region. The final cDNA
25 construct contains nucleotides 32 through 598 of the Flt-3 ligand cDNA (GenBank accession # L23636, denoted herein as SEQ ID NO:7). The construct codes for a secreted form of murine Flt-3 ligand lacking the transmembrane and cytoplasmic domains, and having the amino acid sequence denoted herein as SEQ ID NO:9. This form of murine Flt-3 ligand has been shown to be biologically
30 active. (McClanahan, *et al., ibid.*)

-50-

The PCR cycling conditions were 94°C for 5 minutes followed by 30 cycles of: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute. The PCR product was digested with *EcoRI* and *NheI* and cloned into the same sites of the plasmid VR-1051 (Norman *et al.*, *Vaccine* 1997 Jun;15(8):801-3) using
5 standard molecular biology techniques. Individual clones were then sequenced (Retrogen Inc., San Diego, CA), and a perfect clone was named VR6200 (SEQ ID NO:6).

VR1605 is a generic cloning vector containing the constant regions of the human kappa light chain and gamma 1 heavy chain separated by a CITE (cap
10 independent translational enhancer) sequence. VR1605 was constructed in three steps. (1) The CITE sequence was PCR amplified from the vector pCITE (Novagen, Madison, WI) using the primers 5'- AAA ACT GCA GGC CTT GCT GGC CAC GCG TTA TTT TCC ACC ATA TT -3' (SEQ ID NO:27) and 5'- CGC GGA TCC GGC CGC TGC GGC CAT GGT ATT ATC ATC -3' (SEQ ID
15 NO:28). The PCR cycling conditions were 94°C for 5 minutes followed by 30 cycles of: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute. The 535-bp CITE fragment was cloned into the *PstI* - *BamHI* sites of VR1012 (Norman *et al.*, *Vaccine* Jun;15(8):801-3 (1997)) to create VR1031. (2) The human Kappa constant region was PCR amplified from peripheral blood cDNA
20 (prepared as in the Flt-3 ligand cDNA example above) using the primer set 5'- CGA CGC GTG TGG CTG CAC CAT CTG TCT GGC CCT TCC GGC CAT CTG ATG AGC AGT TG -3' (SEQ ID NO:29) and 5'- CGA CGC GTT CAA CAC TCT CCC CTG TTG AAG CT -3' (SEQ ID NO:30). The PCR cycling conditions were 94°C for 5 minutes followed by 30 cycles of: 94°C for 30
25 seconds, 55°C for 30 seconds, and 72°C for 1 minute. The 320-bp fragment was cloned into VR1031 as an *MluI* fragment to create VR1603. (3) The human Gamma 1 constant region was PCR amplified from peripheral blood cDNA using the primer set 5'- GGA AGA TCT ACC AAG GGC CCA TCG GGC CTC TCC CCC TGG CAC CCT CC -3' (SEQ ID NO:31) and 5'- GGA AGA TCT CAG
30 GAT CTC GGA GAC AGG GAG AGG CT -3' (SEQ ID NO:32). The PCR

-51-

cycling conditions were 94°C for 5 minutes followed by 30 cycles of: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute. The 980-bp fragment was cut with *Bgl*II and *Bam*HI and cloned into the *Bam*HI site of VR1603 to create VR1605 (SEQ ID NO:2). This vector contains the human kappa and gamma 1 constant regions but no variable regions; therefore it does not express a functional protein. It serves as a negative control for the vaccination studies.

VR1623 is a bicistronic chimeric Id vector. For its construction, murine variable region cDNAs were cloned into VR1605 to have a chimeric heavy and light chain surface immunoglobulin expressed from a single mRNA transcript.

10 The variable (V) heavy and light chain segments of the immunoglobulin expressed by 38C13 cells were PCR amplified from pld obtained from Ronald Levy (Syrengelas, *et al.*, *Nat. Med.*, 2:1038-1041 (1996)).

The murine V kappa segment was PCR amplified with the primer set 5'-CTG CAG AAG GCC TTG CTG GCC GCC ATG GGA CCG TCT GTT CAG TTC -3' (SEQ ID NO:33) and 5'- TGG TGC GGC CAC CGT GGC CTT TAT TTC CAA CTT G -3' (SEQ ID NO:34). The PCR cycling conditions were 94°C for 5 minutes followed by 30 cycles of: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute.

The murine V heavy segment was PCR amplified with the primer set 5'-CTG CAG AAG GCC GCA GCG GCC GAG TTG TGG CTG AAC TGG ATT TTC -3' (SEQ ID NO:35) and 5'- CCG ATG GGC CCT TGG GGC CAG CTG AGG AGA CGG T -3' (SEQ ID NO:36). The PCR cycling conditions were 94°C for 5 minutes followed by 30 cycles of: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute.

25 The 38C13 light chains were cloned into VR1605 in a single step as unique *Sfi*I fragments due to the unique five-bp N internal sequence of each *Sfi*I site, to create plasmid VR1623 (SEQ ID NO:1). The kappa variable segment includes nucleotides 1497 to 1890 of the vector VR1623, and the heavy chain variable region includes nucleotides 2723 to 3171 of the vector VR1623.

-52-

Plasmid DNA was transformed into *Escherichia coli* DH10B-competent cells, and a single colony was grown in Terrific Broth (Sambrook, *et al.*, *ibid.*, p. A.2 (1989)) complemented with 30 mg/ml kanamycin in a 2.8 L Fernbach flask at 37°C for approximately 20 hours.

5 Large scale plasmid isolation was carried out using the procedure and reagents supplied by the Qiagen EndoFree Plasmid Giga kit (catalog # 12391). The DNA was precipitated with isopropanol and resuspended in 150 mM Na₂PO₄, pH 7. The concentration was determined by UV spectroscopy.

10 *FLT-3 Ligand in Vitro Expression Demonstrated by Western Blot Analysis*

 Expression of Flt-3 ligand protein from plasmid VR6200 was demonstrated in eukaryotic cells by the following method. UM449 cells (kindly provided by Mark Cameraon and Dr. Gary Nabel at the University of Michigan)
15 were transfected with 5 µg of VR6200 or VR1051, formulated with DMRIE/DOPE (2:1 lipid/DNA molar ratio). Forty eight hours later, culture media was collected and the transfected cells were lysed in 250 µl of 1X cell lysis buffer (Promega, Madison WI, catalog # E153A). The supernatant and cell lysate were assayed for Flt-3 ligand expression by Western blot analysis using standard
20 procedures.

-53-

Briefly, 20 μ l of supernatant and cell lysate was added to an equal volume of sample buffer (NOVEX, San Diego, CA, catalog # LC3675), boiled for 10 minutes and loaded on a 4-20% Tris-Glycine SDS polyacrylamide gel (NOVEX, catalog # EC6025) and electrophoresed according to the manufacturer's instructions. The gel was blotted onto Immobilon-P membrane (Millipore Corp., Bedford, MA, Fisher catalog # IPUH-000-10) and hybridized with polyclonal anti-mouse Flt-3 ligand antiserum (R & D Systems, Inc., Minneapolis, MN, catalog # AF427). The antiserum was diluted 1:1000 in BBS (1X BBS: 200 mM Boric acid, 90 mM NaCl, pH8.3) before use. The secondary antibody used for detection was rabbit anti-Goat IgG Alkaline Phosphatase (1:1000 dilution in BBS) (Jackson ImmunoResearch Laboratories, Inc., Bar Harbor, ME, catalog #305-055-088).

The Western blot showed three bands of molecular weight between 20K-32K daltons reflecting the multiple glycosylation products of Flt-3 ligand (McClanahan *et al.*, *Blood* 1996 Nov 1;88(9):3371-82).

Cell lines and tumor models

The 38C13 B cell lymphoma line (Bergman *et al.*, *Eur. J. Immunol.* 7:413-417(1977) was obtained from Dr. Ron Levy at Stanford University. A working cell bank of passage # 4 38C13 cells was established and maintained at -80°C using standard tissue culture methods. For the experimental tumor cell challenge, 38C13 cells were grown for 48 hours in RPMI 1640, 10% heat-inactivated FCS, 2mM L-glutamine, 100U/ml penicillin, 100 μ g/ml streptomycin, and 50 μ M β -ME at 37°C, 5% CO₂ in a humidified incubator. The cells were washed three times in RPMI, and diluted to 1,000 cells/ml. Mice were injected intraperitoneally (i.p.) with 500 cells (0.5ml) two weeks after the last DNA immunization.

-54-

Animal Immunizations

Animal care throughout the study was in compliance with the "Guide for the Use and Care of Laboratory Animals," U.S. Department of Health and Human Services, National Institutes of Health (NIH Publication No. 86-23, revised 5 1985). C3H/HeN female mice were ordered from Harlan Sprague Dawley Inc. (HSD, San Diego, CA) at 5 to 6 weeks of age. Groups of 10 mice each were used for each study. Each mouse received multiple injections of 100 μ l (50 μ l/leg) of a DNA mixture containing 100 μ g of VR1623 or VR1605, and 100 μ g of VR6200 or VR1051 in 150mM NaH₂PO₄ (pH7). Mice were immunized with 10 DNA intramuscularly by bilateral injection in the rectus femoris. At least one week after the last DNA injection all mice were bled for serum. Two weeks after the last DNA injection, mice were challenged with 500 38C13 tumor cells injected intraperitoneally. All animals were monitored daily, and moribund animals were euthanized.

15

38C13 IgG Anti-Id Antibody Levels in Vaccinated Animals

Serum collected from the animals was tested for Anti-Id IgG antibody levels by serial dilution using a standard ELISA assay. Briefly, the levels of anti-Id IgG antibodies in mouse sera were determined utilizing 38C13 idiotype protein 20 purified from ascites (38c131.2), by Southern Biotechnology Associates Inc. (Birmingham, AL). ELISA plates were coated with 38C13 (2 μ g/ml) and incubated overnight at 4°C. The plates were then washed, blocked with 5% nonfat milk, and incubated with dilutions of the mouse sera for 2-4 hr at room temperature. The plates were then washed and incubated with alkaline 25 phosphatase-conjugated goat anti-mouse Fc-specific IgG (Jackson ImmunoResearch Laboratories Inc., Bar Harbor, ME) for 2 hr at room temperature, washed again, and incubated with substrate (p-nitrophenylphosphate) for 30min at room temperature. O.D. readings were taken at 405 nm using an ELISA plate reader (Molecular Devices, Menlo Park, CA). 30 Serum antibody levels were determined by comparing serum titration curves with

-55-

a standard curve obtained with a known concentration of an affinity-purified anti-Id monoclonal antibody (S1C5) (Southern Biotechnology Associates Inc. Birmingham, AL).

5 *Immune Response Enhancement*

As shown in Figures 7 and 8, soluble Flt-3 ligand greatly enhanced the immunogenicity of co-injected naked DNA encoding the idiotype antigen as measured by increased tumor protection and antibody titer. Three groups of mice were used in the study. One group (n=9) was co-injected with VR6200 and
10 VR1623 (100 µg each) on days 0, 14, and 28, and challenged with 5×10^2 38C13 tumor cells two weeks following the last injection. control groups (n=10 each) were co-injected with VR1623 and VR1051, or VR1605 or alone (200µg) on days 0, 14, and 28, and challenged with 5×10^2 38C13 tumor cells two weeks following the last injection.

15 The co-injection of a Flt-3 ligand-encoding plasmid (100 µg of VR6200) with a tumor-specific antigen-encoding plasmid (100 µg of VR1623) significantly enhanced protection from tumor challenge (Figure 7). Eight out of nine mice injected with VR1623 and VR6200 survived the challenge as compared to zero out of ten mice surviving after being immunized with VR1623 and the control
20 plasmid, VR1051. This increased survival was statistically significant $p=0.00007$. Furthermore, the co-injection of a Flt-3 ligand-encoding plasmid (VR6200) with an idiotype antigen-encoding plasmid (VR1623) resulted in greatly enhanced anti-Id antibody titer relative to mice injected with VR1623 and VR1051, or with VR1623 alone (Figure 8 and Table 1).

Table 1: Serum Anti-IgG ng/ml (prebleed subtracted)				
Animal #	PNegative VR1605	pId VR1623	pId+pBlank VR1623+1051	pId+pFlt-3 lig VR1623+6200
1	0	0	0	13359
2	0	17401	0	13333
3	0	0	0	24050
4	0	511	0	51577
5	0	2851	3090	2203
6	0	3500	0	9
7	0	0	0	22277
8	0	1539	0	25375
9	0	0	3040	527
10	0	0	2156	

pFlt3-ligand mode of action

Flt-3 ligand protein administration has been shown to have anti-tumor effects (Chen K *et al.*, *Cancer Res.* 1997, 57:3511-3516; Lynch DH, *Crit. Rev. Immunol.* (1998) 18:99-107.). To test whether Flt-3 ligand protein encoded *in vivo* by a plasmid vector (i.e. VR6200) acts in a similar manner in tumor protection, the survival of mice vaccinated with pId (VR1623) and pFlt-3 ligand (VR6200) was compared with the survival of mice vaccinated with pNegative (VR1605) and pFlt-3 ligand (VR6200). Four groups of mice (n=10 per group) were injected on days 0 and 7 with either VR1623 or VR1605 in combination with either VR6200 or VR1051 (100 µg of each pDNA), and challenged with 5×10^2 38C13 tumor cells two weeks following the last injection.

As shown in Figure 9, pFlt-3 ligand increased the protection of mice only when co-injected with pId. Injection of pFlt-3ligand without pId (pNegative + pFlt-3ligand group) was as ineffective as injecting negative control plasmids i.e. no protection. This shows that Flt-3 ligand delivered via plasmid DNA, by itself, is not likely to produce systemic anti-tumor activity. Rather, the Flt-3 ligand plasmid acts to enhance the immune response to a co-injected plasmid encoding an antigen.

-57-

Example 2***Treatment Regimen Using DNA Vaccine Encoding Tumor-Specific Idiotypic and Flt-3Ligand for Patients with B-Cell Lymphoma***

To prevent relapse of B-cell lymphoma, patients with non-Hodgkin's B-cell lymphoma are recruited, and a lymph node biopsy is obtained from each patient to produce a custom Id DNA vaccine comprising (1) pDNA encoding human Flt-3 ligand; and (2) pDNA encoding immunoglobulins expressed by each patient's tumor; in a pharmaceutically acceptable vehicle according to the method described below. All patients then receive standard chemotherapy wherein the timing and choice are determined by their physician. The therapy is continued until the patients achieve maximal response. Immunizations are initiated approximately 2 months after the completion of the chemotherapy wherein the patients are in remission period. Patients are injected with 0.8 to 2.0 mg each of pFlt-3lig and pId on day 0 and then 2, 6, 10, and 20 weeks later in alternate deltoids with the DNA vaccine encoding their own tumor Ig protein as described above. Patients are observed for toxicity, immune responses, and tumor status using standard procedures described below for 6-7 years from diagnosis and 5-6 years from the last chemotherapy given before vaccine treatment.

20

Preparation of pDNAs.

VR6230 contains a secreted form of human Flt-3 ligand cDNA. Total RNA from human bone marrow and peripheral blood cells was made with the Qiagen Rneasy Mini Kit as described in Example 1, above. The forward PCR primer GCG GAA TTC GCC GCC ACC ATG ACA GTG CTG GCG CCA GC (SEQ ID NO:37) and the reverse primer GCG GCT AGC TCA AGG GGG CTG CGG GGC TG (SEQ ID NO:38) were synthesized by Sigma-Genosys (The Woodlands, TX), based on the sequence of a human Flt-3 ligand cDNA sequence (GenBank accession #NM 001459, SEQ ID NO:22). The forward primer codes for an *Eco*RI restriction site followed by a consensus Kozak sequence followed

30

-58-

by the Flt-3 ligand ATG start site and coding region. The reverse primer codes for an *NheI* restriction site followed by a stop codon and coding sequence just 5' of the transmembrane region. The final cDNA construct contains nucleotides 93 through 647 of the Flt-3 ligand cDNA, encoding a polypeptide having amino acid
 5 sequence SEQ ID NO:24. The construct codes for a secreted form of human Flt-3 ligand lacking the transmembrane and cytoplasmic domains.

The PCR cycling conditions were 94°C for 5 minutes followed by 30 cycles of: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute. The PCR product was digested with *EcoRI* and *NheI* and cloned into the same sites
 10 of the plasmid VR-1051 (Norman *et al., ibid.*) using standard molecular biology techniques. Individual clones were then sequenced (Retrogen Inc., San Diego, CA), and a perfect clone was named VR6230 (SEQ ID NO:39).

The vector VR-1632 was designed to serve as a generic bicistronic human vaccine vector that contains the murine kappa light chain and gamma 1 heavy
 15 chain constant regions. Human tumor-specific variable regions are cloned into VR-1632 to produce a chimeric immunoglobulin analogous to the chimeric murine vaccine VR-1623. The tumor-specific light and heavy chain variable regions will be cloned into VR-1632 using unique *Sfi* I restriction sites, by a strategy similar to that outlined for VR1623 in Example 1 above. The murine
 20 kappa light and gamma 1 heavy chain constant regions were amplified from peripheral blood lymphocyte cDNA prepared as above and cloned into VR-1031 to create VR1632. The PCR primers used to amplify the murine kappa light chain constant region were: 5'-GGC GGC GGC CGA TGC GGC CCC AAC TGT ATC CAT CTT CCC A-3' (SEQ ID NO:40) and 5'- GCG GCG ACG CGT
 25 TCA ACA CTC ATT CCT GTT GAA G -3'(SEQ ID NO:41). This fragment was cloned as an *Sfi* I – *Mlu* I fragment into VR-1031. The murine gamma 1 constant region was amplified with the PCR primers: 5'- GCG GCC GGC CAA AAC GGC CGC CCC CAT CGG TCT ATC CAC T -3' (SEQ ID NO:42) and 5'- GCG GCG AGA TCT GGA TCT TCA TTT ACC CGG AGT CCG GGA -3' (SEQ ID NO:43) and cloned as an *Sfi* I – *Bgl* II fragment into VR-1031 to form
 30

-59-

VR-1632 (SEQ ID NO:4). The PCR cycling conditions for both fragments were 94°C for 5 minutes followed by 30 cycles of: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute.

The light and heavy chain variable regions from the B cell lymphoma cell line RAMOS were amplified and cloned into VR-1632 to serve as a test vaccine construct (Klein G, *et al. Intervirology*, 5:319-334.) This vaccine plasmid is called VR-1642. The RAMOS lambda variable region was PCR amplified with the primers: 5'- GCG GCG GGC CTT GCT GGC CAT GGC CTG GGC TCT GCT G -3' (SEQ ID NO:44) and 5'- GCG GCG GGC CGC ATC GGC CCC TAG GAC GGT CAG CTT GGT G -3' (SEQ ID NO:45) and cloned into VR-1632 as an *Sfi* I fragment. The RAMOS gamma 1 heavy chain constant region was PCR amplified with the primers: 5'- GCG GCG GGC CGC AGC GGC CAA ACA CCT GTG GTT CTT CCT C -3' (SEQ ID NO:46) and 5'- GCG GCG GGC CGT TTT GGC CGA GGA GAC CGT GAC CGT G -3' (SEQ ID NO:47) and cloned into VR-1632 as an *Sfi* I fragment to yield VR-1642 (SEQ ID NO:3). The PCR cycling conditions for both fragments were 94°C for 5 minutes followed by 30 cycles of: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute.

Measurement of humoral responses in vaccinated individuals.

Tumor Ig protein or isotype matched Igs are captured onto microtiter plates coated with goat anti-human heavy chain antibodies (Biosource International Inc., Camarillo, CA). When the tumor immunoglobulin isotype is an IgG, F(ab')₂ fragments are produced by digestion with immobilized pepsin (Pierce, Rockford, IL) and used to coat microtiter plates directly. Preimmunization and postimmunization patient serum are serially diluted and allowed to bind to the target proteins. The binding of anti-Id antibodies is detected by polyclonal goat antihuman IgG antibodies (Biosource International) coupled to horseradish peroxidase (HRP). A response is interpreted as positive when a fourfold increase in anti-Id antibody titer is found when compared to the

-60-

preimmunization serum, and to the binding of irrelevant isotype-matched proteins used as specificity targets.

5 Measurement of T-cell proliferation in response to vaccination by cellular proliferation assay.

Peripheral blood mononuclear cells (PBMC) are obtained by Ficoll Hypaque (Pharmacia, Uppsala, Sweden) density gradient separation of 40 to 60 mL of heparinized blood samples. PBMC are cultured in quadruplicate in media containing either tumor Ig protein or isotype matched, irrelevant protein at concentrations of 0 to 100 µg/mL as previously described. Determination of [3H]-thymidine incorporation is performed over days 5 to 6. A response is interpreted as positive when incorporation of more than two times background is found on two or more occasions.

15 Statistical analysis.

Freedom from disease progression and survival data are analyzed using Kaplan-Meier analysis and two-sample log rank tests of significance. Freedom from disease progression is measured from the date of last chemotherapy before vaccine treatment to the date of death or last follow-up. The date of last chemotherapy is the reference time point used for these calculations because the impact of vaccine treatments can only be tested when compared to the time of progression from the last proven to cause tumor responses. It is at this point in time in which the relevant baseline clinical status is represented.

25 Example 3

Prophylactic Application of Flt-3ligand-encoding pDNA in Combination with a Malarial Antigen-encoding pDNA in Humans

Immunogenic compositions comprising (1) pDNA encoding human Flt-3 ligand; and (2) pDNA encoding *Plasmodium falciparum* circumsporozoite protein (PfCSP) are prepared according to the method described above. Human subjects

-61-

receive three injections of 0.1, 0.5, 1.0, 2.5, or 5.0 mg of each pDNA in a pharmaceutically acceptable vehicle at 4-week intervals in alternate deltoids. Serum is removed from the subjects and the *Plasmodium falciparum* antibody levels are determined by serial dilution using a standard ELISA assay, as described above. Immune responses of human subjects to the antibody are induced, as indicated by normalized GMT values.

Example 4

Prophylactic Application of Flt-3 ligand-encoding pDNA in Combination with an Influenza A virus Antigen-encoding pDNA in Humans

To prevent influenza virus infection in humans, immunogenic compositions comprising pDNA encoding an influenza A virus hemagglutinin (HA) and pDNA encoding human Flt-3 ligand are prepared according to the method described above. Subjects are injected three times with 0.1, 0.5, 1.0, 2.5, or 5.0 mg of each pDNA in a pharmaceutically acceptable vehicle at 4-week intervals in alternate deltoids. Serum is removed from the humans and antibody levels to the hepatitis antigen are determined by serial dilution using a standard ELISA assay, as described above. Immune responses of the human subjects to the HA antigen are induced, as indicated by normalized GMT values.

20

Example 5

Treatment Regimen with Flt-3 ligand-encoding pDNA in Combination with Hepatitis Antigen-encoding pDNA for Patients with Chronic Hepatitis B or C

To decrease the chronic infection of Hepatitis B and C in human patients, 0.5-10 mg, preferably 1-5 mg of a pDNA encoding the secreted form of human Flt-3 ligand and 1-30 mg, preferably 10-30 mg pDNA encoding either a hepatitis B virus (HBV) antigen, for example a hepatitis B core antigen (HbcAg), a hepatitis B surface antigen (HBsAg); or a hepatitis C virus (HCV) antigen, for example a HCV nonstructural (NS) protein antigen, a HCV nucleocapsid antigen,

30

-62-

or a HCV envelope glycoprotein antigen, in a pharmacologically acceptable carrier is injected to the patients biweekly or monthly. The therapy regimen is continued for a minimum of 24 weeks during which time the patients are monitored for, for example, levels of serum alanine aminotransferase and clearance of hepatitis C virus (HCV) RNA in HCV patients, and serum HBsAg and HBV DNA are in HBV. Liver biopsies are performed at the end of the treatment period. A successful outcome of the therapy in a HBV or HCV patient is indicated, for example, by a normalization of serum alanine aminotransferase levels, a decrease in serum levels of HBsAg, a disappearance or decrease in detectable virus in the patient's serum, and histological improvement in the liver. In some cases, this therapy is used in conjunction with anti-virals such as lamivudine for HBV and ribavirin for HCV.

Example 6

15 Treatment Regimen with FLT-3 ligand-encoding pDNA in Combination with IFN ω Plasmid DNA for Patients with Chronic Hepatitis B or C

To decrease the chronic infection of Hepatitis B and C in human patients, 0.5-10 mg, preferably 1-5 mg of a pDNA encoding the secreted form of human FLT-3 ligand and 1-50 mg, preferably 10-30 mg of a pDNA encoding IFN ω in a pharmacologically acceptable carrier is delivered by injection to patients biweekly or monthly. The therapy regimen is continued for a minimum of 24 weeks during which time the patients are monitored for, for example, levels of serum alanine aminotransferase and clearance of hepatitis C virus (HCV) RNA in HCV patients, and serum HBsAg and HBV DNA for HBV patients. In addition, liver biopsies are performed at the end of the treatment period. A successful outcome of the therapy in HBV or HCV patient is indicated, for example, by a normalization of serum alanine aminotransferase levels, a decrease in serum levels of HbsAg, a disappearance or decrease in detectable virus in the patient's serum, and histological improvement in the liver. In some cases, this

therapy is used in conjunction with anti-virals such as lamivudine for HBV and ribavirin for HCV.

Example 7

5 *Preparation of Cytofectin Formulations*

(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(*syn*-9-tetradeceneyloxy)-1-propanaminium bromide (GAP-DMORIE) was synthesized using the published procedure for preparing the analogue cytofectin GAP-DLRIE (Wheeler *et al.*, *Proc. Natl. Acad. Sci.* 93, 11454-11459 (1996)). Specifically, substituting *syn*-9-tetradecenyl methane sulfonate for dodecenyl methane sulfonate in the initial *bis*-alkylation of 3-dimethylamino-1,2-propanediol yielded the desired dialkenyl amine. Quatranization with 3-bromopropylphthalimide, followed by deprotection of the protected primary amine with hydrazine and extractive purification and sub-micron filtration afforded pure GAP-DMORIE as judged by analytical thin layer chromatography. Product identity was confirmed using high resolution proton NMR and infrared (IR) spectroscopies.

Both the 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE) and 1,2-diphytanoyl-*sn*-glycero-3-phosphoethanolamine (DPyPE) were purchased as chloroform solutions from Avanti Polar Lipids (Alabaster, Alabama).

20 Cytofectin:co-lipid liposomes were prepared using the rehydrated thin-film method described above. Cytofectin formulation/pDNA complexes were prepared by mixing equivalent volumes of a pDNA solution and a solution of cytofectin/co-lipid liposomes.

What Is Claimed Is:

1. A pharmaceutical composition comprising:

(a) about 1 ng to 10 mg of a nucleic acid molecule comprising a first polynucleotide which hybridizes, at 42°C in 50% formamide, 5x SSC, 50 mM sodium phosphate, 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing at 65°C in 0.1x SSC and 0.1% SDS (w/v), to a reference nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, and the complement of any of said sequences, wherein said first polynucleotide encodes a polypeptide having immunity-enhancing activity when administered to a vertebrate;

(b) about 1 ng to 30 mg of a nucleic acid molecule comprising a second polynucleotide encoding one or more antigens or one or more cytokines; and

(c) a pharmaceutically acceptable carrier,

wherein said first and second polynucleotides are non-infectious and non-integrating, and are operably associated with control sequences which direct the expression thereof.

20

2. The pharmaceutical composition of claim 1, wherein said first polynucleotide encodes a polypeptide comprising 15 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24.

25

3. The pharmaceutical composition of claim 2, wherein said first polynucleotide encodes a polypeptide comprising at least 30 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID

-65-

NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24.

4. The pharmaceutical composition of claim 3, wherein said first
5 polynucleotide encodes a polypeptide comprising at least 50 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24.

10 5. The pharmaceutical composition of claim 4, wherein said first polynucleotide encodes a polypeptide comprising at least 150 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and SEQ ID NO:24.

15

6. The pharmaceutical composition of Claim 1, wherein said first polynucleotide encodes amino acids 28 to 163 of SEQ ID NO:8.

7. The pharmaceutical composition of Claim 6, wherein said first
20 polynucleotide encodes amino acids 1 to 163 of SEQ ID NO:8.

8. The pharmaceutical composition of Claim 6, wherein said first polynucleotide encodes amino acids 28 to 189 of SEQ ID NO:8.

25 9. The pharmaceutical composition of Claim 8, wherein said first polynucleotide encodes amino acids 1 to 189 of SEQ ID NO:8.

10. The pharmaceutical composition of Claim 8, wherein said first polynucleotide encodes amino acid residues selected from the group consisting

-66-

of amino acids 28 to 231 of SEQ ID NO:8, and amino acids 28 to 232 of SEQ ID NO:13.

11. The pharmaceutical composition of Claim 9, wherein said first
5 polynucleotide encodes amino acid residues selected from the group consisting
of amino acids 1 to 231 of SEQ ID NO:8, and amino acids 1 to 232 of SEQ ID
NO:13.

12. The pharmaceutical composition of Claim 6, wherein said first
10 polynucleotide encodes amino acids 28 to 220 of SEQ ID NO:11.

13. The pharmaceutical composition of Claim 12, wherein said first
polynucleotide encodes amino acids 1 to 220 of SEQ ID NO:11.

14. The pharmaceutical composition of Claim 6, wherein said first
15 polynucleotide encodes amino acids 28 to 172 of SEQ ID NO:17.

15. The pharmaceutical composition of Claim 14, wherein said first
polynucleotide encodes amino acids 1 to 172 of SEQ ID NO:17.

20

16. The pharmaceutical composition of Claim 1, wherein said first
polynucleotide encodes amino acids 27 to 160 of SEQ ID NO:19.

17. The pharmaceutical composition of Claim 16, wherein said first
25 polynucleotide encodes amino acids 1 to 160 of SEQ ID NO:19.

18. The pharmaceutical composition of Claim 16, wherein said first
polynucleotide encodes amino acids 27 to 185 of SEQ ID NO:19.

-67-

19. The pharmaceutical composition of Claim 18, wherein said first polynucleotide encodes amino acids 1 to 185 of SEQ ID NO:19.
20. The pharmaceutical composition of Claim 18, wherein said first
5 polynucleotide encodes amino acids 27 to 235 of SEQ ID NO:19.
21. The pharmaceutical composition of Claim 19, wherein said first polynucleotide encodes amino acids 1 to 235 of SEQ ID NO:19.
- 10 22. The pharmaceutical composition of Claim 16, wherein said first polynucleotide encodes amino acids 27 to 178 of SEQ ID NO:21.
23. The pharmaceutical composition of Claim 22, wherein said first polynucleotide encodes amino acids 1 to 178 of SEQ ID NO:21.
- 15 24. The pharmaceutical composition of Claim 1, wherein said first polynucleotide encodes amino acids 27 to 185 of SEQ ID NO:23.
25. The pharmaceutical composition of Claim 24, wherein said first
20 polynucleotide encodes amino acids 1 to 185 of SEQ ID NO:23.
26. The pharmaceutical composition of Claim 24, wherein said first polynucleotide encodes amino acids 27 to 235 of SEQ ID NO:23.
- 25 27. The pharmaceutical composition of Claim 26, wherein said first polynucleotide encodes amino acids 1 to 235 of SEQ ID NO:23.
28. The pharmaceutical composition of claim 1, wherein said first polynucleotide encodes three amino acid regions comprising:

-68-

- (a) amino acid residues 34 to 41 of SEQ ID NO:19 arranged consecutively,
- (b) amino acid residues 107 to 113 of SEQ ID NO:19 arranged consecutively, and
- 5 (c) amino acid residues 142 to 150 of SEQ ID NO:19 arranged consecutively.

29. The pharmaceutical composition of claim 1, wherein said first polynucleotide encodes a polypeptide selected from the group consisting of:

10 (a) a polypeptide which, except for at least one amino acid substitution at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147 of SEQ ID NO:19, is identical to amino acids 27 to 160 of SEQ ID NO:19, and

(b) a polypeptide which, except for at least one amino acid
15 substitution at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147 of SEQ ID NO:23, is identical to amino acids 27 to 185 of SEQ ID NO:23;

wherein said amino acid substitution increases the immunity enhancing activity of said polypeptide.

20

30. A pharmaceutical composition comprising:

(a) about 1 ng to 10 mg of a nucleic acid molecule comprising a first polynucleotide wherein said first polynucleotide encodes a first polypeptide which, except for at least one but not more than 20 amino acid substitutions,
25 deletions, or insertions, is identical to a second polypeptide selected from the group consisting of amino acids 28 to 163 of SEQ ID NO:8, amino acids 27 to 160 of SEQ ID NO:19, and amino acids 27 to 185 of SEQ ID NO:23; wherein said first polypeptide has immunity-enhancing activity when administered to a vertebrate;

-69-

(b) about 1 ng to 30 mg of a nucleic acid molecule comprising a second polynucleotide encoding one or more antigens or one or more cytokines; and

(c) a pharmaceutically acceptable carrier,

5 wherein said first and second polynucleotides are non-infectious and non-integrating, and are operably associated with control sequences which direct the expression thereof.

31. The pharmaceutical composition of Claim 30, wherein said second
10 polypeptide comprises amino acids 1 to 163 of SEQ ID NO:8.

32. The pharmaceutical composition of Claim 30, wherein said second polypeptide comprises amino acids 28 to 189 of SEQ ID NO:8.

15 33. The pharmaceutical composition of Claim 32, wherein said second polypeptide comprises amino acids 1 to 189 of SEQ ID NO:8.

34. The pharmaceutical composition of Claim 32, wherein said second polypeptide is selected from the group consisting of amino acids 28 to 231 of
20 SEQ ID NO:8, and amino acids 28 to 232 of SEQ ID NO:13.

35. The pharmaceutical composition of Claim 34, wherein said second polypeptide is selected from the group consisting of amino acids 1 to 231 of SEQ ID NO:8, and amino acids 1 to 232 of SEQ ID NO:13.

25

36. The pharmaceutical composition of Claim 30, wherein said second polypeptide comprises amino acids 28 to 220 of SEQ ID NO:11.

37. The pharmaceutical composition of Claim 36, wherein said second
30 polypeptide comprises amino acids 1 to 220 of SEQ ID NO:11.

-70-

38. The pharmaceutical composition of Claim 30, wherein said second polypeptide comprises amino acids 28 to 172 of SEQ ID NO:17.

5 39. The pharmaceutical composition of Claim 38, wherein said second polypeptide comprises amino acids 1 to 172 of SEQ ID NO:17.

40. The pharmaceutical composition of Claim 30, wherein said second polypeptide comprises amino acids 1 to 160 of SEQ ID NO:19.

10

41. The pharmaceutical composition of Claim 30, wherein said second polypeptide comprises amino acids 27 to 185 of SEQ ID NO:19.

15 42. The pharmaceutical composition of Claim 41, wherein said second polypeptide comprises amino acids 1 to 185 of SEQ ID NO:19.

43. The pharmaceutical composition of Claim 41, wherein said second polypeptide comprises amino acids 27 to 235 of SEQ ID NO:19.

20 44. The pharmaceutical composition of Claim 42, wherein said second polypeptide comprises amino acids 1 to 235 of SEQ ID NO:19.

45. The pharmaceutical composition of Claim 30, wherein said second polypeptide comprises amino acids 27 to 178 of SEQ ID NO:21.

25

46. The pharmaceutical composition of Claim 45, wherein said second polypeptide comprises amino acids 1 to 178 of SEQ ID NO:21.

30 47. The pharmaceutical composition of Claim 30, wherein said second polypeptide comprises amino acids 1 to 185 of SEQ ID NO:23.

-71-

48. The pharmaceutical composition of Claim 30, wherein said second polypeptide comprises amino acids 27 to 235 of SEQ ID NO:23.

5 49. The pharmaceutical composition of Claim 48, wherein said second polypeptide comprises amino acids 1 to 235 of SEQ ID NO:23.

50. The pharmaceutical composition of Claim 30, wherein the number of amino acid substitutions, deletions, or insertions is not more than 10.

10

51. The pharmaceutical composition of Claim 30, wherein the number of amino acid substitutions, deletions, or insertions is not more than 5.

52. The pharmaceutical composition of Claim 30, wherein the number of amino acid substitutions, deletions, or insertions is not more than 1.

15

53. The pharmaceutical composition of claim 30, wherein said amino acid substitutions, deletions or insertions do not occur in regions identical to amino acids 34 to 41, 107 to 113, and 142 to 150 of SEQ ID NO:19.

20

54. The pharmaceutical composition of claim 30, wherein said first polynucleotide encodes a polypeptide selected from the group consisting of:

(a) a polypeptide having amino acids 27 to 160 of SEQ ID NO:19, wherein at least one amino acid substitution occurs at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147, and

25

(b) a polypeptide having amino acids 27 to 185 of SEQ ID NO:23, wherein at least one amino acid substitution occurs at an amino acid position selected from the group consisting of amino acid residues 34, 110, 144, and 147;

30

-72-

wherein said amino acid substitution increases the immunity enhancing activity of said polypeptide.

55. A pharmaceutical composition comprising:

5 (a) about 1 ng to 10 mg of a nucleic acid molecule comprising a first polynucleotide, wherein said first polynucleotide encodes an amino acid sequence that is at least 90% identical to a reference amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, and
10 SEQ ID NO:24, wherein % identity is determined using the Bestfit program with default parameters, and wherein said first polynucleotide encodes a polypeptide having immunity-enhancing activity when administered to a vertebrate;

(b) about 1 ng to 30 mg of a nucleic acid molecule comprising a second polynucleotide encoding one or more antigens or one or more cytokines;
15 and

(c) a pharmaceutically acceptable carrier,

wherein said first and second polynucleotides are non-infectious and non-integrating, and are operably associated with control sequences which direct the expression thereof.

20

56. The pharmaceutical composition of claim 55, wherein said first polynucleotide encodes an amino acid sequence that is at least 95% identical to said reference amino acid sequence.

25 57. The pharmaceutical composition of claim 55, wherein said first polynucleotide encodes an amino acid sequence that is at least 97% identical to said reference amino acid sequence.

-73-

58. The pharmaceutical composition of any one of claims 1, 30, or 55, wherein the nucleic acid molecule of (a) is selected from the group consisting of VR6200 (SEQ ID NO:6) and VR6230 (SEQ ID NO:39).

5 59. The pharmaceutical composition of any one of claims 1, 30, or 55, wherein said antigen is selected from the group consisting of a viral antigen, a bacterial antigen, a protozoan parasite antigen, a helminth parasite antigen, a fungal antigen, an ectoparasite antigen, a tumor associated antigen, and a self antigen associated with autoimmunity.

10

60. The pharmaceutical composition of claim 59, wherein said viral antigen is derived from a virus selected from the group consisting of adenoviruses, alphaviruses, aphoviruses, caliciviruses, coronaviruses, coxsackieviruses, distemper viruses, Ebola viruses, enteroviruses, flaviviruses, hepatitis viruses, herpesviruses, immunodeficiency viruses, infectious peritonitis viruses, influenza viruses, leukemia viruses, Marburg viruses, oncogenic viruses, orthomyxoviruses, papilloma viruses, parainfluenza viruses, paramyxoviruses, parvoviruses, pestiviruses, picorna viruses, pox viruses, rabies viruses, reoviruses, respiratory syncytial viruses, retroviruses, rhinoviruses, rotaviruses, cancer-causing viruses or cancer-related viruses.

20

61. The pharmaceutical composition of Claim 59, wherein said bacterial antigen is derived from an organism having a genus selected from the group consisting of *Actinomyces*, *Bacillus*, *Bacteroides*, *Bordetella*, *Bartonella*,
25 *Borrelia*, *Brucella*, *Campylobacter*, *Capnocytophaga*, *Chlamydia*, *Clostridium*, *Corynebacterium*, *Coxiella*, *Dermatophilus*, *Enterococcus*, *Ehrlichia*, *Escherichia*, *Francisella*, *Fusobacterium*, *Haemobartonella*, *Haemophilus*, *Helicobacter*, *Klebsiella*, L-form bacteria, *Leptospira*, *Listeria*, *Mycobacteria*, *Mycoplasma*, *Neisseria*, *Neorickettsia*, *Nocardia*, *Pasteurella*, *Peptococcus*,
30 *Peptostreptococcus*, *Pneumococcus*, *Proteus*, *Pseudomonas*, *Rickettsia*,

-74-

Rochalimaea, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, and Yersinia.

62. The pharmaceutical composition of claim 59, wherein said
5 protozoan parasite antigen is derived from an organism having a genus selected
from the group consisting of *Babesia, Balantidium, Besnoitia, Cryptosporidium, Eimeria, Encephalitozoon, Entamoeba, Giardia, Hammondia, Hepatozoon, Isospora, Leishmania, Microsporidia, Neospora, Nosema, Pentatrichomonas, Plasmodium, Pneumocystis, Sarcocystis, Schistosoma, Theileria, Toxoplasma,*
10 *and Trypanosoma.*

63. The pharmaceutical composition of claim 59, wherein said
helminth parasite antigen is derived from an organism having a genus selected
from the group consisting of *Acanthocheilonema, Aelurostrongylus,*
15 *Ancylostoma, Angiostrongylus, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Crenosoma, Dictyocaulus, Dioctophyme, Dipetalonema, Diphyllbothrium, Diplydium, Dirofilaria, Dracunculus, Enterobius, Filaroides, Haemonchus, Lagochilascaris, Loa, Mansonella, Muellerius, Nanophyetus, Necator, Nematodirus, Oesophagostomum, Onchocerca, Opisthorchis,*
20 *Ostertagia, Parafilaria, Paragonimus, Parascaris, Physaloptera, Protostrongylus, Setaria, Spirocerca, Spirometra, Stephanofilaria, Strongyloides, Strongylus, Thelazia, Toxascaris, Toxocara, Trichinella, Trichostrongylus, Trichuris, Uncinaria, and Wuchereria.*

64. The pharmaceutical composition of claim 59, wherein said fungal
25 antigen is derived from an organism having a genus selected from the group
consisting of *Absidia, Acremonium, Alternaria, Aspergillus, Basidiobolus, Bipolaris, Blastomyces, Candida, Coccidioides, Conidiobolus, Cryptococcus, Curvalaria, Epidermophyton, Exophiala, Geotrichum, Histoplasma, Madurella,*
30 *Malassezia, Microsporum, Moniliella, Mortierella, Mucor, Paecilomyces,*

-75-

Penicillium, Phialemonium, Phialophora, Prototheca, Pseudallescheria, Pseudomicrodochium, Pythium, Rhinosporidium, Rhizopus, Scolecobasidium, Sporothrix, Stemphylium, Trichophyton, Trichosporon, and Xylohypha.

5 65. The pharmaceutical composition of claim 59, wherein said ectoparasite antigen is derived from an organism selected from the group consisting of fleas, ticks, mosquitos, sand flies, black flies, horse flies, horn flies, deer flies, tsetse flies, stable flies, myiasis-causing flies, biting gnats, ants, spiders, lice, mites, bed bugs, and kissing bugs.

10

 66. The pharmaceutical composition of claim 59, wherein said tumor-associated antigen comprises a tumor-specific immunoglobulin variable region, a GM2 antigen, a Tn antigen, an sTn antigen, a Thompson-Friedenreich antigen (TF), a Globo H antigen, an Le(y) antigen, a MUC1
15 antigen, a MUC2 antigen, a MUC3 antigen, a MUC4 antigen, a MUC5AC antigen, a MUC5B antigen, a MUC7 antigen, a carcinoembryonic antigen, a beta chain of human chorionic gonadotropin (hCG beta) antigen, a HER2/neu antigen, a PSMA antigen, a EGFRvIII antigen, a KSA antigen, a PSA antigen, a PSCA antigen, a GP100 antigen, a MAGE 1 antigen, a MAGE 2 antigen, a
20 TRP 1 antigen, a TRP 2 antigen, and a tyrosinase antigen.

 67. The pharmaceutical composition of claim 66, wherein said tumor-associated antigen comprises a B-cell lymphoma-specific idiotype determinant.

25 68. The pharmaceutical composition of claim 67, wherein said tumor specific antigen further comprises an immunoglobulin constant region.

 69. The pharmaceutical composition of claim 67, wherein said second polynucleotide encoding said tumor-associated antigen is polycistronic.

30

-76-

70. The pharmaceutical composition of claim 69, wherein said second polynucleotide comprises

(a) a first cistron encoding a protein comprising a light chain variable region of a B-cell lymphoma immunoglobulin having a tumor-specific
5 idotype determinant, fused to a constant region, and

(b) a second cistron encoding a protein comprising a heavy chain variable region of a B-cell lymphoma immunoglobulin having a tumor-specific idotype determinant, fused to a constant region.

10 71. The pharmaceutical composition of claim 70, wherein said constant region is derived from a heterologous species relative to said variable region.

72. The pharmaceutical composition of claim 69 wherein said second
15 polynucleotide comprises two cistrons organized in a transcription unit under the control of a single promoter, and wherein said second polynucleotide further comprises an internal ribosome entry site positioned between said cistrons.

73. The pharmaceutical composition of claim 72, wherein said second
20 polynucleotide is selected from the group consisting of VR1623 (SEQ ID NO:1) and VR1642 (SEQ ID NO:3).

74. The pharmaceutical composition of any one of claims 1, 30, or 55, wherein said first and second polynucleotides are present in a single nucleic acid
25 molecule.

75. The pharmaceutical composition of claim 74, wherein said nucleic acid molecule encodes a fusion protein comprising a Flt-3 ligand and one or more antigens or one or more cytokines.

30

-77-

76. The pharmaceutical composition of claim 75, wherein said fusion protein comprises a Flt-3 ligand and a B-cell lymphoma-specific idiotype determinant.
- 5 77. The pharmaceutical composition of any one of claims 1, 30, or 55, wherein the nucleic acid molecule of (a) comprises VR6230 (SEQ ID NO:39), and the nucleic acid molecule of (b) comprises VR1642 (SEQ ID NO:3).
78. The pharmaceutical composition of any one of claims 1, 30, or 55,
10 further comprising a cationic lipid.
79. The pharmaceutical composition of claim 78, wherein said cationic lipid comprises a compound selected from the group consisting of DMRIE, GAP-DMORIE and GAP-DLRIE.
15
80. The pharmaceutical composition of claim 78, wherein said cationic lipid further comprises one or more co-lipids.
81. The pharmaceutical composition of claim 80, wherein said
20 co-lipids are selected from the group consisting of DOPE, DPyPE, and DMPE.
82. The pharmaceutical composition of claim 80, comprising GAP-DMORIE and DPyPE.
- 25 83. The pharmaceutical composition of claim 80, wherein the cationic lipid:co-lipid molar ratio ranges from about 2:1 to 1:2.
84. The pharmaceutical composition of any one of claims 1, 30, or 55, wherein said control sequences are selected from the group consisting of a

-78-

promoter, an enhancer, an operator, a repressor, and a transcription termination signal.

85. The pharmaceutical composition of claim 84, wherein said control
5 sequence is a promoter selected from the group consisting of a cytomegalovirus promoter, a simian virus 40 promoter, and a retrovirus promoter.

86. The pharmaceutical composition of any one of claims 1, 30, or 55,
wherein said first and second polynucleotides are DNA.

10

87. The pharmaceutical composition of any one of claims 1, 30, or 55,
wherein said first and second polynucleotides are RNA.

88. The pharmaceutical composition of any one of claims 1, 30, or 55,
15 wherein said first and second polynucleotides comprise one or more regions regulating gene expression.

89. The pharmaceutical composition of claim 88, wherein said region
regulating gene expression is cell specific or tissue specific.

20

90. The pharmaceutical composition of claim 89, wherein said region
is tumor cell or tumor tissue specific.

91. The pharmaceutical composition of any one of claims 1, 30, or 55,
25 further comprising about 1 ng to 10 mg of a nucleic acid molecule comprising a third polynucleotide encoding a cytokine, or active fragment thereof, wherein said third polynucleotide is non-infectious and non-integrating, and is operably associated with control sequences which direct the expression thereof.

-79-

92. The pharmaceutical composition of claim 91, wherein said cytokine is selected from the group consisting of GM-CSF, G-CSF, M-CSF, CSF, erythropoietin, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, IL-18, IFN α , IFN β , IFN ω , IFN τ , IFN γ , IFN γ inducing factor I, TGF- β , RANTES,
5 MIP-1 α , MIP-1 β , LEIF, SDF-1, and MCP-3.

93. A method for enhancing an immune response in a vertebrate, said method comprising administering to a tissue of said vertebrate the pharmaceutical composition of any one of claims 1, 30, or 55, wherein said first and second
10 polynucleotides are expressed *in vivo* in an amount effective for a polypeptide expressed by said first polynucleotide to enhance the immunogenicity of said one or more antigens or said one or more cytokines.

94. The method of claim 93, wherein said antigen is selected from the
15 group consisting of a viral antigen, a bacterial antigen, a protozoan parasite antigen, a helminth parasite antigen, a fungal antigen, an ectoparasite antigen, a tumor associated antigen, and a self antigen associated with autoimmunity.

95. The method of claim 93, wherein said tissue is selected from the
20 group consisting of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, tongue and connective tissue.

96. The method of claim 93, wherein said first and second
25 polynucleotides are administered onto a mucosal surface.

97. The method of claim 95, wherein said tissue is muscle.

-80-

98. The method of claim 97, wherein said tissue is skeletal muscle, smooth muscle, or myocardium.

99. The method of claim 93, wherein said first and second
5 polynucleotides are administered intravenously.

100. The method of claim 93, wherein said first and second polynucleotides are administered intramuscularly.

101. The method of claim 93, wherein said administration comprises
10 intramuscular injection.

102. The method of claim 93, wherein said first and second polynucleotides are administered by a route selected from the group consisting
15 of transdermal, interdermal, subcutaneous, oral, intraocular, vaginal, rectal, and inhaled.

103. The method of claim 93, wherein said administration is mediated
20 by a catheter.

104. The method of claim 93, wherein said administration is mediated
by a device selected from the group consisting of a particle accelerator, a pump,
an intradermal applicator, a biolistic injector, a pneumatic injector, a sponge
depot, a pill, and a tablet.

105. The method of claim 94, wherein said vertebrate is a mammal.

106. The method of claim 105, wherein said mammal is a human.

-81-

107. The method of claim 105, wherein said construct is free from association with transfection-facilitating proteins, viral particles, liposomes, cationic lipids, and calcium phosphate precipitating agents.
- 5 108. A method of suppressing tumor growth in a mammal, comprising administering into a tissue of said mammal the pharmaceutical composition of any of claims 1, 30, or 55, wherein the growth of said tumor is suppressed.
- 10 109. The method of claim 108, wherein said tumor is selected from the group consisting of melanoma, glioma, and lymphoma.
109. The method of claim 108, wherein said composition is administered intramuscularly to treat B-cell lymphoma.
- 15 111. A method of suppressing growth of B-cell lymphoma in a mammal comprising administering into a tissue of said mammal the pharmaceutical composition of Claim 70.
112. The method of claim 108, further comprising one or more
20 additional cancer treatment methods selected from the group consisting of surgery, radiation therapy, chemotherapy, immunotherapy, and gene therapy.
113. The method of claim 112, wherein said composition is administered prior to the commencement of said one or more additional cancer
25 treatment methods.
114. The method of claim 112, wherein said composition is administered during the practice of said one or more additional cancer treatment methods.

-82-

115. The method of claim 112, wherein said composition is administered after the end of said one or more additional cancer treatment methods.

1/9




FIG. 1

2/9




FIG. 2

3/9




FIG. 3

4/9




FIG. 4

5/9




FIG. 5





FIG. 6

7/9



DAYS POST CHALLENGE

FIG. 7

8/9




FIG. 8

9/9




FIG. 9

-1-

SEQUENCE LISTING

<110> Vical, Inc. et al.

<120> FLT-3-Ligand-Encoding Polynucleotides as a
Polynucleotide-Based Vaccine Enhancer

<130> 1530.013PC02

<140>

<141>

<150> US 60/146,170

<151> 1999-07-30

<160> 47

<170> PatentIn Ver. 2.0

<210> 1

<211> 7521

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cDNA

<400> 1

agttcatagc ccatatatgg agttccgcgt tacataactt acggtaaatg gcccgctgg 60
ctgaccgccc aacgaccccc gccattgac gtcaataatg acgtatgttc ccatagtaac 120
gccaataggg actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt 180
ggcagtacat caagtgtatc atatgccaag tacgccccct attgacgtca atgacggtaa 240
atggccccgcc tggcattatg ccagttacat gaccttatgg gactttccta cttggcagta 300
catctacgta ttagtcatcg ctattacat ggtgatgcgg ttttggcagt acatcaatgg 360
gcgtggatag cggtttgact caoggggatt tccaagtctc caccocattg acgtcaatgg 420
gagtttgttt tggcaccaaa atcaacggga ctttccaaaa tgcgtaaca actccgcccc 480
attgacgcaa atgggcggta ggcggtgtacg gtgggaggtc tatataagca gagctcgttt 540
agtgaaccgt cagatcgctt ggagacgcca tccacgctgt tttgacctcc atagaagaca 600
ccgggaccga tccagcctcc gggccggga acggtgcatt ggaacgcgga ttccccgtgc 660
caagagtgac gtaagtaccg cctatagagt ctataggccc acccccttgg cttcttatgc 720
atgctatact gtttttggct tggggtctat acacccccgc ttcctcatgt tataggtgat 780
ggtatagctt agcctatagg tgtgggttat tgaccattat tgaccactcc cctattggtg 840

-2-

acgatacttt ccattactaa tccataacat ggctctttgc cacaactctc tttattggct 900
atatgccaat acactgtcct tcagagactg acacggactc tgtattttta caggatgggg 960
tctcatttat tatttacaaa ttcacatata caacaccacc gtccccagtg cccgcagttt 1020
ttattaaaca taacgtggga tctccacgag aatctcgggt acgtgttccg gacatgggct 1080
cttctccggt agcggcggag cttctacatc cgagccctgc tcccatgcct ccagegactc 1140
atggtcgctc ggcagctcct tgctcctaac agtggaggcc agacttaggc acagcacgat 1200
gcccaccacc accagtgtgc cgcacaaggc cgtggcggta gggtagtgtg ctgaaaatga 1260
gtcgggggag cgggcttgca ccgctgacgc atttggaaga ctttaaggcag cggcagaaga 1320
agatgcaggc agctgagttg ttgtgttctg ataagagtca gaggttaactc ccgttgcggt 1380
gctgttaacg gtggagggca gtgtagtctg agcagtactc gttgctgccg cgcgcgccac 1440
cagacataat agctgacaga ctaacagact gttcctttcc atgggtcttt tctgcaggcc 1500
ttgctggccg ccatgggacc gtctgttcag ttcctggggc tcttgttgtt ctggcttcat 1560
ggtgctcagt gtgacatcca gatgacacag tctccatcct cactgtctgc atctctggga 1620
ggcaaagtca ccatcacttg caaggcaagc caagacatta acaagtatat agcttggtag 1680
caacacaagc ctggaaaagg tcctaggctg ctcatattt acacatctac attacagcca 1740
ggcatcccat caaggttcag tggaagtggg tctgggagag attattcctt cagcatcagc 1800
aacctggagc ctgaagatat tgcaacttat tattgtctac agtatggtaa tctgtacacg 1860
ttcggctcgg gtaccaagtt ggaaataaag gccacgggtg ccgcaccatc tgtcttcac 1920
ttcccgccat ctgatgagca gttgaaatct ggaactgcct ctgttgtgtg cctgctgaat 1980
aacttctatc ccagagaggc caaagtacag tggaagggtg ataacgccct ccaatcgggt 2040
aactcccagg agagtgtcac agagcaggac agcaaggaca gcacctacag cctcagcagc 2100
accctgacgc tgagcaaagc agactacgag aaacacaaag tctacgcctg cgaagtcacc 2160
catcagggcc tgagctcgcc cgtcaciaaag agcttcaaca ggggagagtg ttgaacgcgt 2220
tattttccac catattgccg tcttttggca atgtgagggc ccggaaacct ggccctgtct 2280
tcttgacgag cattcctagg ggtctttccc ctctcgccaa aggaatgcaa ggtctgttga 2340
atgtcgtgaa ggaagcagtt cctctggaag cttcttgaag acaaacaacg tctgtagcga 2400

-3-

ccctttgcag gcagcggaac cccccacctg gcgacagggtg cctctgcggc caaaagccac 2460
gtgtataaga tacacctgca aaggcggcac aaccccgatg ccacgttggtg agttggatag 2520
ttgtggaaag agtcaaattg ctctcctcaa gcgtattcaa caaggggctg aaggatgccc 2580
agaaggtacc ccattgtatg ggatctgatc tggggcctcg gtgcacatgc tttacatgtg 2640
tttagtcgag gttaaaaaac gtctaggccc cccgaaccac ggggacgtgg ttttcctttg 2700
aaaaacacga tgataatacc atggccgcag cggccgagtt gtggctgaac tggattttcc 2760
ttgtaacact tttaaatggt atccagtgtg aggtgaagct ggtggagtct ggaggaggct 2820
tggtagagcc tgggggttct ctgagtctct cctgtgcagc ttctggattc accttactg 2880
attactacat gagctgggtc cgccagcctc caggaaggc acttgagtgg ttggctttga 2940
ttagaaacaa agctaattgt tacacaacag agtacagtgc atctgtgaag ggtcggttca 3000
ccatctccag agataattcc caaagcatcc tctatcttca aatgaatgcc ctgagagctg 3060
aggacagtgc cacttattac tgtgcaagag atcccaatta ctacgatggt agctacgaag 3120
ggtactttga ctactggggc caaggtagcc tggtcaccgt ctctcagct ggccccaagg 3180
gcccacggt cttcccctg gcaccctct ccaagagcac ctctggggc acagcggccc 3240
tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg 3300
ccctgaccag cggcgtgcac accttccccg ctgtcctaca gtcctcagga ctctactccc 3360
tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac atctgcaacg 3420
tgaatcacia gccagcaac accaagggtg acaagaaagc agagcccaaa tcttgtgacg 3480
aaactcacac atgccaccg tgccagcac ctgaactcct gggggaaccg tcagtcttcc 3540
tcttcccccc aaaaccaag gacaccctca tgatctcccg gaccctgag gtcacatgcg 3600
tgggtgtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac gtggacggcg 3660
tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc acgtaccgtg 3720
tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag tacaagtgca 3780
aggtctccaa caaagccctc ccagcccca tcgagaaaac catctccaaa gccaaagggc 3840
agccccgaga accacagggtg tacaccctgc ccccatcccg ggatgagctg accaagaacc 3900
aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc gtggagtggg 3960

-4-

agagcaatgg gcagccggag aacaactaca agaccacgcc tcccggtgctg gactccgacg 4020
gctccttctt cctctacagc aagctcaccg tggacaagag cagggtggcag caggggaacg 4080
tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag aagagcctct 4140
ccctgtctcc gggatcctga gatccagatc tgctgtgcct tctagttgcc agccatctgt 4200
tgtttgcccc tccccgtgc cttccttgac cctggaaggt gccactcca ctgtcctttc 4260
ctaataaaat gaggaaattg catcgattg tctgagtagg tgtcattcta ttctgggggg 4320
tggggtgggg cagcacagca agggggagga ttgggaagac aatagcaggc atgctgggga 4380
tgcggtgggc tctatgggta cccaggtgct gaagaattga cccggttcct cctgggccag 4440
aaagaagcag gcacatcccc ttctctgtga cacaccctgt ccacgccctt ggttcttagt 4500
tccagcccca ctcataggac actcatagct caggagggtc cgccttcaa tcccaccgc 4560
taaagtactt ggagcggctc ctccctccct catcagcca ccaaaccaaa cctagcctcc 4620
aagagtggga agaaattaaa gcaagatagg ctattaagtg cagagggaga gaaaatgcct 4680
ccaacatgtg aggaagtaat gagagaaatc atagaatttc ttccgcttcc tcgctcactg 4740
actcgtgcg ctcggtcggt cggctgcggc gagcggatc agctcactca aaggcggtaa 4800
tacggttatt cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc 4860
aaaaggccag gaaccgtaaa aaggccgcgt tgctggcggt tttccatagg ctccgcccc 4920
ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat 4980
aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc 5040
cgcttaccgg atacctgtcc gcctttctcc cttcgggaag cgtggcgctt tctcaatgct 5100
cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg 5160
aaccctccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc 5220
cggtaagaca cgacttatcg ccaactggcag cagccactgg taacaggatt agcagagcga 5280
ggtatgtagg cgggtgctaca gagttcttga agtgggtggc taactacggc tacactagaa 5340
ggacagtatt tggatatctgc gctctgctga agccagttac cttcggaaaa agagttggta 5400
gctcttgatc cggcaaacaa accaccgctg gtagcgggtg tttttttgtt tgcaagcagc 5460
agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct acgggggtctg 5520

-5-

acgctcagtg gaacgaaaac tcacgttaag ggattttggt catgagatta tcaaaaagga 5580
tcttcaccta gatcctttta aattaaaaat gaagttttta atcaatctaa agtatatatg 5640
agtaaacttg gtctgacagt taccaatgct taatcagtga ggcacctatc tcagcgatct 5700
gtctatttcg ttcattccata gttgcctgac tccggggggg gggggcgctg aggtctgcct 5760
cgtgaagaag gtgttgctga ctcataccag gcctgaatcg ccccatcatc cagccagaaa 5820
gtgagggagc cacggttgat gagagctttg ttgtaggtgg accagttggt gattttgaac 5880
ttttgctttg ccacggaacg gtctgcgttg tcgggaagat gcgtgatctg atccttcaac 5940
tcagcaaaaag ttcgatttat tcaacaaagc cgccgtcccg tcaagtcagc gtaatgctct 6000
gccagtgtta caaccaatta accaattctg attagaaaaa ctcatcgagc atcaaatgaa 6060
actgcaattt attcatatca ggattatcaa taccatattt ttgaaaaagc cgtttctgta 6120
atgaaggaga aaactcaccg aggcagttcc ataggatggc aagatcctgg tatcgggtctg 6180
cgattccgac tcgtccaaca tcaatacaac ctattaattt cccctcgtca aaaataaggt 6240
tatcaagtga gaaatcacca tgagtgcga ctgaatccgg tgagaatggc aaaagcttat 6300
gcatttcttt ccagacttgt tcaacaggcc agccattacg ctcgatcatc aaatcactcg 6360
catcaaccaa accgttattc attcgtgatt gcgcctgagc gagacgaaat acgcgatcgc 6420
tgttaaaagg acaattacaa acaggaatcg aatgcaaccg gcgcaggaac actgccagcg 6480
catcaacaat attttcacct gaatcaggat attcttctaa tacctggaat gctgttttcc 6540
cggggatcgc agtgggtgagt aaccatgcat catcaggagt acggataaaa tgcttgatgg 6600
tcggaagagg cataaattcc gtcagccagt ttagtctgac catctcatct gtaacatcat 6660
tggcaacgct acctttgcca tgtttcagaa acaactctgg cgcatcgggc ttcccataca 6720
atcgatagat tgtcgcacct gattgccga cattatcgcg agcccattta taccatata 6780
aatcagcatc catgttgga tttaatcgcg gcctagagca agacgtttcc cgttgaatat 6840
ggctcataac accccttgta ttactgttta tgtaagcaga cagttttatt gttcatgatg 6900
atatattttt atcttgatgca atgtaacatc agagattttg agacacaacg tggctttccc 6960
cccccccca ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttg 7020
aatgtattta gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac 7080

-6-

ctgacgtcta agaaaccatt attatcatga cattaaccta taaaaatagg cgtatcacga 7140
ggccctttcg tctcgcgcggt ttcggtgatg acggtgaaaa cctctgacac atgcagctcc 7200
cggagacggt cacagcttgt ctgtaagcgg atgccgggag cagacaagcc cgtcagggcg 7260
cgtcagcggg tgttggcggg tgcggggct ggcttaacta tgcggcatca gagcagattg 7320
tactgagagt gcaccatatg cgggtgtgaaa taccgcacag atgcgtaagg agaaaatacc 7380
gcatcagatt ggctattcta gattgcatac gttgtatcca tatcataata tgtacattta 7440
tattggctca tgtccaacat taccgccatg ttgacattga ttattgacta gttattaata 7500
gtaatcaatt acgggggtcat t 7521

<210> 2

<211> 6709

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cDNA

<400> 2

tgcgcgcttt cgggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacgggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180
accatattgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg 300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac 360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaattg 420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc 480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 540
tgcccacttg gcagtacatc aagtgtatca tatgccaaagt acgcccccta ttgacgtcaa 600
tgacggtaaa tgcccgcct ggcattatgc ccagtacatg accttatggg actttcctac 660
ttggcagtag atctacgtat tagtcatcgc tattacatg gtgatgcggg tttggcagta 720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga 780

-7-

cgatcaatggg agtttggttt ggcacccaaa tcaacgggac tttccaaaat gtcgtaacaa 840
ctccgcccc a ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag 900
agctcgttta gtgaaccgtc agatcgctg gagacgccat ccacgtgtt ttgacctcca 960
tagaagacac cgggaccgat ccagcctccg cgcccgga cgggtgattg gaacgcggat 1020
tccccgtgcc aagagtgcg taagtaccgc ctatagagtc tataggcca ccccttggc 1080
ttcttatgca tgctatactg tttttggctt ggggtctata ccccccgct tcctcatgtt 1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc 1200
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct 1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtatttttac 1320
aggatgggg ctcatttatt atttaccat tccatatac aacaccaccg tcccagtg 1380
ccgcagtttt tattaacat aacgtgggat ctccacgga atctcggga cgtgttccg 1440
acatgggctc ttctccgga gggcgaggc ttctacatcc gagccctgct cccatgcctc 1500
cagcgactca tggctgctcg gcagctcctt gctcctaaca gtggaggcca gacttaggca 1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggc gtggcggtag ggtatgtgtc 1620
tgaaaatgag ctcggggagc gggttgcac cgctgacgca tttggaagac ttaaggcagc 1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtactcc 1740
cgttgcggtg ctgttaacgg tggagggcag ttagtctga gcagtactcg ttgctgccgc 1800
gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt 1860
ctgcaggcct tgggtggcac gcgtggctgc accatctgtc tggcccttcc ggcatctga 1920
tgagcagttg aaatctgga ctgcctctgt tgtgtgcctg ctgaataact tctatcccag 1980
agaggccaaa gtacagtga aggtggataa cgcctccaa tcgggtaact cccaggagag 2040
tgtcacagag caggacagca aggacagcac ctacagcctc agcagcacc tgacgtgag 2100
caaagcagac tacgagaaac acaaagtcta cgcctgcga gtcaccatc agggcctgag 2160
ctcgcccgtc acaaagagct tcaacagggg agagtgtga acgcgttatt ttccaccata 2220
ttgcgtctt ttggcaatgt gagggcccg aaacctggc ctgtcttctt gacgagcatt 2280
cctaggggtc tttccctct cgccaaagga atgcaaggc tgttgaatgt cgtgaaggaa 2340

-8-

gcagttcctc tggaagcttc ttgaagacaa acaacgtctg tagcgaccct ttgcaggcag 2400
cggaaccccc cacctggcga caggtgcctc tgcggccaaa agccacgtgt ataagataca 2460
cctgcaaagg cggcacaacc ccagtgccac gttgtgagtt ggatagttgt ggaaagagtc 2520
aaatggctct cctcaagcgt attcaacaag gggctgaagg atgccagaa ggtaccccat 2580
tgtatgggat ctgatctggg gcctcgggtgc acatgcttta catgtgttta gtcgaggtta 2640
aaaaacgtct agggcccccg aaccacgggg acgtggtttt cctttgaaaa acacgatgat 2700
aataccatgg ccgcagcggc cggatctacc aaggggcccat cgggcctctc cccctggcac 2760
cctcctccaa gagcacctct gggggcacag cggccctggg ctgcctggtc aaggactact 2820
tccccgaacc ggtgacggtg tcgtggaact caggcgccct gaccagcggc gtgcacacct 2880
tcccggctgt cctacagtcc tcaggactct actccctcag cagcgtgggt accgtgccct 2940
ccagcagctt gggcaccag acctacatct gcaacgtgaa tcacaagccc agcaacacca 3000
aggtggacaa gaaagcagag cccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc 3060
cagcacctga actcctgggg ggaccgtcag tcttcctctt cccccaaaa cccaaggaca 3120
ccctcatgat ctcccgacc cctgaggtca catgcgtggt ggtggacgtg agccacgaag 3180
accctgaggt caagttcaac tggtagctgg acggcgtgga ggtgcataat gccaagacaa 3240
agccgcggga ggagcagtac aacagcacgt accgggtggt cagcgtccct caccgtcctg 3300
caccaggact ggctgaatgg caaggagtag aagtgaagg tctccaacaa agccctccca 3360
gcccccatcg agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac 3420
accctgcccc catcccgga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc 3480
aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac 3540
aactacaaga ccacgcctcc cgtgctggac tccgacggct ctttcttct ctacagcaag 3600
ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat 3660
gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg atcctgagat 3720
ccagatctgc tgtgcttct agttgccagc catctgttgt ttgcccctcc cccgtgcctt 3780
ccttgaccct ggaagggtgcc actcccactg tcctttccta ataaaatgag gaaattgcat 3840
cgcattgtct gagtaggtgt cattctattc tgggggggtg ggtggggcag cacagcaagg 3900

-9-

gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggctct atgggtaccc 3960
aggtgctgaa gaattgaccc ggttcctcct gggccagaaa gaagcaggca catccccctc 4020
tctgtgacac accctgtcca cgccccctgg tcttagttcc agccccactc ataggacact 4080
catagctcag gagggctccg ccttcaatcc caccgcgtaa agtacttgga gcggtctctc 4140
cctccctcat cagcccacca aaccaaactc agcctccaag agtgggaaga aattaaagca 4200
agataggcta ttaagtgcag agggagagaa aatgcctcca acatgtgagg aagtaatgag 4260
agaaatcata gaatttcttc cgcttcctcg ctactgact cgctgcgctc ggtcgttcgg 4320
ctgcggcgag cggatatcagc tcaactcaaag gcggaatac ggttatccac agaatcaggg 4380
gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag 4440
gccgcgttgc tggcgttttt ccataggctc cgccccctg acgagcatca caaaaatcga 4500
cgctcaagtc agaggtggcg aaaccgcaca ggactataaa gataccaggc gtttccccct 4560
ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata cctgtccgcc 4620
tttctccctt cgggaagcgt ggcgctttct caatgctcac gctgtaggta tctcagttcg 4680
gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac ccccggttca gcccgaccgc 4740
tgcgccttat ccggttaacta tcgtcttgag tccaaccgcg taagacacga cttatcgcca 4800
ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg tgctacagag 4860
ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg tatctgcgct 4920
ctgctgaagc cagttacctt cgaaaaaga gttggtagct cttgatccgg caaacaacc 4980
accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag aaaaaagga 5040
tctcaagaag atcctttgat cttttctacg ggggtctgacg ctcagtgga cgaaaactca 5100
cgtaaggga ttttgggtcat gagattatca aaaaggatct tcacctagat ctttttaaat 5160
taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc tgacagttac 5220
caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc atccatagtt 5280
gcctgactcc gggggggggg ggcgctgagg tctgcctcgt gaagaagggtg ttgctgactc 5340
ataccaggcc tgaatcgccc catcatccag ccagaaagtg agggagccac ggttgatgag 5400
agctttgttg taggtggacc agttggtgat tttgaacttt tgctttgcca cggaacggtc 5460

-10-

tgcgttgctcg ggaagatgcg tgatctgata cttcaactca gcaaaagtgc gatttattca 5520
acaaagccgc cgtcccgta agtcagcgta atgctctgcc agtggtacaa ccaattaacc 5580
aattctgatt agaaaaactc atcgagcatt aaatgaaact gcaatttatt catatcagga 5640
ttatcaatac catatTTTTTg aaaaagccgt ttctgtaatg aaggagaaaa ctcaccgagg 5700
cagttccata ggatggcaag atcctggtat cggctctgca ttccgactcg tccaacatca 5760
atacaacctt ttaatttccc ctctgcaaaa ataaggttat caagtggaga atcaccatga 5820
gtgacgactg aatccggtga gaatggcaaa agcttatgca tttctttcca gacttggtca 5880
acaggccagc cattacgctc gtcatacaaaa tcaactgcat caaccaaacc gttattcatt 5940
cgtgattgct cctgagcgag acgaaatagc cgatcgctgt taaaaggaca attacaaaca 6000
ggaatcgaat gcaaccggcg caggaaact gccagcgcat caacaatatt ttcacctgaa 6060
tcaggatatt cttctaatac ctggaatgct gttttcccg ggatcgcat ggtgagtaac 6120
catgcatcat caggagtacg gataaaatgc ttgatggctg gaagaggcat aaattccgctc 6180
agccagttta gtctgacct ctcatctgta acatcattgg caacgctacc tttgcatgt 6240
ttcagaaaca actctggcg atcgggcttc ccatacaatc gatagattgt cgcacctgat 6300
tgcccgacat tatcgcgagc ccatttatac ccataaaat cagcatccat gttggaattt 6360
aatcgcggcc tcgagcaaga cgtttcccg tgaatatggc tcataacacc ccttgattta 6420
ctgtttatgt aagcagacag ttttattgtt catgatgata tttttttatc ttgtgcaatg 6480
taacatcaga gattttgaga cacaacgtgg ctttcccccc cccccatta ttgaagcatt 6540
tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa aaataaaca 6600
ataggggttc cgcgcacatt tccccgaaaa gtgccacctg acgtctaaga aaccattatt 6660
atcatgacat taacctataa aaataggcgt atcacagggc cttttcgtc 6709

<210> 3

<211> 7528

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cDNA

-11-

<400> 3

tggccatggc ctgggctctg ctgctcctca ccctcctcac tcagggcaca gggtcctggg 60
cccagtctgc cctgactcag cctgcctccg tgtctgggtc tcctggacag tcgatcacca 120
tctcctgcac tggaaccagc agtgatgttg ggagttataa ccttgtctcc tggtagcaac 180
aaaaccagc caaagccccc aaactcatga tttatgatgt cagtaatcgg ccctcagga 240
tttctaatacgt cttctctggc tccaagtctg gcaacacggc ctccctgacc atctctgggc 300
tccaggctga cgacgaggct gattattact gcacctcata taaaacgac agcaattctc 360
aggtattcgg cggaggcacc aagctgaccg tcctaggggc cgatgcggcc ccaactgtat 420
ccatcttccc accatccagt gagcagttaa catctggagg tgctcagtc gtgtgcttct 480
tgaacaactt ctacccaaa gacatcaatg tcaagtggaa gattgatggc agtgaacgac 540
aaaatggcgt cctgaacagt tggactgac aggacagcaa agacagcacc tacagcatga 600
gcagcaccct cacgttgacc aaggacgagt atgaacgaca taacagctat acctgtgagg 660
ccactcacia gacatcaact tcacccattg tcaagagctt caacaggaat gagtgttgaa 720
cgcgttattt tccaccatat tgccgtctt tggcaatgtg agggcccgga aacctggccc 780
tgtcttcttg acgagcattc ctaggggtct tccccctc gccaaaggaa tgcaaggctc 840
gttgaatgtc gtgaaggag cagttcctct ggaagcttct tgaagacaaa caacgtctgt 900
agcgaccctt tgcaggcagc ggaacccccc acctggcgac aggtgcctct gcggccaaa 960
gccacgtgta taagatacac ctgcaaaggc ggcaaaccc cagtgccacg ttgtgagttg 1020
gatagttgtg gaaagagtca aatggctctc ctcaagcgta ttcaacaagg ggctgaagg 1080
tgcccagaag gtacccatt gtatgggatc tgatctggg cctcggtgca catgctttac 1140
atgtgtttag tcgagggttaaaaacgtcta ggcccccg accacgggga cgtggttttc 1200
ctttgaaaaa cacgatgata ataccatggc cgcagcggcc aaacacctgt ggttcttct 1260
cctcctggtg gcagctccca gatgggtcct gtcccagggt cagctacagc agtggggcgc 1320
aggactgttg aagccttcgg agacctgtc cctcacctgc ggtgtttatg gtgggtcctt 1380
cagtgggttac tactggagct ggatccgcca gccccaggg aaggggctgg agtggattgg 1440
ggaaatcaat catagtggaa gcaccaacta caaccgtcc ctcaagagtc gagtcccat 1500
atcagtagac acgtccaaga agcagctctc cctgaagttg agctctgtga acgcccgga 1560

-12-

cacggctgtg tattactgtg cgagagttat tactagggcg agtcctggca cagacgggag 1620
gtacggtatg gacgtctggg gccaagggac cacggtcacg gtctcctcgg ccaaaacggc 1680
cgccccatcg gtctatccac tggcccctgt gtgtggagat acaagtggct cctcggtgac 1740
tctaggatgc ctggtaagg gttatttccc tgagccagtg accttgacct ggaactctgg 1800
atccctgtcc agtgggtgtg acaccttccc agctgtcctg cagtctgacc tctacaccct 1860
cagcagctca gtgactgtaa cctcgagcac ctggcccagc cagtccatta cctgcaatgt 1920
ggcccacccg gcaagcagca ccaaggtgga caagaaaatt gagcccagag ggcccacaat 1980
caagccctgt cctccatgca aatgcccagc acctaacctc ttgggtggac catccgtctt 2040
catcttccct ccaaagatca aggatgtact catgatctcc ctgagcccca tagtcacatg 2100
tgtgggtgtg gatgtgagcg aggatgacct agatgtccag atcagctggg ttgtgaacaa 2160
cgtggaagta cacacagctc agacacaaac ccatagagag gattacaaca gtactctccg 2220
gggtggcagt gccctcccca tccagcacca ggactggatg agtggcaagg agttcaaagt 2280
caaggtcaac aacaaagacc tcccagcgcc catcgagaga accatctcaa aacccaaagg 2340
gtcagtaaga gctccacagg tatatgtctt gcctccacca gaagaagaga tgactaagaa 2400
acaggtcact ctgacctgca tggtcacaga cttcatgcct gaagacattt acgtggagtg 2460
gaccaacaac gggaaaacag agctaaacta caagaacact gaaccagtcc tggactctga 2520
tggttcttac ttcatgtaca gcaagctgag agtggaaaag aagaactggg tggaaagaaa 2580
tagctactcc tgttcagtgg tccacgaggg tctgcacaat caccacacga ctaagagctt 2640
ctcccggact cggggtaaat gaagatccag atctgctgtg ccttctagtt gccagccatc 2700
tggtgtttgc cctcctcccg tgccttcctt gaccctggaa ggtgccactc ccactgtcct 2760
ttcctaataa aatgaggaaa ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg 2820
gggtgggggtg gggcagcaca gcaaggggga ggattgggaa gacaatagca ggcattgctg 2880
ggatgcgggtg ggctctatgg gtaccaggt gctgaagaat tgaccgggtt cctcctgggc 2940
cagaaagaag caggcacatc ccttctctg tgacacaccc tgtccacgcc cctggttctt 3000
agttccagcc ccaatcatag gacactcata gctcaggagg gctccgcctt caatcccacc 3060
cgctaaagta cttggagcgg tctctcctc cctcatcagc ccaccaaacc aaacctagcc 3120

-13-

tccaagagtg ggaagaaatt aaagcaagat aggctattaa gtgcagaggg agagaaaaatg 3180
cctccaacat gtgaggaagt aatgagagaa atcatagaat ttcttccgct tcctcgctca 3240
ctgactcgct gcgctcggtc gttcggctgc ggcgagcggg atcagctcac tcaaaggcgg 3300
taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 3360
agcaaaaggc caggaaccgt aaaaaggccg cgttgcgtgc gtttttccat aggctccgcc 3420
cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac 3480
tataaagata ccaggcggtt cccctggaa gctccctcgt gcgctctcct gttccgaccc 3540
tgccgcttac cggataacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcaat 3600
gctcacgctg taggtatctc agttcgggtg aggtcgttcg ctccaagctg ggctgtgtgc 3660
acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 3720
acccggtaaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 3780
cgaggtatgt aggcggtgct acagagttct tgaagtggg gcctaactac ggctacacta 3840
gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 3900
gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc 3960
agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggg 4020
ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa 4080
ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc taaagtatat 4140
atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga 4200
tctgtctatt tcgttcaccc atagttgcct gactccgggg gggggggggc ctgaggtctg 4260
cctcgtgaag aagggtgttc tgactcatac caggcctgaa tcgccccatc atccagccag 4320
aaagtgaggg agccacggtt gatgagagct ttgtttagg tggaccagtt ggtgattttg 4380
aacttttgct ttgccacgga acggtctgcg ttgtcgggaa gatgcgtgat ctgatccttc 4440
aactcagcaa aagttcgatt tattcaacaa agccgccgtc ccgtcaagtc agcgtaatgc 4500
tctgccagtg ttacaaccaa ttaaccaatt ctgattagaa aaactcatcg agcatcaaat 4560
gaaactgcaa ttattcata tcaggattat caataccata tttttgaaa agccgtttct 4620
gtaatgaagg agaaaactca ccgaggcagt tccataggat ggcaagatcc tggtatcggt 4680

-14-

ctgcgattcc gactcgcca acatcaatac aacctattaa tttcccctcg tcaaaaataa 4740
ggttatcaag tgagaaatca ccatgagtga cgactgaatc cggtgagaat ggcaaaagct 4800
tatgcatttc tttccagact tgttcaacag gccagccatt acgctcgtca tcaaaatcac 4860
tcgcatcaac caaacggtta ttcattcgtg attgcgcctg agcgagacga aatacgcgat 4920
cgctgttaaa aggacaatta caaacaggaa tcgaatgcaa ccggcgcagg aacactgcc 4980
gcgcatcaac aatattttca cctgaatcag gatattcttc taatacctgg aatgctgttt 5040
tcccggggat cgcagtggg agtaaccatg catcatcagg agtacggata aaatgcttga 5100
tggtcggaag aggcataaat tccgtcagcc agtttagtct gaccatctca tctgtaacat 5160
cattggcaac gctacctttg ccatgtttca gaaacaactc tggcgcacgc ggcttcccat 5220
acaatcgata gattgtcgca cctgattgcc cgacattatc gcgagcccat ttatacccat 5280
ataaatcagc atccatgttg gaatttaatc gcggcctcga gcaagacggt tcccgttgaa 5340
tatggctcat aacaccctt gtattactgt ttatgtaagc agacagtttt attgttcag 5400
atgatataatt tttatcttgt gcaatgtaac atcagagatt ttgagacaca acgtggcttt 5460
ccccccccc ccattattga agcatttatc agggttattg tctcatgagc ggatacatat 5520
ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc cgaaaagtgc 5580
cacctgacgt ctaagaaacc attattatca tgacattaac ctataaaaat aggcgatca 5640
cgaggccctt tcgtctcgcg cgtttcgggtg atgacgggtga aaacctctga cacatgcagc 5700
tcccggagac ggtcacagct tgtctgtaag cggatgccg gagcagacaa gcccgtcagg 5760
gcgcgtcagc ggggtgttggc ggggtgtcggg gctggcttaa ctatgcggca tcagagcaga 5820
ttgtactgag agtgcacat atgcggtgtg aaataccgca cagatgcgta aggagaaaat 5880
accgcatcag attggctatt ggccattgca tacgttgtat ccatatcata atatgtacat 5940
ttatattggc tcatgtccaa cattaccgcc atgttgacat tgattattga ctagttatta 6000
atagtaatca attacgggggt cattagttca tagcccatat atggagttcc gcgttacata 6060
acttacggt aatggcccg cgtggtgacc gcccaacgac ccccgcccat tgacgtcaat 6120
aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga 6180
gtatttacgg taaactgcc acttggcagt acatcaagt tatcatatgc caagtacgcc 6240

-15-

ccctattgac gtcaatgacg gtaaattggcc cgcctggcat tatgcccagt acatgacctt 6300
atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtgat 6360
gcggttttgg cagtacatca atgggcgtgg atagcggttt gactcacggg gatttccaag 6420
tctccacccc attgacgtca atgggagttt gttttggcac caaaatcaac gggactttcc 6480
aaaatgtcgt aacaactccg cccattgac gcaaattggc ggtaggcgtg tacggtggga 6540
ggtctatata agcagagctc gtttagtgaa ccgtcagatc gcctggagac gccatccacg 6600
ctgttttgac ctccatagaa gacaccggga ccgatccagc ctccgcggcc gggaacggtg 6660
cattggaacg cggattcccc gtgccaagag tgacgtaagt accgcctata gagtctatag 6720
gcccaccccc ttggcttctt atgcatgcta tactgttttt ggcttggggt ctatacacc 6780
ccgcttcctc atgttatagg tgatggtata gcttagccta taggtgtggg ttattgacca 6840
ttattgacca ctcccctatt ggtgacgata ctttccatta ctaatccata acatggctct 6900
ttgccacaac tctctttatt ggctatatgc caataactg tccttcagag actgacacgg 6960
actctgtatt ttacaggat ggggtctcat ttattattta caaattcaca tatacaacac 7020
caccgtcccc agtgcccgca gtttttatta aacataacgt gggatctcca cgcgaatctc 7080
gggtacgtgt tccggacatg ggctcttctc cggtagcggc ggagcttcta catccgagcc 7140
ctgctcccat gcctccagcg actcatggtc gctcggcagc tccttgctcc taacagtgga 7200
ggccagactt aggcacagca cgatgccac caccaccagt gtgccgcaca aggccgtggc 7260
ggtagggtat gtgtctgaaa atgagctcgg ggagcgggct tgcaccgctg acgcatttgg 7320
aagacttaag gcagcggcag aagaagatgc aggcagctga gttgttgtgt tctgataaga 7380
gtcagaggta actcccgttg cgggtctgtt aacgggtggag ggagtgtag tctgagcagt 7440
actcgttgct gccgcgcgcg ccaccagaca taatagctga cagactaaca gactgttct 7500
ttccatgggt cttttctgca ggcttgc 7528

<210> 4

<211> 6729

<212> DNA

<213> Artificial Sequence

<220>

-16-

<223> Description of Artificial Sequence: cDNA

<400> 4

```
tcgcgcgttt cggatgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg 300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac 360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg 420
ccgcctggc tgaccgcca acgaccccg cccattgacg tcaataatga cgtatgttcc 480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 540
tgcccacttg gcagtacatc aagtgtatca tatgccagt acgcccccta ttgacgtcaa 600
tgacggtaaa tggccgcct ggcattatgc ccagtacatg accttatggg actttcctac 660
ttggcagtac atctacgtat tagtcacgc tattaccatg gtgatgcggg tttggcagta 720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga 780
cgtcaatggg agtttgttt ggacacaaa tcaacgggac tttccaaaat gtcgtaacaa 840
ctccgccccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag 900
agctcgttta gtgaaccgtc agatgcctg gagacgccat ccacgctgtt ttgacctcca 960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cgggtgcattg gaacgcggat 1020
tccccgtgcc aagagtgcg taagtaccgc ctatagagtc tataggcca ccccttggc 1080
ttcttatgca tgctatactg tttttggctt ggggtctata ccccccgct tctcatgtt 1140
ataggtgatg gtatagctta gcctataggt gtgggttatt gaccattatt gaccactccc 1200
ctattggtga cgatactttc cattactaat ccataacatg gctctttgcc acaactctct 1260
ttattggcta tatgccaata cactgtcctt cagagactga cacggactct gtatttttac 1320
aggatggggc ctcatattt atttacaaat tcacatatac aacaccaccg tccccagtgc 1380
ccgcagtttt tattaacat aacgtgggat ctccacgca atctcgggta cgtgttccgg 1440
acatgggctc ttctccgta gggcgaggc ttctacatcc gagccctgct cccatgcctc 1500
```

-17-

cagcgactca tggctgctcg gcagctcctt gtccttaaca gtggaggcca gacttaggca 1560
cagcacgatg cccaccacca ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc 1620
tgaaaatgag ctcggggagc gggcttgacac cgctgacgca tttggaagac ttaaggcagc 1680
ggcagaagaa gatgcaggca gctgagttgt tgtgttctga taagagtcag aggtaactcc 1740
cgttgcggtg ctgttaacgg tggagggcag tgtagtctga gcagtactcg ttgctgccgc 1800
gcgcgccacc agacataata gctgacagac taacagactg ttcctttcca tgggtctttt 1860
ctgcaggcct tgctggccac gcgtggccga tgcggcccca actgtatcca tcttcccacc 1920
atccagtgag cagttaacat ctggaggtgc ctcagtcgtg tgcttcttga acaacttcta 1980
cccaaagac atcaatgtca agtggaagat tgatggcagt gaacgacaaa atggcgctcct 2040
gaacagttgg actgatcagg acagcaaaga cagcacctac agcatgagca gcacctcac 2100
gttgaccaag gacgagtatg aacgacataa cagctatacc tgtgaggcca ctcacaagac 2160
atcaacttca ccattgtca agagcttcaa caggaatgag tgttgaacgc gttattttcc 2220
accatattgc cgtcttttgg caatgtgagg gcccgaaac ctggccctgt cttcttgacg 2280
agcattccta ggggtctttc ccctctcgcc aaaggaatgc aaggctctgtt gaatgtcgtg 2340
aaggaagcag ttcctctgga agcttcttga agacaaacaa cgtctgtagc gaccctttgc 2400
aggcagcgga accccccacc tggcgacagg tgcctctgcg gccaaaagcc acgtgtataa 2460
gatacacctg caaaggcggc acaaccccag tgccacgttg tgagttggat agttgtggaa 2520
agagtcaa at ggctctcctc aagcgtattc aacaaggggc tgaaggatgc ccagaaggta 2580
ccccattgta tgggatctga tctggggcct cgggtgcacat gctttacatg tgtttagtcg 2640
aggttaaaaa acgtctaggc cccccgaacc acggggacgt ggttttcctt tgaaaaacac 2700
gatgataata ccatggccgc agcggccgga tctcgtctcc tcggccaaaa cggccgcccc 2760
atcggctctat ccactggccc ctgtgtgtgg agatacaagt ggctcctcgg tgactctagg 2820
atgcctggtc aagggttatt tccctgagcc agtgacctg acctggaact ctggatccct 2880
gtccagtggg gtgcacacct tcccagctgt cctgcagtct gacctetaca ccctcagcag 2940
ctcagtgact gtaacctcga gcacctggcc cagccagtcc attacctgca atgtggccca 3000
cccggaagc agcaccaagg tggacaagaa aattgagccc agagggccca caatcaagcc 3060

-18-

ctgtcctcca tgcaaatgcc cagcacctaa cctcttgggt ggaccatccg tcttcatctt 3120
ccctccaaag atcaaggatg tactcatgat ctccctgagc cccatagtca catgtgtggt 3180
gggtgatgtg agcgaggatg acccagatgt ccagatcagc tggtttgtga acaacgtgga 3240
agtacacaca gctcagacac aaacccatag agaggattac aacagtactc tccgggtggt 3300
cagtgccttc cccatccagc accaggactg gatgagtggc aaggagttca aatgcaaggt 3360
caacaacaaa gacctcccag cgcccatcga gagaaccatc tcaaaaccca aagggtcagt 3420
aagagctcca caggtatatg tcttgcctcc accagaagaa gagatgacta agaaacaggt 3480
cactctgacc tgcatggtca cagacttcat gcctgaagac atttacgtgg agtggaccaa 3540
caacgggaaa acagagctaa actacaagaa cactgaacca gtcctggact ctgatggttc 3600
ttacttcatg tacagcaagc tgagagtgga aaagaagaac tgggtggaaa gaaatagcta 3660
ctcctgttca gtggtccacg agggcttgca caatcaccac acgactaaga gcttctcccg 3720
gactccgggt aaatgaagat ccagatctgc tgtgccttct agttgccagc catctgttgt 3780
ttgcccctcc cccgtgcctt ccttgaccct ggaaggtgcc actcccactg tcctttccta 3840
ataaaatgag gaaattgcat cgcattgtct gagtaggtgt cattctattc tggggggtgg 3900
gggtggggcag cacagcaagg gggaggattg ggaagacaat agcaggcatg ctgggggatgc 3960
gggtgggctct atgggtaccc aggtgctgaa gaattgaccc ggttcctcct gggccagaaa 4020
gaagcaggca catccccttc tctgtgacac accctgtcca cgcccctggt tcttagttcc 4080
agccccactc ataggacact catagctcag gagggctccg ccttcaatcc caccgcctaa 4140
agtacttga gcggtctctc cctccctcat cagcccacca aaccaaacct agcctccaag 4200
agtgggaaga aattaaagca agataggcta ttaagtgcag agggagagaa aatgcctcca 4260
acatgtgagg aagtaatgag agaaatcata gaatttcttc cgcttcctcg ctactgact 4320
cgctgcgctc ggtcggttcg ctgcgggcag cggtatcagc tcaactcaaag gcggtaatc 4380
ggttatccac agaatacagg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa 4440
aggccaggaa ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc cgccccctg 4500
acgagcatca caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa 4560
gataccaggc gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc 4620

-19-

ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct caatgctcac 4680
gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac 4740
ccccgttca gcccgaccgc tgcgccttat ccggtaaacta tcgtcttgag tccaacccgg 4800
taagacacga cttatcgcca ctggcagcag cactggtaa caggattagc agagcgaggt 4860
atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga 4920
cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct 4980
cttgatccgg caaacaacc accgctggta gcggtggttt ttttgttgc aagcagcaga 5040
ttacgcgcag aaaaaaagga tctcaagaag atcctttgat cttttctacg gggctctgacg 5100
ctcagtggaa cgaaaactca cgttaaggga ttttggctcat gagattatca aaaaggatct 5160
tcacctagat ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt 5220
aaacttggtc tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc 5280
tatttcgttc atccatagtt gcctgactcc gggggggggg ggcgctgagg tctgcctcgt 5340
gaagaagggtg ttgctgactc ataccaggcc tgaatcgccc catcatccag ccagaaagtg 5400
agggagccac ggttgatgag agctttgttg taggtggacc agttggtgat tttgaacttt 5460
tgctttgcc aaggaacggtc tgcgttgctg ggaagatgcg tgatctgac cttcaactca 5520
gcaaaagttc gatttattca acaaagccgc cgtcccgtca agtcagcgta atgctctgcc 5580
agtgttacaa ccaattaacc aattctgatt agaaaaactc atcgagcatc aaatgaaact 5640
gcaatttatt catatcagga ttatcaatac catatttttg aaaaagccgt ttctgtaatg 5700
aaggagaaaa ctcaccgagg cagttccata ggatggcaag atcctggtat cggctctgcga 5760
ttccgactcg tccaacatca atacaacctt ttaatttccc ctgctcaaaa ataaggttat 5820
caagtgagaa atcaccatga gtgacgactg aatccggtga gaatggcaaa agcttatgca 5880
tttctttcca gacttggtca acaggccagc cattacgctc gtcacaaaa tcaactcgcat 5940
caaccaaacc gttattcatt cgtgattgcg cctgagcgag acgaaatacg cgatcgctgt 6000
taaaaggaca attacaaaca ggaatcgaat gcaaccggcg caggaacact gccagcgcat 6060
caacaatatt ttcacctgaa tcaggatatt cttctaatac ctggaatgct gttttcccg 6120
ggatcgaggt ggtgagtaac catgcatcat caggagtacg gataaaatgc ttgatggctg 6180

-20-

gaagaggcat aaattccgtc agccagttta gtctgaccat ctcatctgta acatcattgg 6240
caacgctacc ttgccatgt ttcagaaaca actctggcgc atcgggcttc ccatacaatc 6300
gatagattgt cgcacctgat tgcccacat tatcgcgagc ccatttatac ccatataaat 6360
cagcatccat gttggaattt aatcgcggcc tcgagcaaga cgtttcccg tgaatatggc 6420
tcataacacc ccttgattta ctgtttatgt aagcagacag ttttattgtt catgatgata 6480
tatttttatc ttgtgcaatg taacatcaga gattttgaga cacaacgtgg ctttcccccc 6540
ccccccatta ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat 6600
gtatttagaa aaataaacia ataggggttc cgcgcacatt tccccgaaaa gtgccacctg 6660
acgtctaaga aaccattatt atcatgacat taacctataa aaataggcgt atcacgaggc 6720
cctttcgtc 6729

<210> 5

<211> 4779

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cDNA

<400> 5

tggccattgc atacgttgta tccatatcat aatatgtaca tttatattgg ctcatgtcca 60
acattaccgc catgttgaca ttgattattg actagttatt aatagtaatc aattacgggg 120
tcattagttc atagccata tatggagtgc cgcgttacat aacttacggt aaatggcccg 180
cctggctgac cgccaacga ccccgccca ttgacgtcaa taatgacgta tgttcccata 240
gtaacgcaa tagggacttt ccattgacgt caatgggtgg agtatttacg gtaaactgcc 300
catttggcag tacatcaagt gtatcatatg ccaagtacgc cccctattga cgtcaatgac 360
ggtaaattggc ccgcctggca ttatgccag tacatgacct tatgggactt tcttacttgg 420
cagtacatct acgtattagt catcgctatt accatgggtga tgcggttttg gcagtacatc 480
aatgggcgtg gatagcgggt tgactcacgg ggatttccaa gtctccaccc cattgacgtc 540
aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc 600
gccccattga cgcaaatggg cggtaggcgt gtacggtggg aggtctatat aagcagagct 660

-21-

cgttttagtga accgtcagat cgcctggaga cgccatocac gctgttttga cctccataga 720
agacaccggg accgatccag cctccgcggc cggaacggg gcattggaac gcggattccc 780
cgtgccaaga gtgacgtaag tacgcctat agactctata ggcacacccc tttggctctt 840
atgcatgcta tactgttttt ggcttggggc ctatacacc cgccttcctt atgctatagg 900
tgatggtata gcttagccta taggtgtggg ttattgacca ttattgacca ctcccctatt 960
ggtgacgata ctttccatta ctaatccata acatggctct ttgccacaac tatctctatt 1020
ggctatatgc caataactctg tccttcagag actgacacgg actctgtatt ttacaggat 1080
ggggtcccat ttattattta caaattcaca tatacaaaa cgccgtcccc cgtgcccgca 1140
gtttttatta aacatagcgt gggatctcca cgcaaatctc gggtagctgt tccggacatg 1200
ggctcttctc cggtagcggc ggagcttcca catccgagcc ctgggtcccat gcctccagcg 1260
gctcatggtc gctcggcagc tccttgctcc taacagtggg gccagactt aggcacagca 1320
caatgccac caccaccagt gtgccgcaca aggccgtggc ggtagggat gtgtctgaaa 1380
atgagcgtgg agattgggct cgcacggctg acgcagatgg aagacttaag gcagcggcag 1440
aagaagatgc aggcagctga gttgttgtat tctgataaga gtcagaggta actcccgttg 1500
cgggtgtgtt aacgggtggg ggagtgtag tctgagcagt actcgttgct gccgcgcgcg 1560
ccaccagaca taatagctga cagactaaca gactgttcct ttccatgggt cttttctgca 1620
gtcaccgtcg tcggatatcg aattccgtac gacgcgtggg taccgactgc agtcacctgg 1680
tgctagcggg tcccctaggg tcgaccacgt gtgatccaga tctacttctg gctaataaaa 1740
gatcagagct ctagagatct gtgtgttggg tttttgtgtg gtaccaggt gctgaagaat 1800
tgaccgggtt cctcctgggc cagaaagaag caggcacatc cccttctctg tgacacaccc 1860
tgtccacgcc cctggttctt agttccagcc ccaactcatg gacactcata gtcaggagg 1920
gctccgcctt caatcccacc cgctaaagta cttggagcgg tctctccctc cctcatcagc 1980
ccaccaaacc aaacctagcc tccaagagt ggaagaaatt aaagcaagat aggtatttaa 2040
gtgcagaggg agagaaaatg cctccaacat gtgaggaagt aatgagagaa atcatagaat 2100
ttcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcgg 2160
atcagctcac tcaaaggcgg taatacgggt atccacagaa tcaggggata acgcaggaaa 2220

-22-

gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc 2280
gtttttccat aggtccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag 2340
gtggcgaaac cgcacaggac tataaagata ccaggcgttt cccctggaa gctccctcgt 2400
gcgctctcct gttccgaccc tgccgcttac cggataacctg tccgcctttc tcccttcggg 2460
aagcgtggcg ctttctcaat gctcacgctg taggtatctc agttcgggtg aggtcggtcg 2520
ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg 2580
taactatcgt cttgagtcca acccggttaag acacgaacta tcgccactgg cagcagccac 2640
tggtaacagg attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtgggtg 2700
gcctaactac ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt 2760
taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg 2820
tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc 2880
tttgatcttt tctacggggg ctgacgctca gtggaacgaa aactcacgtt aagggatttt 2940
ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt 3000
taaataaatc taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag 3060
tgaggcacct atctcagcga tctgtctatt tcgttcaccc atagttgcct gactccgggg 3120
ggggggggcg ctgaggtctg cctcgtgaag aagggtgttg tgactcatac caggcctgaa 3180
tcgccccatc atccagccag aaagtgaggg agccacgggt gatgagagct ttgttgtagg 3240
tggaaccagt ggtgattttg aacttttgct ttgccacgga acggtctgcg ttgtcgggaa 3300
gatgcgtgat ctgatccttc aactcagcaa aagttcgatt tattcaacaa agccgccgtc 3360
ccgtcaagtc agcgtaatgc tctgccagtg ttacaaccaa ttaaccaatt ctgattagaa 3420
aaactcatcg agcatcaaat gaaactgcaa tttattcata tcaggattat caataccata 3480
tttttgaaaa agccgtttct gtaatgaagg agaaaactca ccgaggcagt tccataggat 3540
ggcaagatcc tggatatcgg ctgcgattcc gactcgtcca acatcaatac aacctattaa 3600
tttccctcgc tcaaaaataa gggtatcaag tgagaaatca ccatgagtga cgactgaatc 3660
cgggtgagaat ggcaaaagct tatgcatttc tttccagact tgttcaacag gccagccatt 3720
acgctcgtca tcaaaatcac tcgcatcaac caaacggtta ttcattcgtg attgcgcctg 3780

-23-

agcgagacga aatacgcgat cgctgttaaa aggacaatta caaacaggaa tcgaatgcaa 3840
ccggcgagg aacactgcc aacatcaaac aatattttca cctgaatcag gatattcttc 3900
taatacctgg aatgctgttt tcccggggat cgcagtggtg agtaaccatg catcatcagg 3960
agtacggata aaatgcttga tggtcggaag aggcataaat tccgtcagcc agtttagtct 4020
gaccatctca tctgtaacat cattggcaac gctacctttg ccatgtttca gaaacaactc 4080
tggcgcatcg ggcttcccat acaatcgata gattgtcgca cctgattgcc cgacattatc 4140
gcgagcccat ttatacccat ataaatcagc atccatgttg gaatttaatc gcggcctcga 4200
gcaagacgtt tcccgttgaa tatggctcat aacacccctt gtattactgt ttatgtaagc 4260
agacagtttt attgttcatg atgatataatt tttatcttgt gcaatgtaac atcagagatt 4320
ttgagacaca acgtggcttt cccccccccc ccattattga agcattttatc agggttattg 4380
tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 4440
cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc attattatca tgacattaac 4500
ctataaaaaat aggcgtatca cgaggccctt tcgtctcgcg cgtttcggtg atgacggtga 4560
aaacctctga cacatgcagc tcccggagac ggtcacagct tgtctgtaag cggatgccgg 4620
gagcagacaa gcccgtcagg gcgcgtcagc ggggtgtggc ggggtgcggg gctggcttaa 4680
ctatgcggca tcagagcaga ttgtactgag agtgacccat atgcggtgtg aaataccgca 4740
cagatgcgta aggagaaaat accgcatcag attggctat 4779

<210> 6

<211> 5322

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cDNA

<400> 6

tggccattgc atacgttgta tccatatcat aatatgtaca tttatattgg ctcatgtcca 60
acattaccgc catgttgaca ttgattattg actagttatt aatagtaatc aattacgggg 120
tcattagttc atagcccata tatggagttc cgcgttacat aacttacggt aaatggcccg 180
cctggctgac cgcccaacga cccccgcca ttgacgtcaa taatgacgta tgttcccata 240

-24-

gtaacgccaa tagggacttt ccattgacgt caatgggtgg agtatttacg gtaaactgcc 300
cacttggcag tacatcaagt gtatcatatg ccaagtacgc cccctattga cgtcaatgac 360
ggtaaattggc ccgcctggca ttatgcccag tacatgacct tatgggactt tcttacttgg 420
cagtacatct acgtattagt catcgctatt accatgggtga tgcgggtttg gcagtacatc 480
aatgggcgtg gatagcgggt tgaactcacgg ggatttccaa gtctccaccc cattgacgtc 540
aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc 600
gccccattga cgcaaattgg cggtaggcgt gtacgggtgg aggtctatat aagcagagct 660
cgttttagtga accgtcagat cgcctggaga cgccatccac gctgttttga cctccataga 720
agacaccggg accgatccag cctccgcggc cgggaacggt gcattggaac gcggattccc 780
cgtgccaaaga gtgacgtaag taccgcctat agactctata ggcacacccc ttggtctctt 840
atgcatgcta tactgttttt ggcttggggc ctatacacc cgccttcctt atgctatagg 900
tgatggtata gcttagccta taggtgtggg ttattgacca ttattgacca ctcccctatt 960
ggtgacgata ctttccatta ctaatccata acatggctct ttgccacaac tatctctatt 1020
ggctatatgc caatactctg tccttcagag actgacacgg actctgtatt ttacaggat 1080
ggggtcccat ttattattta caaatcaca tatacaacaa cgccgtcccc cgtgcccgca 1140
gtttttatta aacatagcgt gggatctcca cgcgaaatct gggtagctgt tccggacatg 1200
ggctcttctc cggtagcggc ggagcttcca catccgagcc ctgggtcccat gcctccagcg 1260
gctcatggtc gctcggcagc tccttgctcc taacagtgga ggccagactt aggcacagca 1320
caatgccac caccaccagt gtccgcaca aggccgtggc ggtagggtat gtgtctgaaa 1380
atgagcgtgg agattgggct cgcacggctg acgcagatgg aagacttaag gcagcggcag 1440
aagaagatgc aggcagctga gttgtgtat tctgataaga gtcagaggta actcccgttg 1500
cgggtctgtt aacggtggag ggcagtgtag tctgagcagt actcgttgct gccgcgcgcg 1560
ccaccagaca taatagctga cagactaaca gactgttctt ttccatgggt cttttctgca 1620
gtcacgcgtc tcggatatcg aattcgccgc caccatgaca gtgctggcgc cagcctggag 1680
cccaaattcc tccctgttgc tgctgttgct gctgctgagt ccttgctgc gggggacacc 1740
tgactgttac ttcagccaca gtcccatctc ctccaacttc aaagtgaagt ttagagagtt 1800

-25-

gactgaccac ctgcttaaag attaccacgt cactgtggcc gtcaatcttc aggacgagaa 1860
gcactgcaag gccttgtgga gcctcttcct agcccagcgc tggatagagc aactgaagac 1920
tgtggcaggg tctaagatgc aaacgcttct ggaggacgtc aacaccgaga tacatcttgt 1980
cacctcatgt accttcacgc ccctaccaga atgtctgcga ttcgtccaga ccaacatctc 2040
ccacctcctg aaggacacct gcacacagct gcttgctctg aagccctgta tcgggaaggc 2100
ctgccagaat ttctctcggg gcctggaggt gcagtgccag ccggactcct ccacctgct 2160
gcccccaagg agtcccatag ccctagaagc cacggagctc ccagagcctc ggcccaggca 2220
gtgagctagc ggatcccta gggtcgacca cgtgtgatcc agatctactt ctggctaata 2280
aaagatcaga gctctagaga tctgtgtgtt ggttttttgt gtggtacca ggtgctgaag 2340
aattgaccgc gttcctcctg ggccagaaa aagcaggcac atccccttct ctgtgacaca 2400
ccctgtccac gcccctggtt cttagtcca gccccactca taggacactc atagctcagg 2460
agggctccgc cttcaatccc acccgctaaa gtacttggag cggctctctc ctccctcatc 2520
agcccaccaa accaaaccta gcctccaaga gtgggaagaa attaaagcaa gataggctat 2580
taagtgcaga gggagagaaa atgcctcaa catgtgagga agtaatgaga gaaatcatag 2640
aatttcttcc gttcctcgc tactgactc gctgcgctcg gtcgttcggc tgcggcgagc 2700
ggatcagct cactcaaagg cggtaatagc gttatccaca gaatcagggg ataacgcagg 2760
aaagaacatg tgagcaaaag gccagcaaaa ggccagggaac cgtaaaaagg ccgcgttgct 2820
ggcgtttttc cataggctcc gccccctga cgagcatcac aaaaatcgac gctcaagtca 2880
gagggtggcg aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct 2940
cgtgcgctct cctgttcgga ccctgccgct taccggatac ctgtccgcct ttctccctc 3000
gggaagcgtg gcgctttctc aatgctcacg ctgtaggat ctcagttcgg tgtaggctcg 3060
tcgctccaag ctgggctgtg tgcacgaacc ccccgctcag cccgaccgct gcgccttata 3120
cggtaactat cgtcttgagt ccaaccgggt aagacacgac ttatcgccac tggcagcagc 3180
cactggtaac aggattagca gagcgaggta tgtaggcggg gctacagagt tcttgaagtg 3240
gtggcctaac tacggctaca ctagaaggac agtatttggg atctgcgctc tgctgaagcc 3300
agttaccttc ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag 3360

-26-

cggtggtttt tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga 3420
tcctttgatc ttttctacgg ggtctgacgc tcagtggaaac gaaaactcac gttaagggat 3480
tttggtcatg agattatcaa aaaggatctt cacctagatc cttttaaat aaatatgaag 3540
ttttaaatca atctaaagta tatatgagta aacttggctt gacagttacc aatgcttaat 3600
cagtgaggca cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccg 3660
gggggggggg gcgctgaggt ctgcctcgtg aagaagggtg tgctgactca taccaggcct 3720
gaatcgcccc atcatccagc cagaaagtga gggagccacg gttgatgaga gctttgttgt 3780
aggtggacca gttggtgatt ttgaactttt gctttgccac ggaacggtct gcgttgctcg 3840
gaagatgctg gatctgatcc ttcaactcag caaaagttcg atttattcaa caaagccgcc 3900
gtcccgtaaa gtcagcgtaa tgctctgcca gtgttacaac caattaacca attctgatta 3960
gaaaaactca tcgagcatca aatgaaactg caatttatc atatcaggat tatcaatacc 4020
atatttttga aaaagccggt tctgtaatga aggagaaaac tcaccgaggc agttccatag 4080
gatggcaaga tcctggtatc ggtctgcgat tccgactcgt ccaacatcaa tacaacctat 4140
taatttcccc tcgtcaaaaa taaggttatc aagtgagaaa tcaccatgag tgacgactga 4200
atccggtgag aatggcaaaa gcttatgcat ttctttccag acttgttcaa caggccagcc 4260
attacgctcg tcatcaaaat cactcgcac aaccaaacgg ttattcattc gtgattgcgc 4320
ctgagcgaga cgaaatacgc gatcgcgtgtt aaaaggacaa ttacaaacag gaatcgaatg 4380
caaccggcgc aggaacactg ccagcgcac aacaatattt tcacctgaat caggatattc 4440
ttctaatacc tggaatgctg ttttcccggt gatcgagtg gtgagtaacc atgcatcatc 4500
aggagtacgg ataaaatgct tgatggtcgg aagaggcata aattccgtca gccagtttag 4560
tctgaccatc tcatctgtaa catcattggc aacgctacct ttgccatgtt tcagaaacaa 4620
ctctggcgca tcgggcttcc catacaatcg atagattgtc gcacctgatt gcccgacatt 4680
atcgcgagcc catttatacc catataaatc agcatccatg ttggaattta atcgcgccct 4740
cgagcaagac gtttcccggt gaatatggct cataacaccc cttgtattac tgtttatgta 4800
agcagacagt tttattgttc atgatgatat atttttatct tgtgcaatgt aacatcagag 4860
attttgagac acaacgtggc tttccccccc cccccattat tgaagcattt atcagggtta 4920

-27-

ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaaca aa taggggttcc 4980
 gcgcacattt ccccgaaaag tgccacctga cgtctaagaa accattatta tcatgacatt 5040
 aacctataaa aatagggcgta tcacgaggcc ctttcgtctc gcgcgtttcg gtgatgacgg 5100
 tgaaaacctc tgacacatgc agctcccgga gacggtcaca gcttgtctgt aagcggatgc 5160
 cgggagcaga caagcccgtc agggcgcgtc agcgggtggt ggcggtgtc ggggctggct 5220
 taactatgcg gcatcagagc agattgtact gagagtgcac catatgcggt gtgaaatacc 5280
 gcacagatgc gtaaggagaa aataccgcat cagattggct at 5322

<210> 7

<211> 829

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (32)..(724)

<220>

<221> CDS

<222> (32)..(598)

<400> 7

ctgtcacagg catgaggggt ccccggcaga g atg aca gtg ctg gcg cca gcc	52
Met Thr Val Leu Ala Pro Ala	
1 5	
tggtggc cca aat tcc tcc ctg ttg ctg ctg ttg ctg ctg ctg agt cct	100
Trp Ser Pro Asn Ser Ser Leu Leu Leu Leu Leu Leu Ser Pro	
10 15 20	
tgc ctg cgg ggg aca cct gac tgt tac ttc agc cac agt ccc atc tcc	148
Cys Leu Arg Gly Thr Pro Asp Cys Tyr Phe Ser His Ser Pro Ile Ser	
25 30 35	
tcc aac ttc aaa gtg aag ttt aga gag ttg act gac cac ctg ctt aaa	196
Ser Asn Phe Lys Val Lys Phe Arg Glu Leu Thr Asp His Leu Leu Lys	
40 45 50 55	
gat tac cca gtc act gtg gcc gtc aat ctt cag gac gag aag cac tgc	244
Asp Tyr Pro Val Thr Val Ala Val Asn Leu Gln Asp Glu Lys His Cys	
60 65 70	
aag gcc ttg tgg agc ctc ttc cta gcc cag cgc tgg ata gag caa ctg	292
Lys Ala Leu Trp Ser Leu Phe Leu Ala Gln Arg Trp Ile Glu Gln Leu	

-28-

75	80	85	
aag act gtg gca ggg tct aag atg caa acg ctt ctg gag gac gtc aac			340
Lys Thr Val Ala Gly Ser Lys Met Gln Thr Leu Leu Glu Asp Val Asn			
90	95	100	
acc gag ata cat ttt gtc acc tca tgt acc ttc cag ccc cta cca gaa			388
Thr Glu Ile His Phe Val Thr Ser Cys Thr Phe Gln Pro Leu Pro Glu			
105	110	115	
tgt ctg cga ttc gtc cag acc aac atc tcc cac ctc ctg aag gac acc			436
Cys Leu Arg Phe Val Gln Thr Asn Ile Ser His Leu Leu Lys Asp Thr			
120	125	130	135
tgc aca cag ctg ctt gct ctg aag ccc tgt atc ggg aag gcc tgc cag			484
Cys Thr Gln Leu Leu Ala Leu Lys Pro Cys Ile Gly Lys Ala Cys Gln			
140	145	150	
aat ttc tct cgg tgc ctg gag gtg cag tgc cag ccg gac tcc tcc acc			532
Asn Phe Ser Arg Cys Leu Glu Val Gln Cys Gln Pro Asp Ser Ser Thr			
155	160	165	
ctg ctg ccc cca agg agt ccc ata gcc cta gaa gcc acg gag ctc cca			580
Leu Leu Pro Pro Arg Ser Pro Ile Ala Leu Glu Ala Thr Glu Leu Pro			
170	175	180	
gag cct cgg ccc agg cag ctg ttg ctc ctg ctg ctg ctg ctg cct ctc			628
Glu Pro Arg Pro Arg Gln Leu Leu Leu Leu Leu Leu Leu Pro Leu			
185	190	195	
aca ctg gtg ctg ctg gca gcc gcc tgg ggc ctt cgc tgg caa agg gca			676
Thr Leu Val Leu Leu Ala Ala Trp Gly Leu Arg Trp Gln Arg Ala			
200	205	210	215
aga agg agg ggg gag ctc cac cct ggg gtg ccc ctc ccc tcc cat ccc			724
Arg Arg Arg Gly Glu Leu His Pro Gly Val Pro Leu Pro Ser His Pro			
220	225	230	
ctgttgctcc tgctgctgct gctgcctctc acaactgggtgc tgctggcagc			774
cgccctggggc ctctgctggc aaagggcaag aaggaggggg gagctccacc			824
ctgggggtgcc cctccccctcc cateccctagg attcgagcct tgtgcatcgt			874
tgactcagcc aggggtcttat ctgggttaca cctgtaatct cagcccttgg			924
gagcccagag caggattgct gaatgggtctg g			955

<210> 8

<211> 231

<212> PRT

-29-

<213> Mus musculus

<400> 8

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu Leu Leu
 1 5 10 15

Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp Cys Tyr
 20 25 30

Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val Lys Phe Arg Glu
 35 40 45

Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr Val Ala Val Asn
 50 55 60

Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser Leu Phe Leu Ala
 65 70 75 80

Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly Ser Lys Met Gln
 85 90 95

Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe Val Thr Ser Cys
 100 105 110

Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val Gln Thr Asn Ile
 115 120 125

Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu Ala Leu Lys Pro
 130 135 140

Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys Leu Glu Val Gln
 145 150 155 160

Cys Gln Pro Asp Ser Ser Thr Leu Leu Pro Pro Arg Ser Pro Ile Ala
 165 170 175

Leu Glu Ala Thr Glu Leu Pro Glu Pro Arg Pro Arg Gln Leu Leu Leu
 180 185 190

Leu Leu Leu Leu Leu Pro Leu Thr Leu Val Leu Leu Ala Ala Ala Trp
 195 200 205

Gly Leu Arg Trp Gln Arg Ala Arg Arg Arg Gly Glu Leu His Pro Gly
 210 215 220

Val Pro Leu Pro Ser His Pro
 225 230

<210> 9

<211> 189

<212> PRT

-30-

<213> Mus musculus

<400> 9

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu Leu Leu
 1 5 10 15

Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp Cys Tyr
 20 25 30

Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val Lys Phe Arg Glu
 35 40 45

Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr Val Ala Val Asn
 50 55 60

Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser Leu Phe Leu Ala
 65 70 75 80

Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly Ser Lys Met Gln
 85 90 95

Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe Val Thr Ser Cys
 100 105 110

Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val Gln Thr Asn Ile
 115 120 125

Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu Ala Leu Lys Pro
 130 135 140

Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys Leu Glu Val Gln
 145 150 155 160

Cys Gln Pro Asp Ser Ser Thr Leu Leu Pro Pro Arg Ser Pro Ile Ala
 165 170 175

Leu Glu Ala Thr Glu Leu Pro Glu Pro Arg Pro Arg Gln
 180 185

<210> 10

<211> 852

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (7)..(666)

<400> 10

gcagag atg aca gtg ctg gcg cca gcc tgg agc cca aat tcc tcc ctg 48
 Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu
 1 5 10

-31-

ttg ctg ctg ttg ctg ctg ctg agt cct tgc ctg cgg ggg aca cct gac	96
Leu Leu Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp	
15 20 25 30	
tgt tac ttc agc cac agt ccc atc tcc tcc aac ttc aaa gtg aag ttt	144
Cys Tyr Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val Lys Phe	
35 40 45	
aga gag ttg act gac cac ctg ctt aaa gat tac cca gtc act gtg gcc	192
Arg Glu Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr Val Ala	
50 55 60	
gtc aat ctt cag gac gag aag cac tgc aag gcc ttg tgg agc ctc ttc	240
Val Asn Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser Leu Phe	
65 70 75	
cta gcc cag cgc tgg ata gag caa ctg aag act gtg gca ggg tct aag	288
Leu Ala Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly Ser Lys	
80 85 90	
atg caa acg ctt ctg gag gac gtc aac acc gag ata cat ttt gtc acc	336
Met Gln Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe Val Thr	
95 100 105 110	
tca tgt acc ttc cag ccc cta cca gaa tgt ctg cga ttc gtc cag acc	384
Ser Cys Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val Gln Thr	
115 120 125	
aac atc tcc cac ctc ctg aag gac acc tgc aca cag ctg ctt gct ctg	432
Asn Ile Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu Ala Leu	
130 135 140	
aag ccc tgt atc ggg aag gcc tgc cag aat ttc tct cgg tgc ctg gag	480
Lys Pro Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys Leu Glu	
145 150 155	
gtg cag tgc cag ccg ggt aac ggt gcc ccc aga gcc cag cac cat ggt	528
Val Gln Cys Gln Pro Gly Asn Gly Gly Pro Arg Ala Gln His His Gly	
160 165 170	
gcc acc agg ctc aca gcc aca gcc ttg cta act gtg tgt cca ggg ctt	576
Ala Thr Arg Leu Thr Ala Thr Ala Leu Leu Thr Val Cys Pro Gly Leu	
175 180 185 190	
ctg ctc cca cta gtt ggc act tca cac atg ttc ttt ctc cct tat ttt	624
Leu Leu Pro Leu Val Gly Thr Ser His Met Phe Phe Leu Pro Tyr Phe	
195 200 205	
ctc tct ttt ctt tct tct ttt tta aag atg tat ctt tat gtg	666
Leu Ser Phe Leu Ser Ser Phe Leu Lys Met Tyr Leu Tyr Val	
210 215 220	

-32-

tgagtgtttt acctacatgc ctgtaagtgc actgaatgtg tgtctggtgc ctgcagaggc 726
 cagaagaggg caccagatcc cctgaaactg gagtctctgc tccgtgtgaa ccaccacgtg 786
 ggtgctggga cccaggtcca atgcaagagc acccagggtt cttacctgct gagccaccac 846
 ttcaac 852

<210> 11
 <211> 220
 <212> PRT
 <213> Mus musculus

<400> 11
 Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu Leu Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp Cys Tyr
 20 25 30
 Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val Lys Phe Arg Glu
 35 40 45
 Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr Val Ala Val Asn
 50 55 60
 Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser Leu Phe Leu Ala
 65 70 75 80
 Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly Ser Lys Met Gln
 85 90 95
 Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe Val Thr Ser Cys
 100 105 110
 Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val Gln Thr Asn Ile
 115 120 125
 Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu Ala Leu Lys Pro
 130 135 140
 Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys Leu Glu Val Gln
 145 150 155 160
 Cys Gln Pro Gly Asn Gly Gly Pro Arg Ala Gln His His Gly Ala Thr
 165 170 175
 Arg Leu Thr Ala Thr Ala Leu Leu Thr Val Cys Pro Gly Leu Leu Leu
 180 185 190

-33-

Pro Leu Val Gly Thr Ser His Met Phe Phe Leu Pro Tyr Phe Leu Ser
 195 200 205

Phe Leu Ser Ser Phe Leu Lys Met Tyr Leu Tyr Val
 210 215 220

<210> 12

<211> 1152

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (256)..(951)

<400> 12

gaattcgcgg ccgcgtcgac attctgggga cgtcggtcgg ggttcttaga agaggagatg 60

acttttcaca gtcactgagg ctctgtcagg aagcctgggg gagcaggagg cggaaaccga 120

cccacatcaa gggcggcagg gccgggcggc ggggtacagg ggttgggggg gaaggggctg 180

cagggtatga gcccagagacc tgccctcctg tcacttccaa gaacctgtca caggcatgag 240

gggtccccgg cagag atg aca gtg ctg gcg cca gcc tgg agc cca aat tcc 291

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser
 1 5 10

tcc ctg ttg ctg ctg ttg ctg ctg ctg agt cct tgc ctg cgg ggg aca 339

Ser Leu Leu Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr
 15 20 25

cct gac tgt tac ttc agc cac agt ccc atc tcc tcc aac ttc aaa gtg 387

Pro Asp Cys Tyr Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val
 30 35 40

aag ttt aga gag ttg act gac cac ctg ctt aaa gat tac cca gtc act 435

Lys Phe Arg Glu Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr
 45 50 55 60

gtg gcc gtc aat ctt cag gac gag aag cac tgc aag gcc ttg tgg agc 483

Val Ala Val Asn Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser
 65 70 75

ctc ttc cta gcc cag cgc tgg ata gag caa ctg aag act gtg gca ggg 531

Leu Phe Leu Ala Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly
 80 85 90

tct aag atg caa acg ctt ctg gag gac gtc aac acc gag ata cat ttt 579

Ser Lys Met Gln Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe
 95 100 105

-34-

```

gtc acc tca tgt acc ttc cag ccc cta cca gaa tgt ctg cga ttc gtc 627
Val Thr Ser Cys Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val
    110                      115                      120

cag acc aac atc tcc cac ctc ctg aag gac acc tgc aca cag ctg ctt 675
Gln Thr Asn Ile Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu
125                      130                      135                      140

ggg ctg aag ccc tgt atc ggg aag gcc tgc cag aat ttc tct cgg tgc 723
Gly Leu Lys Pro Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys
                      145                      150                      155

ctg gag gtg cag tgc cag ccg gac tcc tcc acc ctg ctg ccc cca agg 771
Leu Glu Val Gln Cys Gln Pro Asp Ser Ser Thr Leu Leu Pro Pro Arg
                      160                      165                      170

agt ccc ata gcc cta gaa gcc acg gag ctc cca gag cct cgg ccc agg 819
Ser Pro Ile Ala Leu Glu Ala Thr Glu Leu Pro Glu Pro Arg Pro Arg
                      175                      180                      185

cag ctg ttg ctc ctg ctg ctg ctg ctg ctg cct ctc aca ctg gtg ctg 867
Gln Leu Leu Leu Leu Leu Leu Leu Leu Pro Leu Thr Leu Val Leu
    190                      195                      200

ctg gca gcc gcc tgg ggc ctt cgc tgg caa agg gca aga agg agg ggg 915
Leu Ala Ala Ala Trp Gly Leu Arg Trp Gln Arg Ala Arg Arg Arg Gly
205                      210                      215                      220

gag ctc cac cct ggg gtg ccc ctc ccc tcc cat ccc taggatgcga 961
Glu Leu His Pro Gly Val Pro Leu Pro Ser His Pro
                      225                      230

gccttgtagca tcgttgactc agccagggtc ttatctcgat gaggtctcaa tatgttgccc 1021

aaactgactt tgaaaacctc gatgcacctt cctgccccac aaacttccaa acagctgggc 1081

ttacgggcat gctatataca acaaggcttt cttttcttct ttcttggtgc tagagttggg 1141

aaccaaaaca a 1152

```

<210> 13
 <211> 232
 <212> PRT
 <213> Mus musculus

<400> 13
 Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu Leu Leu
 1 5 10 15
 Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp Cys Tyr

30

<400> 14

-36-

atg aca gtg ctg gcg cca gcc tgg agc cca aat tcc tcc ctg ttg ctg	48
Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu Leu Leu	
1 5 10 15	
ctg ttg ctg ctg ctg agt cct tgc ctg cgg ggg aca cct gac tgt tac	96
Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp Cys Tyr	
20 25 30	
ttc agc cac agt ccc atc tcc tcc aac ttc aaa gtg aag ttt aga gag	144
Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val Lys Phe Arg Glu	
35 40 45	
ttg act gac cac ctg ctt aaa gat tac cca gtc act gtg gcc gtc aat	192
Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr Val Ala Val Asn	
50 55 60	
ctt cag gac gag aag cac tgc aag gcc ttg tgg agc ctc ttc cta gcc	240
Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser Leu Phe Leu Ala	
65 70 75 80	
cag cgc tgg ata gag caa ctg aag act gtg gca ggg tct aag atg caa	288
Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly Ser Lys Met Gln	
85 90 95	
acg ctt ctg gag gac gtc aac acc gag ata cat ttt gtc acc tca tgt	336
Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe Val Thr Ser Cys	
100 105 110	
acc ttc cag ccc cta cca gaa tgt ctg cga ttc gtc cag acc aac atc	384
Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val Gln Thr Asn Ile	
115 120 125	
tcc cac ctc ctg aag gac acc tgc aca cag ctg ctt gct ctg aag ccc	432
Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu Ala Leu Lys Pro	
130 135 140	
tgt atc ggg aag gcc tgc cag aat ttc tct cgg tgc ctg gag gtg cag	480
Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys Leu Glu Val Gln	
145 150 155 160	
tgc cag ccg ggt aac ggt ggc ccc aga gcc cag cac cat ggt gcc acc	528
Cys Gln Pro Gly Asn Gly Gly Pro Arg Ala Gln His His Gly Ala Thr	
165 170 175	
agg ctc aca gcc aca gcc ttg cta act gtg tgt cca ggg ctt ctg ctc	576
Arg Leu Thr Ala Thr Ala Leu Leu Thr Val Cys Pro Gly Leu Leu Leu	
180 185 190	
cca cta gtt ggc act tca cac atg ttc ttt ctc cct tat ttt ctc tct	624
Pro Leu Val Gly Thr Ser His Met Phe Phe Leu Pro Tyr Phe Leu Ser	
195 200 205	

-37-

ttt ctt tct tct ttt tta aag atg tat ctt tat gtg tga 663
 Phe Leu Ser Ser Phe Leu Lys Met Tyr Leu Tyr Val
 210 215 220

<210> 15
 <211> 220
 <212> PRT
 <213> Mus musculus

<400> 15
 Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu Leu Leu
 1 5 10 15

Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp Cys Tyr
 20 25 30

Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val Lys Phe Arg Glu
 35 40 45

Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr Val Ala Val Asn
 50 55 60

Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser Leu Phe Leu Ala
 65 70 75 80

Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly Ser Lys Met Gln
 85 90 95

Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe Val Thr Ser Cys
 100 105 110

Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val Gln Thr Asn Ile
 115 120 125

Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu Ala Leu Lys Pro
 130 135 140

Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys Leu Glu Val Gln
 145 150 155 160

Cys Gln Pro Gly Asn Gly Gly Pro Arg Ala Gln His His Gly Ala Thr
 165 170 175

Arg Leu Thr Ala Thr Ala Leu Leu Thr Val Cys Pro Gly Leu Leu Leu
 180 185 190

Pro Leu Val Gly Thr Ser His Met Phe Phe Leu Pro Tyr Phe Leu Ser
 195 200 205

Phe Leu Ser Ser Phe Leu Lys Met Tyr Leu Tyr Val
 210 215 220

-38-

<210> 16
 <211> 519
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)..(516)

<400> 16
 atg aca gtg ctg gcg cca gcc tgg agc cca aat tcc tcc ctg ttg ctg 48
 Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu Leu Leu
 1 5 10 15
 ctg ttg ctg ctg ctg agt cct tgc ctg cgg ggg aca cct gac tgt tac 96
 Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp Cys Tyr
 20 25 30
 ttc agc cac agt ccc atc tcc tcc aac ttc aaa gtg aag ttt aga gag 144
 Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val Lys Phe Arg Glu
 35 40 45
 ttg act gac cac ctg ctt aaa gat tac cca gtc act gtg gcc gtc aat 192
 Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr Val Ala Val Asn
 50 55 60
 ctt cag gac gag aag cac tgc aag gcc ttg tgg agc ctc ttc cta gcc 240
 Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser Leu Phe Leu Ala
 65 70 75 80
 cag cgc tgg ata gag caa ctg aag act gtg gca ggg tct aag atg caa 288
 Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly Ser Lys Met Gln
 85 90 95
 acg ctt ctg gag gac gtc aac acc gag ata cat ttt gtc acc tca tgt 336
 Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe Val Thr Ser Cys
 100 105 110
 acc ttc cag ccc cta cca gaa tgt ctg cga ttc gtc cag acc aac atc 384
 Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val Gln Thr Asn Ile
 115 120 125
 tcc cac ctc ctg aag gac acc tgc aca cag ctg ctt gct ctg aag ccc 432
 Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu Ala Leu Lys Pro
 130 135 140
 tgt atc ggg aag gcc tgc cag aat ttc tct cgg tgc ctg gag gtg cag 480
 Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys Leu Glu Val Gln
 145 150 155 160

-39-

tgc cag ccg gat agg gtc tca tta tgc agg cta ggc tga 519
 Cys Gln Pro Asp Arg Val Ser Leu Cys Arg Leu Gly
 165 170

<210> 17

<211> 172

<212> PRT

<213> Mus musculus

<400> 17

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Asn Ser Ser Leu Leu Leu
 1 5 10 15

Leu Leu Leu Leu Leu Ser Pro Cys Leu Arg Gly Thr Pro Asp Cys Tyr
 20 25 30

Phe Ser His Ser Pro Ile Ser Ser Asn Phe Lys Val Lys Phe Arg Glu
 35 40 45

Leu Thr Asp His Leu Leu Lys Asp Tyr Pro Val Thr Val Ala Val Asn
 50 55 60

Leu Gln Asp Glu Lys His Cys Lys Ala Leu Trp Ser Leu Phe Leu Ala
 65 70 75 80

Gln Arg Trp Ile Glu Gln Leu Lys Thr Val Ala Gly Ser Lys Met Gln
 85 90 95

Thr Leu Leu Glu Asp Val Asn Thr Glu Ile His Phe Val Thr Ser Cys
 100 105 110

Thr Phe Gln Pro Leu Pro Glu Cys Leu Arg Phe Val Gln Thr Asn Ile
 115 120 125

Ser His Leu Leu Lys Asp Thr Cys Thr Gln Leu Leu Ala Leu Lys Pro
 130 135 140

Cys Ile Gly Lys Ala Cys Gln Asn Phe Ser Arg Cys Leu Glu Val Gln
 145 150 155 160

Cys Gln Pro Asp Arg Val Ser Leu Cys Arg Leu Gly
 165 170

<210> 18

<211> 1080

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

-40-

<222> (84)..(788)

<400> 18

```

ccgggggggca tgagggtccg agacttggtc ttcgtgccct tccaagaccc ggcgacagga 60

ggcatgaggg gccccggcc gaa atg aca gtg ctg gcg cca gcc tgg agc cca 113
      Met Thr Val Leu Ala Pro Ala Trp Ser Pro
              1              5              10

aca acc tat ctc ctc ctg ctg ctg ctg ctg agc tcg gga ctc agt ggg 161
Thr Thr Tyr Leu Leu Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly
              15              20              25

acc cag gac tgc tcc ttc caa cac agc ccc atc tcc tcc gac ttc gct 209
Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser Asp Phe Ala
              30              35              40

gtc aaa atc cgt gag ctg tct gac tac ctg ctt caa gat tac cca gtc 257
Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val
              45              50              55

acc gtg gcc tcc aac ctg cag gac gag gag ctc tgc ggg ggc ctc tgg 305
Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp
              60              65              70

cgg ctg gtc ctg gca cag cgc tgg atg gag cgg ctc aag act gtc gct 353
Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys Thr Val Ala
              75              80              85              90

ggg tcc aag atg caa ggc ttg ctg gag cgc gtg aac acg gag ata cac 401
Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr Glu Ile His
              95              100              105

ttt gtc acc aaa tgt gcc ttt cag ccc ccc ccc agc tgt ctt cgc ttc 449
Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe
              110              115              120

gtc cag acc aac atc tcc cgc ctc ctg cag gag acc tcc gag cag ctg 497
Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu
              125              130              135

gtg gcg ctg aag ccc tgg atc act cgc cag aac ttc tcc cgg tgc ctg 545
Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu
              140              145              150

gag ctg cag tgt cag ccc gac tcc tca acc ctg cca ccc cca tgg agt 593
Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser
              155              160              165              170

ccc cgg ccc ctg gag gcc aca gcc ccg aca gcc ccg cag ccc cct ctg 641
Pro Arg Pro Leu Glu Ala Thr Ala Pro Thr Ala Pro Gln Pro Pro Leu
              175              180              185

```

-41-

```

ctc ctc cta ctg ctg ctg ccc gtg ggc ctc ctg ctg ctg gcc gct gcc 689
Leu Leu Leu Leu Leu Leu Pro Val Gly Leu Leu Leu Leu Ala Ala Ala
      190              195              200

tgg tgc ctg cac tgg cag agg acg cgg cgg agg aca ccc cgc cct ggg 737
Trp Cys Leu His Trp Gln Arg Thr Arg Arg Arg Thr Pro Arg Pro Gly
      205              210              215

gag cag gtg ccc ccc gtc ccc agt ccc cag gac ctg ctg ctt gtg gag 785
Glu Gln Val Pro Pro Val Pro Ser Pro Gln Asp Leu Leu Leu Val Glu
      220              225              230

cac tgacctggcc aaggcctcat cctgcggagc cttaaacaac gcagtgcagac 838
His
235

agacatctat catcccatTT tacaggggag gatactgagg cacacagagg ggagtcacca 898

gccagaggat gtatagcctg gacacagagg aagttggcta gaggccggtc ccttccttgg 958

gcccctctca ttccctcccc agaatggagg caacgccaga atccagcacc ggccccatTT 1018

acccaactct gaacaaagcc cttgccccca tgaaattgTT tataaatcat ccttttctcc 1078

ca 1080

```

<210> 19

<211> 235

<212> PRT

<213> Homo sapiens

<400> 19

```

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Thr Thr Tyr Leu Leu Leu
  1              5              10              15

```

```

Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly Thr Gln Asp Cys Ser Phe
      20              25              30

```

```

Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
      35              40              45

```

```

Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
      50              55              60

```

```

Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
      65              70              75              80

```

```

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
      85              90              95

```

-42-

Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 100 105 110

Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 115 120 125

Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 130 135 140

Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 145 150 155 160

Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Glu Ala
 165 170 175

Thr Ala Pro Thr Ala Pro Gln Pro Pro Leu Leu Leu Leu Leu Leu
 180 185 190

Pro Val Gly Leu Leu Leu Leu Ala Ala Ala Trp Cys Leu His Trp Gln
 195 200 205

Arg Thr Arg Arg Arg Thr Pro Arg Pro Gly Glu Gln Val Pro Pro Val
 210 215 220

Pro Ser Pro Gln Asp Leu Leu Leu Val Glu His
 225 230 235

<210> 20

<211> 537

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(537)

<400> 20

atg aca gtg ctg gcg cca gcc tgg agc cca aca acc tat ctc ctc ctg 48
 Met Thr Val Leu Ala Pro Ala Trp Ser Pro Thr Thr Tyr Leu Leu Leu
 1 5 10 15

ctg ctg ctg ctg agc tcg gga ctc agt ggg acc cag gac tgc tcc ttc 96
 Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly Thr Gln Asp Cys Ser Phe
 20 25 30

caa cac agc ccc atc tcc tcc gac ttc gct gtc aaa atc cgt gag ctg 144
 Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
 35 40 45

tct gac tac ctg ctt caa gat tac cca gtc acc gtg gcc tcc aac ctg 192
 Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

-43-

50	55	60	
cag gac gag gag ctc tgc ggg ggc ctc tgg cgg ctg gtc ctg gca cag			240
Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln			
65	70	75	80
cgc tgg atg gag cgg ctc aag act gtc gct ggg tcc aag atg caa ggc			288
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly			
	85	90	95
ttg ctg gag cgc gtg aac acg gag ata cac ttt gtc acc aaa tgt gcc			336
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala			
	100	105	110
ttt cag ccc ccc ccc agc tgt ctt cgc ttc gtc cag acc aac atc tcc			384
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser			
	115	120	125
cgc ctc ctg cag gag acc tcc gag cag ctg gtg gcg ctg aag ccc tgg			432
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp			
	130	135	140
atc act cgc cag aac ttc tcc cgg tgc ctg gag ctg cag tgt cag ccc			480
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro			
	145	150	155
gta gag acg gtg ttt cac cgt gtc agc cag gat ggt ctc gat ctc ctg			528
Val Glu Thr Val Phe His Arg Val Ser Gln Asp Gly Leu Asp Leu Leu			
	165	170	175
acc tcg tga			537
Thr Ser			

<210> 21

<211> 178

<212> PRT

<213> Homo sapiens

<400> 21

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Thr Thr Tyr Leu Leu Leu
1 5 10 15

Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly Thr Gln Asp Cys Ser Phe
20 25 30

Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
35 40 45

Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
50 55 60

-44-

Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
 65 70 75 80
 Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 85 90 95
 Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 100 105 110
 Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 115 120 125
 Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 130 135 140
 Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 145 150 155 160
 Val Glu Thr Val Phe His Arg Val Ser Gln Asp Gly Leu Asp Leu Leu
 165 170 175
 Thr Ser

<210> 22
 <211> 859
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (93)..(797)

<220>
 <221> CDS
 <222> (93)..(647)

<400> 22
 tggaaagggc tgtcaccggc cttggcccct tccacaccca actggggcaa gcctgaccgc 60
 gcgacaggag gcatgagggg cccccggccg aa atg aca gtg ctg gcg cca gcc 113
 Met Thr Val Leu Ala Pro Ala
 1 5
 tgg agc cca aca acc tat ctc ctc ctg ctg ctg ctg agc tcg gga 161
 Trp Ser Pro Thr Thr Tyr Leu Leu Leu Leu Leu Leu Ser Ser Gly
 10 15 20
 ctc agt ggg acc cag gac tgc tcc ttc caa cac agc ccc atc tcc tcc 209
 Leu Ser Gly Thr Gln Asp Cys Ser Phe Gln His Ser Pro Ile Ser Ser
 25 30 35

-45-

gac ttc gct gtc aaa atc cgt gag ctg tct gac tac ctg ctt caa gat	257
Asp Phe Ala Val Lys Ile Arg Glu Leu Ser Asp Tyr Leu Leu Gln Asp	
40 45 50 55	
tac cca gtc acc gtg gcc tcc aac ctg cag gac gag gag ctc tgc ggg	305
Tyr Pro Val Thr Val Ala Ser Asn Leu Gln Asp Glu Glu Leu Cys Gly	
60 65 70	
gcg ctc tgg cgg ctg gtc ctg gca cag cgc tgg atg gag cgg ctc aag	353
Ala Leu Trp Arg Leu Val Leu Ala Gln Arg Trp Met Glu Arg Leu Lys	
75 80 85	
act gtc gct ggg tcc aag atg caa ggc ttg ctg gag cgc gtg aac acg	401
Thr Val Ala Gly Ser Lys Met Gln Gly Leu Leu Glu Arg Val Asn Thr	
90 95 100	
gag ata cac ttt gtc acc aaa tgt gcc ttt cag ccc ccc ccc agc tgt	449
Glu Ile His Phe Val Thr Lys Cys Ala Phe Gln Pro Pro Pro Ser Cys	
105 110 115	
ctt cgc ttc gtc cag acc aac atc tcc cgc ctc ctg cag gag acc tcc	497
Leu Arg Phe Val Gln Thr Asn Ile Ser Arg Leu Leu Gln Glu Thr Ser	
120 125 130 135	
gag cag ctg gtg gcg ctg aag ccc tgg atc act cgc cag aac ttc tcc	545
Glu Gln Leu Val Ala Leu Lys Pro Trp Ile Thr Arg Gln Asn Phe Ser	
140 145 150	
cgg tgc ctg gag ctg cag tgt cag ccc gac tcc tca acc ctg cca ccc	593
Arg Cys Leu Glu Leu Gln Cys Gln Pro Asp Ser Ser Thr Leu Pro Pro	
155 160 165	
cca tgg agt ccc cgg ccc ctg gag gcc aca gcc ccg aca gcc ccg cag	641
Pro Trp Ser Pro Arg Pro Leu Glu Ala Thr Ala Pro Thr Ala Pro Gln	
170 175 180	
ccc cct ctg ctc ctc cta ctg ctg ctg ccc gtg ggc ctc ctg ctg ctg	689
Pro Pro Leu Leu Leu Leu Leu Leu Leu Pro Val Gly Leu Leu Leu Leu	
185 190 195	
gcc gct gcc tgg tgc ctg cac tgg cag agg acg cgg cgg agg aca ccc	737
Ala Ala Ala Trp Cys Leu His Trp Gln Arg Thr Arg Arg Arg Thr Pro	
200 205 210 215	
cgc cct ggg gag cag gtg ccc ccc gtc ccc agt ccc cag gac ctg ctg	785
Arg Pro Gly Glu Gln Val Pro Pro Val Pro Ser Pro Gln Asp Leu Leu	
220 225 230	
ctt gtg gag cac ctgctcctcc tactgtctgtct gcccggtgggc ctcctgtctgc	837
Leu Val Glu His	
235	

-46-

tggccgctgc ctggtgcctg cactggcaga ggacgcggcg gaggacaccc cgccctgggg 897

agcaggtgcc ccccgctccc agtccccagg acctgctgct tgtggagcac tgacctggcc 957

aaggcctcat cctggggagg atacgtaggc acacagaggg gagtcaccag cc 1009

<210> 23

<211> 235

<212> PRT

<213> Homo sapiens

<400> 23

Met Thr Val Leu Ala Pro Ala Trp Ser Pro Thr Thr Tyr Leu Leu Leu
1 5 10 15

Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly Thr Gln Asp Cys Ser Phe
20 25 30

Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
35 40 45

Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
50 55 60

Gln Asp Glu Glu Leu Cys Gly Ala Leu Trp Arg Leu Val Leu Ala Gln
65 70 75 80

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
85 90 95

Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
100 105 110

Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
115 120 125

Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
130 135 140

Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
145 150 155 160

Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Glu Ala
165 170 175

Thr Ala Pro Thr Ala Pro Gln Pro Pro Leu Leu Leu Leu Leu Leu
180 185 190

Pro Val Gly Leu Leu Leu Leu Ala Ala Ala Trp Cys Leu His Trp Gln
195 200 205

-47-

Arg Thr Arg Arg Arg Thr Pro Arg Pro Gly Glu Gln Val Pro Pro Val
 210 215 220

Pro Ser Pro Gln Asp Leu Leu Leu Val Glu His
 225 230 235

<210> 24
 <211> 185
 <212> PRT
 <213> Homo sapiens

<400> 24
 Met Thr Val Leu Ala Pro Ala Trp Ser Pro Thr Thr Tyr Leu Leu Leu
 1 5 10 15

Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly Thr Gln Asp Cys Ser Phe
 20 25 30

Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
 35 40 45

Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
 50 55 60

Gln Asp Glu Glu Leu Cys Gly Ala Leu Trp Arg Leu Val Leu Ala Gln
 65 70 75 80

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
 85 90 95

Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
 100 105 110

Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
 115 120 125

Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
 130 135 140

Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
 145 150 155 160

Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Glu Ala
 165 170 175

Thr Ala Pro Thr Ala Pro Gln Pro Pro
 180 185

<210> 25
 <211> 36
 <212> DNA

-48-

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

<400> 25

cacgaattcg ccgccaccat gacagtgtg gcgcca

36

<210> 26

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

<400> 26

gccgctagct cactgcctgg gccgaggctc t

31

<210> 27

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

<400> 27

aaaactgcag gccttgctgg ccacgcgtta tttccacca tatt

44

<210> 28

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

<400> 28

cgcggatccg gccgctgcgg ccatggtatt atcatc

36

<210> 29

<211> 56

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

-49-

<400> 29
cgacgcgtgt ggctgcacca tctgtctggc ccttccggcc atctgatgag cagttg 56

<210> 30
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 30
cgacgcgttc aacactctcc cctgttgaag ct 32

<210> 31
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 31
ggaagatcta ccaagggcc atcgggcctc tccccctggc accctcc 47

<210> 32
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 32
ggaagatctc aggatctcgg agacagggag aggct 35

<210> 33
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 33
ctgcagaagg ccttgctggc cgccatggga ccgtctgttc agttc 45

-50-

<210> 34
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 34
tggtgcggcc accgtggcct ttatttccaa ctt 33

<210> 35
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 35
ctgcagaagg ccgcagcggc cgagttgtgg ctgaactgga ttttc 45

<210> 36
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 36
ccgatgggccc cttggggcca gctgaggaga cggt 34

<210> 37
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 37
gcggaattcg ccgccaccat gacagtgtg gcgccagc 38

<210> 38
<211> 29
<212> DNA

-51-

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

<400> 38

gcggctagct caagggggct gcggggctg

29

<210> 39

<211> 5310

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cDNA

<400> 39

tgccattgc atacgttgta tccatatcat aatatgtaca tttatattgg ctcatgtcca 60
acattaccgc catgttgaca ttgattattg actagttatt aatagtaatc aattacgggg 120
tcattagttc atagcccata tatggagttc cgcggtacat aacttacggt aaatggcccg 180
cctggctgac cgcccaacga cccccgcca ttgacgtcaa taatgacgta tgttcccata 240
gtaacgccaa tagggacttt ccattgacgt caatgggtgg agtattttacg gtaaactgcc 300
cacttggcag tacatcaagt gtatcatatg ccaagtacgc cccctattga cgtcaatgac 360
ggtaaatggc ccgcctggca ttatgccag tacatgacct tatgggactt tctacttgg 420
cagtacatct acgtattagt catcgctatt accatggtga tgcggttttg gcagtacatc 480
aatgggcgtg gatagcgggt tgactcacgg ggatttccaa gtctccaccc cattgacgtc 540
aatgggagtt tgttttggca ccaaaatcaa cgggactttc caaaatgtcg taacaactcc 600
gccccattga cgcaaatggg cggtaggcgt gtacggtggg aggtctatat aagcagagct 660
cgtttagtga accgtcagat cgcctggaga cgccatccac gctgttttga cctccataga 720
agacaccggg accgatccag cctccgcggc cgggaacggt gcattggaac gcggattccc 780
cgtgccaaaga gtgacgtaag taccgcctat agactctata ggcacacccc tttggctctt 840
atgcatgcta tactgttttt ggcttggggc ctatacacc cgccttcctt atgctatagg 900
tgatggtata gcttagccta taggtgtggg ttattgacca ttattgacca ctcccctatt 960
ggtgacgata ctttccatta ctaatccata acatggctct ttgccacaac tatctctatt 1020

-52-

ggctatatgc caatactctg tccttcagag actgacacgg actctgtatt ttacaggat 1080
ggggtcccat ttattattta caaattcaca tatacaacaa cgccgtcccc cgtgcccga 1140
gtttttatta aacatagcgt gggatctcca cgcgaatctc gggtagctgt tccggacatg 1200
ggctcttctc cggtagcggc ggagcttcca catccgagcc ctgggtcccat gcctccagcg 1260
gctcatggtc gctcggcagc tccttgctcc taacagtgga ggccagactt aggcacagca 1320
caatgcccac caccaccagt gtgccgcaca aggccgtggc ggtagggat gtgtctgaaa 1380
atgagcgtgg agattgggct cgcacggctg acgcagatgg aagacttaag gcagcggcag 1440
aagaagatgc aggcagctga gttgttgat tctgataaga gtcagaggta actcccgttg 1500
cgggtgctgtt aacgggtggag ggagtgtag tctgagcagt actcgttgct gccgcgcgcg 1560
ccaccagaca taatagctga cagactaaca gactgttcc ttccatgggt cttttctgca 1620
gtcaccgtcg tcgatatcg aattcgccgc caccatgaca gtgctggcgc cagcctggag 1680
cccaacaacc tatctctcc tgcgtgctgct gctgagctcg ggactcagtg ggaccagga 1740
ctgctccttc caacacagcc ccatctctc cgacttcgct gtcaaaatcc gtgagctgtc 1800
tgactacctg cttcaagatt acccagtcac cgtggcctcc aacctgcagg acgaggagct 1860
ctgccccgcg ctctggcggc tggctcctggc acagcgtgg atggagcggc tcaagactgt 1920
cgctgggtcc aagatgcaag gcttgctgga gcgcgtgaac acggagatac actttgtcac 1980
caaatgtgcc tttcagcccc cccccagctg tcttcgcttc gtccagacca acatctcccg 2040
cctctgcag gagacctccg agcagctggg ggcgtgaag ccctggatca ctcgccagaa 2100
cttctcccgg tgctggagc tgagtgta gcccgactcc tcaaccctgc ccccccatg 2160
gagtccccgg cccctggagg ccacagcccc gacagccccg cagccccctt gagctagcgg 2220
atcccctagg gtcgaccacg tgtgatccag atctacttct ggctaataaa agatcagagc 2280
tctagagatc tgtgtgttg ttttttgtgt ggtaccagg tgctgaagaa ttgaccgggt 2340
tcctcctggg ccagaaagaa gcaggcacat cccctctct gtgacacacc ctgtccacgc 2400
ccctggttct tagttccagc cccactcata ggacactcat agctcaggag ggctccgcct 2460
tcaatccac ccgctaaagt acttgagcg gtctctcct ccctcatcag ccaccaaac 2520
caaacctagc ctccaagagt gggaagaaat taaagcaaga taggctatta agtgagagg 2580

-53-

gagagaaaat gcctccaaca tgtgaggaag taatgagaga aatcatagaa tttcttccgc 2640
ttcttcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca 2700
ctcaaaggcg gtaatacggg tatccacaga atcaggggat aacgcaggaa agaacatgtg 2760
agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca 2820
taggctccgc cccctgacg agcatcacia aaatcgacgc tcaagtcaga ggtggcgaaa 2880
cccgacagga ctataaagat accaggcggt tccccctgga agctccctcg tgcgctctcc 2940
tggtccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc 3000
gcttttctca tgctcacgct gtaggtatct cagttcgggt taggtcgttc gctccaagct 3060
gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg 3120
tcttgagtcc aaccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag 3180
gattagcaga gcgaggtatg taggcgggtg tacagagttc ttgaagtgtt ggcctaacta 3240
cggctacact agaaggacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg 3300
aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt 3360
tggttgcaag cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt 3420
ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggattt tggatcatgag 3480
attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat 3540
ctaaagtata tatgagtaaa cttggtctga cagttacca tgcttaatca gtgaggcacc 3600
tatctcagcg atctgtctat ttcgttcac catagttgcc tgactccggg gggggggggc 3660
gctgaggtct gcctcgtgaa gaagggtgtg ctgactcata ccaggcctga atcgccccat 3720
catccagcca gaaagtgagg gagccacggg tgatgagagc tttgttgtag gtggaccagt 3780
tggtgatattt gaacttttgc tttgccacgg aacgggtctgc gttgtcggga agatgcgtga 3840
tctgatcctt caactcagca aaagttcgat ttattcaaca aagccgccgt cccgtcaagt 3900
cagcgtaatg ctctgccagt gttacaacca attaaccaat tctgattaga aaaactcatc 3960
gagcatcaaa tgaaactgca atttattcat atcaggatta tcaataccat atttttgaaa 4020
aagccgtttc tgtaatgaag gagaaaactc accgaggcag ttccatagga tggcaagatc 4080
ctggtatcgg tctgcgattc cgactcgtcc aacatcaata caacctatta atttcccctc 4140

-54-

gtcaaaaata aggttatcaa gtgagaaatc accatgagtg acgactgaat ccggtgagaa 4200
 tggcaaaagc ttatgcattt ctttcagac ttgttcaaca ggccagccat tacgctcgtc 4260
 atcaaaatca ctcgcatcaa ccaaaccgtt attcattcgt gattgcgcct gagcgagacg 4320
 aaatacgcgga tcgctgttaa aaggacaatt acaaacagga atcgaatgca accggcgcgag 4380
 gaacactgcc agcgcatcaa caatattttc acctgaatca ggatattctt ctaataacctg 4440
 gaatgctgtt ttcccgggga tcgcagtggt gagtaaccat gcatcatcag gagtacggat 4500
 aaaatgcttg atggtcggaa gaggcataaa ttccgtcagc cagtttagtc tgaccatctc 4560
 atctgtaaca tcattggcaa cgctaccttt gccatgtttc agaaacaact ctggcgcatc 4620
 gggcttccca tacaatcgat agattgtcgc acctgattgc ccgacattat cgcgagccca 4680
 tttataccca tataaatcag catccatgtt ggaatttaac cgcgccctcg agcaagacgt 4740
 ttcccggtga atatggctca taacaccctt tgtattactg tttatgtaag cagacagttt 4800
 tattgttcat gatgatatat ttttatcttg tgcaatgtaa catcagagat tttgagacac 4860
 aacgtggctt tcccccccc cccattattg aagcatttat cagggttatt gtctcatgag 4920
 cggatacata tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc 4980
 ccgaaaagtg ccacctgacg tctaagaaac cattattatc atgacattaa cctataaaaa 5040
 taggcgtatc acgaggccct ttcgtctcgc gcgtttcggg gatgacggtg aaaacctctg 5100
 acacatgcag ctcccgga cggtcacagc ttgtctgtaa gcggatgccg ggagcagaca 5160
 agcccgtcag ggcgcgtcag cgggtgttg cgggtgtcgg ggctggctta actatgcggc 5220
 atcagagcag attgtactga gagtgcacca tatgcggtgt gaaataccgc acagatgcgt 5280
 aaggagaaaa taccgcatca gattggctat 5310

<210> 40

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

<400> 40

ggcggcgccc gatgcggccc caactgtatc catcttccca

40

-55-

<210> 41
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 41
gcggcgacgc gttcaacact cattcctgtt gaag 34

<210> 42
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 42
gcggcgggcc aaaacggccg ccccatcgg tctatccact 40

<210> 43
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 43
gcggcgagat ctggatcttc atttaccgg agtccggga 39

<210> 44
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA Primer

<400> 44
gcggcgggcc ttgctggcca tggcctgggc tctgctg 37

<210> 45
<211> 40
<212> DNA

-56-

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

<400> 45

gcggcgggcc gcatcgggcc ctaggacggt cagcttggtg

40

<210> 46

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

<400> 46

gcggcgggcc gcagcgggcca aacacctgtg gttcttcctc

40

<210> 47

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Primer

<400> 47

gcggcgggcc gttttggccg aggagaccgt gaccgtg

37